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ABSTRACT OF DISSERTATION

POST DISCHARGE NAUSEA AND VOMITING IN AMBULATORY SURGICAL
PATIENTS: INCIDENCE AND MANAGEMENT STRATEGIES
Approximately 65% of all surgeries are conducted in the outpatient surgery setting
involving more than 35 million patients. Thirty-five to fifty percent of these outpatients will
experience post discharge nausea and vomiting (PDNV), nausea and vomiting that occurs after
discharge from the health care facility after surgery. A dearth of literature details the problems
associated with nausea and vomiting experienced by patients after discharge home from
outpatient surgery.
The purposes of this dissertation were to (1) review the current knowledge in the area of
post discharge nausea and vomiting; (2) present results of an integrative review of the research
literature to determine best evidence for prevention of PDNV in adults or rescue of patients who
suffer from post discharge nausea and vomiting (PDNV); (3) present a critical review and
analysis of measurement of nausea and vomiting after discharge from outpatient surgery, and (4)
present findings of a prospective research study.
The purposes of the research study were to: 1) describe the incidence and severity of
PDNV over a 7-day period in a sample of adult surgical patients undergoing outpatient surgeries
under general anesthesia, 2) describe the pharmacologic and nonpharmacologic modalities of care
used by patients with PDNV to manage it, 3) compare the incidence and severity of PDNV
between those who do and do not use pharmacologic and nonpharmacologic modalities, and 4)
determine outcomes associated with PDNV. This study was part of a multi-site study that had as
a primary objective development of a simplified risk model for predicting patients most likely to
suffer PDNV. In this research study we described the incidence and severity of PDNV in adult
outpatients after ambulatory surgery, described the pharmacologic and nonpharmacologic
modalities of care used by patients with PDNV to manage it, compared the incidence and severity
of PDNV between those who do and do not use pharmacologic and nonpharmacologic modalities,
and determined outcomes associated with PDNV.
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CHAPTER ONE
Nausea and vomiting after surgery was discussed in the literature as early as 1899 when
Blumfeld linked vomiting after surgery to ether anesthesia. At that time the incidence of
postoperative nausea and vomiting (PONV) was 75%.1 By 1956, Knapp and Beecher were
evaluating antiemetic drugs available for patients and discussed the differences between nausea,
vomiting and retching.2 During the 1990s, research began extensively with publication of an
editorial calling PONV the “big, little problem”3 and with two significant articles, in which the
authors discussed the etiology, treatment and prevention of PONV.4, 5 Research focused first on
nausea and vomiting immediately after inpatient surgery.

Since that time, the number of

ambulatory surgeries has increased exponentially, with the resulting adverse effects of nausea and
vomiting impacting patients as they recover at home.
The treatment and consequences of post discharge nausea and vomiting (PDNV) have not
been as thoroughly assessed and evaluated as postoperative nausea and vomiting (PONV), nausea
and vomiting experienced immediately after surgery and in the hospital. Much time and effort
has been expended in research and publication regarding PONV. However, most of this research
was conducted in the post anesthesia care unit (PACU), up to 24 hours in a hospitalized patient,
or in postanesthesia phase II immediately before patient discharge home.6
Approximately 65% of all surgeries are conducted in the outpatient surgery setting7
involving more than 35 million patients.8 Thirty-five to fifty percent of these outpatients will
experience post discharge nausea and vomiting (PDNV), nausea and vomiting that occurs after
discharge from the health care facility after surgery.6, 9-12 That figure translates into millions of
patients who suffer from PDNV yearly.13-15 Unfortunately, the incidence of PDNV is underreported.16 A dearth of literature details the problems associated with nausea and vomiting
experienced by patients after discharge home from outpatient surgery.6, 17 Just this past year, one
editorial, “We’re tired of waiting,” emphasized the effect of PDNV on daily function and pointed
out that patients are tired of waiting for PDNV to end.18 In a second editorial last year the authors
discussed PDNV as an overlooked aspect of ambulatory anesthesia and pointed out the necessity
for further research in this arena.19
In the first published study specifically conducted for the purpose of investigating PDNV
in the outpatient, Carroll, et al.11 found an overall incidence of 35% for PDNV in 211 ambulatory
surgery patients. In a systematic review of randomized, controlled studies, the authors reported an
overall incidence of post discharge nausea as 32.6% and the overall incidence of post discharge
vomiting as 14.7%.12 In another systematic review in which post discharge symptoms were
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examined, the authors found that the incidence of post discharge nausea ranged from 0% to 55%
and post discharge vomiting ranged from 0% to 16%.20 However, it has been difficult to compare
the different incidences reported because the definitions of PDNV vary per researcher. A recent
multidisciplinary and evidence-based guideline published by the American Society of
PeriAnesthesia Nurses is the first guideline to address PDNV.

Contained within this guideline

are definitions of PONV and PDNV (See Figures 1-1 and 1-2) that have been formulated to aid in
further research.9
Only a small number of studies are available in which the investigator specifically
examines strategies to reduce PDNV.6, 21 In one recent study, patients responded to PDNV with
inappropriate responses such as stopping pain medication.22 In another study, 35% of patients
who experienced PDNV lost time from work or normal activities.10 Postanesthesia care for the
patient experiencing PDNV is not standardized, and there has been no research to determine the
pharmacologic and nonpharmacologic modalities that have been used with PDNV and how that
relates to PDNV. Until a very recent multi-site study23, predictors for PDNV had not been
determined, although it was assumed those predictors might be similar to predictors for PONV.9
Risk Factors
Risk factors specific to PDNV are only now being determined. More is known about risk
factors associated with PONV.24-26 The cause of PONV is multifactorial.16 Risk factors for PONV
can be described as those related to the patient, the surgical procedure, the anesthesia, and the
postoperative period.13, 25 Apfel, et al.24 developed a risk score to predict the risk that a patient
would experience PONV. The final score was derived from four predictors: female gender,
history of motion sickness or PONV, nonsmoking, and the use of postoperative opioids. If no
risk factors were present, the incidence of PONV was 10%. With 1, 2, 3, or 4 risk factors present,
the incidences for an individual patient were 21%, 39%, 61%, and 79%, respectively. Koivuranta
et al.27 developed a risk assessment tool that included five variables in the risk score calculation:
female gender, nonsmoking status, history of PONV, history of motion sickness, and length of
surgery (> 60 minutes). The incidences based on the risk factors were 17%, 18%, 42%, 74%, and
87% respectively.
In general, increased age has been associated with a decreased incidence of PONV,
although the predictive value was not supported in several studies.9, 25

Better health status as

determined by the American Society of Anesthesiologists (ASA) physical status classification
system is a possible risk factor for PONV.26, 28 The ASA classification system ranges from 1 (a
patient who is normal and healthy) to 6 (a brain-dead patient who is having organs harvested)29
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In other words, the healthier patient is more at risk for PONV than patients determined as less
healthy. This may have implications for PDNV because outpatient surgery is usually performed
only on patients who have a better health status, typically a physical status of 1-3.30 Other factors
that are associated with PONV include use of volatile anesthetics,31 use of nitrous oxide,28
duration of anesthesia32, duration of surgery24,

32

, and type of surgery.28 There is conflicting

evidence on the impact of pain.25, 33 There is no definitive answer as to whether PONV is related
to PDNV11, 34, although the answer may lie with differing physiologic mechanisms for PONV and
PDNV.17 Until now, experts have recommended using the same risk factor assessment tool for
PDNV as that used for PONV based on benefit versus risk.

9

Apfel et al. have recently

determined predictors for a simplified assessment tool for early PDNV (48 hours after surgery).23
The five statistically significant independent risk factors for PDNV for the first 48 hours are
female gender, age less than 50 years, history of PONV, opioids administered in the PACU, and
nausea in the PACU.23
Consequences
Identified consequences of PDNV in the outpatient surgery patient include impaired sleep
time due to vomiting35, drowsiness as a side effect of the rescue antiemetic34, increased anxiety
for parents of pediatric patients36, a delay in resumption of activities of daily living (ADL)11, 20, a
negative effect on quality of life,

37

and a decision by the patient not to self-administer an

analgesic for pain because they believe it is related to the nausea and vomiting.22, 38
Other potential consequences of PDNV are numerous, but are speculative because they
are based on information about PONV. The patient may be unable to tolerate fluids or food and
become dehydrated, possibly with an accompanying electrolyte disturbance such as alkalemia.
The patient may aspirate contents after postoperative emesis resulting in pneumonia.
Additionally, the patient may experience sweating, tachycardia, increased salivation,
hypertension, hypotension or cardiac dysrhythmias. Surgical consequences include disruption of
suture lines, bleeding from the wound, increased intracranial and intraocular pressure, and
esophageal tears.14,

39

Economic consequences include delayed discharge home, unplanned

admission to the hospital, increased medication use, and nursing costs, as well as possible loss of
work wages for the patient.14, 39, 40

3

Management and Treatment
Prevention of PDNV begins with the anesthesia plan preoperatively with prophylaxis
warranted only in high-risk patients. Risk factors can determine high risk patients for PONV, and
soon a simplified risk assessment tool will be available in the literature to further assess the
potential for PDNV in outpatients.9,

23, 25

In one review of the literature only one systematic

review and three studies specific to management and treatment of PDNV were discovered.6 Five
algorithms published for care and treatment of PONV were discussed in this same review, but
none of those algorithms guide management of nausea and vomiting for the surgical outpatient
after discharge.6

Recent multidisciplinary and evidence-based guidelines published by the

American Society of PeriAnesthesia Nurses are the first guidelines to address PDNV.9 The
overall evidence concerning antiemetics as prophylaxis or other pharmacologic or
nonpharmacologic treatment for PDNV is sparse.17 However, based on the limited evidence
available, and until the risk assessment tool for PDNV is published, patients are assessed for
PDNV using a PONV risk factor assessment tool. If the patient is at risk for PDNV, prophylaxis
is considered with dexamethasone, scopolamine patch, NK-1 receptor antagonist, or P6
acstimulation.9 If the patient experiences PDNV, rescue treatment may include ondansetron
dissolving tablets, promethezine suppositories or tablets, or a scopolamine patch.9
Summary
Modalities of care for patients who experience PDNV have been documented in no
studies. Risk factors have only recently been determined,23and only one study has reported selfcare activities for the patient experiencing PDNV.22 The three most common responses of selfcare for PDNV were stopping pain medications, altering physical activities and ingesting food or
liquids.22 Many patients initiated no self-care activities at all, and none of the patients reported
the use of complementary interventions.22 Little research is available that describes the incidence
and severity of nausea and vomiting after discharge home.

Severity of nausea is rarely

documented. Management and treatment of PDNV has been seriously overlooked with patients
suffering at home unable to return to work or perform other activities of daily living. In one
school project, the author discovered that patients who had experienced PDNV were very
reluctant to return for future surgery.41

Therefore, initial exploration of the incidence and

severity of PDNV, pharmacologic and nonpharmacologic modalities of care for these patients,
and relationship to quality of life after surgery must occur in order to determine future relief for
patients in the form of self-care.

4

The purposes of The dissertation were to (1) review the current knowledge in the area of
post discharge nausea and vomiting; (2) present results of an integrative review of the research
literature to determine best evidence for prevention of PDNV in adults or rescue of patients who
suffer from post discharge nausea and vomiting (PDNV); (3) present a critical review and
analysis of measurement of nausea and vomiting after discharge from outpatient surgery, and (4)
present findings of a prospective research study. The purposes of the study conducted as a part of
this dissertation were to: 1) describe the incidence and severity of PDNV over a 7-day period in a
sample of adult surgical patients undergoing outpatient surgeries under general anesthesia, 2)
describe the pharmacologic and nonpharmacologic modalities of care used by patients with
PDNV to manage it, 3) compare the incidence and severity of PDNV between those who do and
do not use pharmacologic and nonpharmacologic modalities, 4) determine outcomes associated
with PDNV, and 5) determine predictions for late (Days 3-7) PDNV. This study was part of a
multi-site study that had as a primary objective development of a simplified risk model for
predicting patients most likely to suffer PDNV.23

Overview of Chapters
Chapters Two and three review the literature that is available concerning post discharge
nausea and vomiting. Chapter Two is a review of any study that been published through 2005 on
the subject of PDNV. The purpose of Chapter Two was to review the current knowledge in the
area of discharge nausea and vomiting.6 The findings were that PDNV had not been as thoroughly
assessed and evaluated as nausea and vomiting immediately post surgery. Future implications
were discussed as were research recommendations for the ambulatory surgery population.
Chapter Three focused on interventional studies that specifically addressed the effect of an
intervention designed to prevent PDNV or rescue the patient who develops PDNV.17 This chapter
presents an integrative review of the literature that determined best evidence for prevention of
PDNV in adults or for rescue of patients who suffer from PDNV. The chapter synthesized
evidence from interventional studies conducted with adult patients using pharmacologic or
nonpharmacologic modalities of care.
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Chapter Four includes discussion of the measurement of nausea and vomiting.
Inconsistent measurement of nausea, vomiting and retching has made it difficult to compare the
incidence of PDNV among studies. Further complicating the situation is that differing definitions
of the terms PONV and PDNV have been used throughout the literature. There is a lack of
standardized instruments in studies of PONV and PDNV and a reliance on instruments developed
by the individual investigator. A critical review and analysis of measurement of nausea and
vomiting after discharge from outpatient surgery is presented as are new directions for
measurement.
Chapter Five is a study that describes the incidence and severity of PDNV over a 7-day
period in a sample of adult surgical patients undergoing outpatient surgeries under general
anesthesia, describes the pharmacologic and nonpharmacologic modalities of care used by
patients with PDNV to manage it, compares the incidence and severity of PDNV between those
who do and do not use pharmacologic and nonpharmacologic modalities, and determines
outcomes associated with PDNV. The study was comprised of data from 12 study sites across
the United States for the first 48 hours post surgery and from 2 study sites for 7 days post surgery.
Findings from the study presented in Chapter Five show that over a third of ambulatory
surgery patients continue to suffer the effects of PDNV during the first week after surgery, some
suffering symptoms up to 7 days. Several factors were associated with an increased risk of
PDNV including younger age, female gender, previous PONV or motion sickness, ASA status,
and OR (operating room) time. Patients were more likely to use minor self-care strategies to
manage symptoms than to use antiemetics.

The presence of nausea and vomiting was

significantly related to quality of life (QOL). In this study, we recommend that future studies
focus on patient education needs, use of risk assessment tools for PDNV and randomized
controlled trials that determine appropriate long-term antiemetics and non-pharmacologic
methods to control nausea and vomiting.
Chapter Six provides an overview of review and study findings, suggests
recommendations on the development of comprehensive and effective interventions to promote
prevention of PDNV and management of symptoms should they occur, and provides future
research recommendations for patient education, risk assessment tools and further research into
management strategies.

6

Future Impact of the Study
The data in this dissertation point out the extraordinary number of patients who undergo
ambulatory surgery and then go home to struggle with nausea and vomiting. There are some
patients who continue to have problems up to 7 days later. This dissertation builds a foundation
for future studies to examine interventions that decrease the impact of nausea and vomiting.
Further research can be conducted to look at newer long-acting antiemetics and the
appropriateness of use for discharged ambulatory surgery patients. Use of nonpharmacologic
methods of care to manage PDNV is a wide-open field for research in this population. Of special
interest is research to determine an algorithm that patients could follow to alleviate symptoms.
Also of special interest is the effect of anxiety on these patients and the effect of a patient
education intervention. Now that it has been confirmed that patients do suffer at home, typically
without notifying the healthcare provider, the science can be built on further interventional
studies.

Copyright © Jan Odom Forren 2009
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Figure 1.1 PONV Timeline

Used with permission.9

Figure 1.2 PDNV Timeline

Used with permission.9
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CHAPTER TWO
POST DISCHARGE NAUSEA AND VOMITING: A REVIEW OF CURRENT
LITERATURE

ABSTRACT
Postoperative nausea and vomiting continues to occur in approximately one third of
patients who have surgery despite newer medications and emerging guidelines for care. There is
a paucity of literature that relates to patients who experience post discharge nausea and vomiting
after outpatient surgery.

The purpose of this article is to review the current knowledge in the

area of post discharge nausea and vomiting. The findings were that the problems with post
discharge nausea and vomiting (PDNV) have not been as thoroughly assessed and evaluated as
nausea and vomiting immediately post surgery. More research needs to be conducted in this
population, as the rate of surgeries performed in this setting will only increase.
Introduction
Postoperative nausea and vomiting (PONV) is a known complication for patients after
surgery and has been called the “big, ‘little problem.’ ”1 In spite of newer anesthetic agents,
antiemetic medications, and considerable research into the subject, one third of all postoperative
patients continue to experience PONV at some point after surgery.2-4 In a recent study of six
interventions for prevention of PONV, the average incidence was 34%.5 The incidence of PONV
in high-risk patients with four determined risk factors can be as high as 70-80%.6
Today, approximately 65% of all surgeries are conducted in the outpatient surgery
setting.7 The Federated Ambulatory Surgery Association states that approximately 6 million
surgeries are performed yearly in 3,300 ambulatory surgery centers.8 The current healthcare
environment requires that patients are quickly and efficiently moved through the system from
admission to discharge.
Only a small number of studies are available that specifically examine strategies to
reduce PDNV.9 Much time and effort has been expended in research and publication regarding
PONV. However, most of this research was conducted in the post anesthesia care unit (PACU) or
in postanesthesia phase II immediately before patient discharge home. There is a paucity of
literature that details the problems associated with nausea and vomiting experienced by patients
after discharge home. The problems with post discharge nausea and vomiting (PDNV) have not
been as thoroughly assessed and evaluated as PONV immediate post surgery. When conducting
the literature review for this article, using “post discharge nausea and vomiting” as a keyword
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elicited only 2 articles from CINAHL (1982-2004). PubMed delivered 56 articles with the same
keyword, but some articles that only had one or two lines applicable to the subject.
To perform the literature search for appropriate articles, the author used the keywords
“ambulatory surgery” (933 results), “nausea and vomiting” (948 results), and “postoperative
complications” (5749 results). Combining those three keywords in one search resulted in 26
articles. The authors then searched the abstracts for suitable articles. The authors also searched
the reference lists in those articles for additional articles.

The result was 24 articles that

specifically mention nausea and vomiting after discharge home. Of those 24 articles, several had
only one –two sentences that were applicable. One of the articles was a systematic review and
analysis of postdischarge symptoms, including nausea and vomiting. The purpose of this review
is to synthesize a review of the literature that has been published on the subject of post discharge
nausea and vomiting.

Post Discharge Nausea and Vomiting

Incidence
It is possible that PDNV has been underreported in the past because the symptoms were
not identified.10 Upon discharge, patients are not as accessible to surveillance and care by
healthcare workers, which may have contributed to underreporting of these symptoms.11 Carroll,
et al.11found an overall incidence of more than 35% in 211 ambulatory surgery patients who had
one of four selected surgeries: laparoscopy, dilation and curettage, arthroscopy, or hernia repair.
Interestingly, most of the patients who experienced PDNV in the study had not experienced
PONV before discharge. Wu, Berenholtz, Pronovost, and Fleisher found an incidence of post
discharge nausea (PDN) that ranged from 0% to 55% and an incidence of post discharge emesis
(PDV) that ranged from 0% - 16% in a systematic review that evaluated the incidence of reported
postdischarge symptoms and included PDNV.12 In a systematic review of randomized, controlled
studies published in the English literature, the authors examined whether routine prophylaxis with
antiemetics affected the incidence of PDNV after ambulatory surgery. The overall incidence of
PDN was reported as 32.6% (35.7% placebo and 31.2% treatment) and the overall incidence of
PDV was 14.7% (19.6% placebo and 12.1% treatment).13
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Risk Factors
The cause of PONV is multifactorial.10 Risk factors can be described as related to the
patient, the surgical procedure, the anesthesia, and the postoperative period.2

Apfel, et al.

developed a risk score to predict the chances a patient would experience PONV. The final score
had four predictors: female gender, history of motion sickness or PONV, nonsmoking, and the
use of postoperative opioids. If no risk factors were present, the incidence of PONV was 10%.
With 1, 2, 3, or 4 risk factors present, the incidences were 21%, 39%, 61%, and 79%,
respectively.6
There are no studies that specifically determine risk factors related to PDNV. Carvalho
et al.14 evaluated the influence of inhalational versus total intravenous anesthesia (TIVA)
maintenance on functional recovery and symptom distress after gynecological surgery.

No

significant differences were found between the two groups with respect to functional recovery,
nausea, vomiting or pain. In one study of 211 outpatients who had one of four selected surgeries,
PDNV was not related to PONV in the immediate postoperative period11while in another study 95
healthy, female patients who had PONV immediately after laparoscopic surgery were reported to
be four times more likely to experience PDNV.15

Consequences
PONV is known to have physiologic consequences as well as an impact on patient
satisfaction.3, 16-20 Identified consequences for the post discharge patient include impaired sleep
time due to vomiting21, drowsiness as a side effect of the rescue antiemetic15, increased anxiety
for parents of pediatric patients22, a delay in resumption of activities of daily living (ADL)11, 12,
and a decision by the patient not to self-administer an analgesic for pain because they believe it is
related to the nausea and vomiting.23, 24

PDNV Published Information
Pfisterer, et al.

25

studied the incidence and impact of PONV before and after discharge

following outpatient surgery. A total of 586 patients from nine countries were enrolled in the
study.

Upon leaving the facility sixty-four patients experienced PONV, with 29 reporting

moderate and 8 reporting severe symptoms. Another 76 patients experienced PDNV while
traveling home. Some patients experienced PDNV five days after surgery. There was also an
impact on activities of daily living and time lost from work. Of the 129 patients who experienced
PDNV, 35% lost time from work or normal activities requiring 21 patients to take one or more
days off work and 21 friends and relatives to take time off from work to assist the patient. The
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authors go on to state that PONV is “either not adequately recognized or treated in hospital and
beyond, or that some of the anti-emetic agents may be inadequate”.25
Enever, et al.26 compared postdischarge morbidity after outpatient dental care under
general anesthesia between pediatric patients with and without disabilities. Symptoms were
similar in both groups and included nausea and vomiting (20%), unexpected drowsiness (13%),
and need for pain relief at home (42%). One patient was readmitted for persistent nausea and
vomiting. Ernst and Thwaites27 evaluated post discharge pain, nausea and vomiting of outpatients
undergoing elective surgeries over a 2-month period.

The types of surgeries were general

surgery, orthopedic, dental, ENT, and gynecology. They discovered that more patients suffered
from nausea and vomiting after discharge (33% nausea; 10% vomiting) than before discharge
(16% nausea; 6% vomiting).

The authors concluded that pain, nausea, and vomiting are

persistent problems after discharge and that they increase in incidence after discharge.
Amanor-Boadu and Soyannwo28 followed pediatric patients from time of discharge to
first outpatient visit. They discovered that the most prevalent problem was pain (18.9%), but also
discovered that vomiting (12.2%) was a significant finding. These authors did not address nausea
in this population. The authors conclude that “concerns for safety and comfort of the patients
should extend beyond the recovery room to the ward and home”.28
Young, et al.29examined whether enhanced discharge education would make a difference
once patients returned home after outpatient surgery. While compiling symptoms that occurred
after surgery, the authors discovered that many patients stated they were not feeling hungry, had
no interest in food, or felt nauseous during the first two days at home. The enhanced teaching
package, a procedure-specific patient educational tool that was implemented, had no effect on
patient recovery or the patient’s ability to self-manage. The authors concluded that the patient’s
own understanding of self-care affected the recovery more significantly than the enhanced
teaching package.
Waterman, et al.30 conducted qualitative research of postoperative pain, nausea, and
vomiting after discharge. They discovered that one third of patients found the pain and nausea
worse than they had imagined. They also discovered that some patients are reluctant to take their
pain medications because they felt they were related to the nausea. One patient stated, “The first
day post-op was awful….I had pain but I was reluctant to take painkillers because of nausea.”31
The authors incorporate recommendations based on their interviews with the patients that include
advising patients preoperatively on how to manage nausea and side effects of drugs and deferring
discharge for those who have higher levels of pain or who are nauseous.

12

Kangas-Saarela, et al.32studied patients’ experiences with outpatient surgery. This was a
survey of the incidences of pain, nausea, and vomiting and patient satisfaction. Overall, 11.3% of
patients surveyed experienced nausea either during recovery, travel home, or after arriving home.
The authors believe that the lower than usual incidence of nausea was due to the high number of
orthopedic cases who received regional anesthesia during surgery. See Table 2-1 for a summary
of studies.

Management and Treatment
Prevention of PONV and PDNV begins with the anesthesia plan preoperatively. Because
only one-third of surgical patients will experience PONV or PDNV, prophylaxis is warranted
only in high-risk patients.33 The decision to give antiemetics should be based on risk factors with
a focused plan of care developed to decrease the chances the patient will experience
PONV/PDNV, e.g. use of local anesthetics to decrease opioid need or limiting use of
neuromuscular agents to avoid reversal agents. There is no one drug that can block all pathways
mediating nausea and vomiting. Different classes of drugs are available that affect one or more
receptor sites, and alternative treatments for PONV are becoming more common although not yet
tested specifically in the PDNV population.2, 3, 33-35 Most alternative treatments are completed in
conjunction with pharmacologic methods of controlling nausea and vomiting.
One systematic review and three studies were found in which the efficacy of
pharmacologic treatment was considered in patients with PDNV. Gupta, et al.13 conducted a
systematic review of randomized controlled trials to determine if the routine prophylactic use of
antiemetics affected the incidence of PDNV after ambulatory surgery. A total of 815 patient had
PDN with an overall incidence of 26% PDN in the treatment group and 40.4% in the placebo
group. A significantly lower risk of PDN was discovered with ondansetron 4mg, dexamethasone
4-10 mg and combination treatment with more than one drug compared to placebo. The overall
incidence of PDV was 14.6 % in the treatment group and 26.5% in the placebo group. The
relative risk was lower with ondansetron 4mg and combination treatment with two or more drugs
than with placebo.
Tang, et al.36compared ondansetron and droperidol as a prophylactic antiemetic agent for
elective outpatient gynecologic procedures. This study was included in the above systematic
review. Droperidol 1.25 mg and ondansetron 4 mg significantly reduced the incidence of PDNV
when compared to placebo or droperidol 0.625 mg. Parlow, et al.15 assessed the efficacy of
prophylactic administration of promethazine for PDNV after ambulatory laparoscopy.

An

intramuscular injection of either saline or promethazine 0.6 mg/kg was administered to patients
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immediately prior to discharge home. There was no difference between the placebo group and
treatment group regarding the incidence of PDNV. The incidence of “excessive drowsiness” was
notably higher in those patients who had received promethazine (P = 0.008).
Wright, et al.37 evaluated the effectiveness of promethazine suppositories in decreasing
nausea and vomiting in adult outpatients following discharge home.

Patients who had a

prolonged stay in PACU due to PONV, developed PONV after the IV was discontinued, or had a
long car trip home were given two promethazine suppositories (25 mg each) upon discharge. A
high percentage of the patients who had PDNV used the suppositories. All patients who used the
suppositories stated that their PDNV improved after use, and no significant side effects were
reported. Promethazine suppositories were determined to be clinically, as well as, cost effective.

Guidelines for Determining Prevention and Treatment
There were five algorithms published for the care and treatment of PONV. Gan10 lists
patient and surgical risk factors and advises avoidance of those risk factors. The algorithm is
specific for prophylactic antiemetic therapy and lists options for mild to moderate risk (1-2
factors), moderate to high risk (3-4 factors) or very high risk (>4 factors). The author believes
that a multimodal approach to prevention of PONV should be adopted that includes identification
of preoperative risk factors, reduction of avoidable risk factors, and use of combination
antiemetics. The guideline is based on the 45 references, a mixture of clinical and research,
included in the article.
Watcha4identified guidelines for prophylaxis and therapy of PONV.

Patients were

divided into four groups based on estimated risk: low risk (<10 %), mild to moderate risk (1030%), high risk (30-60%), and extremely high risk (>60%). This guideline lists suggested
prophylaxis, as well as, suggested rescue antiemetics. The references for the guideline are two
editorials published by White and Watcha.38,

39

One discusses the use of meta-analysis in

improving an understanding of treatment of PONV, and the other includes recommendations on
prophylaxis of high-risk patients based on several studies referenced in the editorial.
Gan, et al.40, in a consensus guideline, listed an algorithm for management of PONV.
The algorithm begins with evaluation of risk and divides patients into low, moderate or high-risk
groups. This algorithm does suggest consideration of nonpharmacologic therapies, consideration
of regional anesthesia, and reduction of baseline risk factors, as well as, antiemetics alone or in
combination for treatment. This group of experts considered an evidence rating scale that was
based on study design and also considered strength of recommendation based on expert opinion.
The panel consisted of ten physicians, 1 pharmacist, and 1 certified registered nurse anesthetist.
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Notably missing from the panel were expert perianesthesia registered nurses. There has been
concern voiced in the literature about the make-up and selection of the expert panel and the fact
that the panel was funded by a pharmaceutical company.41, 42 Others considered it important that
for the first time, an international expert panel attempted to determine a guideline based on
evidence-based strategies.20
Tramer20 describes a possible decision tree for PONV prophylaxis. Patients are identified
as positive or negative for risk. If patients are positive for risk factors, the decision tree suggests
keeping baseline risk low and describes a prophylactic antiemetic cocktail. Tramer recognizes the
difficulty in defining what “high-risk” actually means and assuring that the appropriate patients
are identified.

Tramer further discusses the need for evidence concerning the efficacy of

therapeutic antiemetic cocktails. He believes that trials are needed to determine the best rescue
treatment for patients who continue to vomit after surgery and that minimal effective doses are
unknown. Tramer’s premise is that more research is needed for dissemination of best practices
and implementation of evidenced-based guidelines.
Golembiewski and O’Brien34 illustrate the most extensive algorithm that covers the
immediate perioperative period. It begins with assessment of risk factors in the preoperative
period. Patients are divided into mild to moderate risk (1-2 factors), moderate to high risk (3-4
factors), or very high risk (>4 factors). For all groups there is consideration of intraoperative and
postoperative factors that can decrease the incidence of PONV or treat PONV should it occur, and
then suggests rescue antiemetics. The algorithm is based on nine references; two that discuss
systematic reviews of the literature.
None of the algorithms, guidelines, or decision trees attempts to guide management of
nausea and vomiting in the post discharge phase of patient care. Two of the algorithms address
prophylactic antiemetic therapy only. Even those algorithms that discuss postoperative care are
specific to the immediate postanesthesia phase of care. The only guidelines based on an evidence
rating scale were those from Gan, et al.40

Future Implications
Very little research has been conducted specifically regarding PDNV. We do know that
postdischarge symptoms, including PDNV, can affect patient recovery and resumption of normal
activities. We do not know how those symptoms impact the recovery, how extensive the delay in
recovery remains, or the costs attributable to these symptoms.12

15

Pfisterer, et al.25suggest the need to consider risk factors when using antiemetics for
outpatients. The authors also suggest that future studies should compare the use and effectiveness
of older antiemetics with newer antiemetics. They state that the newer anti-emetics seem to result
in less impact on post discharge activity (due to less drowsiness or other side effects.) Other
authors10 suggest that study of the neurokinin 1 (NK-1) receptor antagonists may hold hope for
the future in terms of preventing or limiting PDNV. Further suggestions for research include
creation of valid and reliable instruments to collect information on postdischarge symptoms.12
Carroll, et al.11 found that patients who experienced PDNV were more likely to report
delay and inability to perform their normal daily activities. The authors also discovered that
patients usually did not call the health professional or purchase products to treat the problem.
Fetzer, et al.24discovered that only 7 of 190 subjects who experienced PDNV contacted a health
care provider for PDNV symptoms. These authors discovered that patients’ most common
response to PDNV was to stop the pain medication, even though pain can contribute to nausea
and vomiting.
One practice implication would be to provide education for patients including more
detailed instructions for managing the PDNV episodes.11 The patient’s ability to self-manage
should be considered because Young et al.29 discovered that the ability to self-manage was related
to the patient’s understanding of self-care. Fetzer, et al.24call for an antiemetic algorithm for
patients to use upon discharge home. This algorithm would take other algorithms one step further
by adding the period of time that patients are recovering at home. This algorithm would also need
to be written in lay-terms, easy to understand and follow. Instructions for patients’ home care
could also include suggestions for complementary therapy. Further research is needed to validate
the usefulness of complementary therapies at home for PDNV.
The economic impact of postdischarge symptoms, including PDNV, is not known.12
Research implications include studying the economic impact of PDNV on delays in resumption
of normal activities and examining cost-effectiveness, cost-benefit, cost utility, as well as, direct
and indirect costs. These costs include not only the costs of unplanned hospital admission or
increased rescue medication, but also delays in return to work, time that must be taken off, not
only by the patient, but by the caregiver.12
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Conclusion
In conclusion, PDNV continues to be a problem for at least one third of patients after
return home. More research needs to be conducted in this arena as the rate of surgeries in the
outpatient setting is only going to rise. Suggestions for study include antiemetic efficacy in the
post discharge setting, the effectiveness of a detailed education program for these patients, and
economic impact.

Copyright © Jan Odom Forren 2009
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Table 2.1 Studies Addressing PDNV
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Reference

Publication
Year

Study

Amanor-Boadu
et al. 28

1997

Complications after pediatric
outpatient surgery

Carroll, et al. 11

1995

Patient experiences with
nausea and vomiting after
discharge from outpatient
surgery

Carvalho, et al.14

2002

Longterm functional
recovery: Inhalation vs.
TIVA

Enever, et al. 26

2000

Postoperative morbidity
following outpatient dental
care under general
anesthesia in pediatric
patients with and without
disabilities

PDNV

PDN

PDV

Findings

12.2%

Need to continue to trend
complications post-discharge to
aid in prevention

35%

Significantly more likely to
report impairment in daily
activities if PDNV present. Little
correlation between predischarge
NV and PDNV. Few patients
called HCP or purchased
products to treat NV.
35%
(during
journey)

20%

10.3% (during
journey)

Incidence of PONV similar
between 2 groups (TIVA and
inhalation)
No differences between groups
of patients with and without
disabilities. N/V most commonly
reported symptom

Table 2.1 (Continued) Studies Addressing PDNV
Publication
Year

Study

Ernst, et al.27

1997

Incidence and impact of
pain, nausea and
vomiting after
outpatient surgery

Fetzer, et al.24

2005

Self-care activities for
PDNV

Grenier, et al.22

1998

Quality at home of
pediatric patients after
outpatient surgery

Gupta, et al.13

2003

Routine prophylactic
use of antiemetics on
incidence of PDNV
after ambulatory
surgery

32.6%

Kangas-Saarela,
et al.32

1999

Patients’ experiences of
outpatient surgery

6%

19

Reference

PDNV

PDN

PDV

Findings

33%

10%

Pain, nausea, vomiting serious and
persistent problems post discharge,
increasing in incidence after
discharge.

PDNV required for inclusion in study

Few patients contacted their HCP.
Significant number of pts believed
PDNV due to analgesics and therefore
did not self-administer analgesics.

9%

PDV and agitation was one of 3 main
causes for anxiety by parents

14.7%

Prophylactic treatment with
ondansetron 4mg or combination with
2 drugs produced significant decrease
in PDNV

Decreased incidence of PDN
probably due to high number of
patients in study who received
regional anesthesia.

Table 2.1 (Continued) Studies Addressing PDNV
Publication
Year

Study

PDNV

Kokinsky, et al.21

1999

Postoperative comfort
after pediatric outpatient
surgery

20%

Parlow, et al.15

1999

PDNV after ambulatory
laparoscopy is not
reduced by promethazine
prophylaxis

48%

Pfisterer, et al. 25

2001

An international study of
PONV in outpatient
surgery

21.4% (prophylactic antiemetic)
19.2% (no prophylactic antiemetic)

Tang, et al.36

1996

Comparison of
ondansetron and
droperidol for antiemetic
prophylaxis in outpatient
gynecological procedures

20

Reference

PDN

PDV

Findings
Incidence of PDNV significantly
higher in those patients given
intraoperative opioid (fentanyl)

68% (P)
57% (D)
41% (D2)
32% (O)

17%

52% (P)
27% (D)
15% (D2)
14% (O)

Patients requiring an antiemetic in
PACU are at higher risk for PDNV.
Prophylactic promethazine IM
before discharge did not reduce the
incidence of PDNV.
Some patients reported N/V up to 5
days after surgery. Inadequate
control of PDNV remains a problem.
Incidence of emesis and need for
rescue significantly lower with both
droperidol and ondansetron groups.

Table 2.1 (Continued) Studies Addressing PDNV
Reference
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Publication
Year

Study

Waterman, et
al.30

1999

Postoperative pain,
nausea, and vomiting—a
qualitative perspective

Watt-Watson, et
al. 23

2004

Pain management
following discharge after
outpatient surgery

Wright, et al 37

1999

Wu, et al. 12

2002

Efficacy of promethazine
suppositories for home
use after outpatient
surgery
Systematic review and
analysis of postdischarge
symptoms after outpatient
surgery

Young, et al 29

2000

Does enhanced discharge
instruction make a
difference after outpatient
surgery.

PDNV

PDN

PDV

Findings
One-third of the group (55) reported pain and
nausea worse than imagined.

14%

Patients stopped taking analgesics despite
considerable pain due to side effects of
constipation or nausea.

55%

Promethazine suppositories well tolerated; used
by 89% of patients with access. All patients who
used reported decrease in nausea.
0-55%

0-16%

Post discharge symptoms may be significant
factor in patient’s resumption of normal activities
patient recovery. Need further studies to
determine impact.

13-16% (Day 1)
7-9% (Day 4)

Majority of patients did not experience problems
with recovery at home. Patients needed carer
assistance for average of 3 days. The enhanced
teaching package
made no difference

CHAPTER THREE
EVIDENCE-BASED INTERVENTIONS FOR POST DISCHARGE NAUSEA AND
VOMITING: A REVIEW OF THE LITERATURE

ABSTRACT
Postoperative nausea and vomiting (PONV) and post discharge nausea and vomiting
(PDNV) continue to be a problem for one third of all patients who require surgery and anesthesia.
Very few studies have been reported that specifically target PDNV in the outpatient surgery
population for interventions after discharge home.

Twenty studies were identified that

specifically addressed the effect of an intervention for the purpose of preventing PDNV or
rescuing the patient who develops PDNV.

This article presents an integrative review of the

research literature to determine the best evidence for prevention of PDNV in adults or for the
rescue of patients who suffer from PDNV.

Introduction
Postoperative nausea and vomiting (PONV) continues to be a problem in the
postanesthesia setting for one third of all patients who require surgery and anesthesia.

1-5

The

incidence can be as high as 70-80% among patients with predetermined risk factors.6
Unfortunately, as many as 30% to 50% of outpatients will continue to struggle with post
discharge nausea and vomiting (PDNV) after arrival home.3,

7, 8

With over 60 to 65% of all

surgeries performed currently performed in the ambulatory surgery setting, thousands of patients
experience PDNV.9 PONV and PDNV are not conditions that typically contribute to mortality;
however, it has been called the “big, little problem”10 because of patient aversion to nausea and
vomiting, the effect on quality of recovery, the potential for morbidity and hospitalization in high
risk patients and loss of patient satisfaction.
Many investigators have focused on assessment of the patient risk for PONV.11, 12 In one
study, a risk assessment using only 4 or 5 factors was determined as effective as other tools that
predicted nausea and vomiting using up to 13 criteria.11 Other studies have focused on effects of
anesthetic agents or other medications on the incidence and severity of PONV. 13-14 Prophylactic
use of antiemetics has been considered, as well as the most effective timing of the administration
of those antiemetics.7,

16, 17

Historically, most studies were limited to inpatient populations,

although a few analyzed data for 24 hours after surgery. Some studies combine inpatient and
outpatient data for the first 24 hours post operative. While PONV has been well described and
30

interventions tested there is limited research on PDNV and interventions that could improve the
care of outpatient surgery patients after discharge. The purpose of this article is to present results
of an integrative review of the research literature to determine best evidence for prevention of
PDNV in adults or rescue of patients who suffer from PDNV.
Defining PDNV
A precise definition for PDNV has not been established. Researchers have called for the
post discharge period to be defined in a standardized manner.7 PDNV is clearly related to the
discharge of a patient after ambulatory surgery. But there have been questions as to whether
PDNV encompasses the first 24 hours after discharge or whether a patient who was nauseated or
had emesis during transport home had PONV or PDNV. The members of the multidisciplinary
PONV/PDNV Strategic Work Team, convened by the American Society of PeriAnesthesia
Nurses, distinguished PDNV from PONV for the purpose of the consensus guideline and for
future research. PONV was defined as nausea and/or vomiting that occurs within the first 24hour period following surgery in relation to inpatients.
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PDNV is “nausea and/or vomiting that

occurs after discharge from the health care facility following surgery.”18

The terminology

“delayed PDNV” is used for nausea and/or vomiting that occurs beyond the initial 24 hours after
surgery.
Researchers have posited that a patient history of PONV is predictive of PONV.
However, findings have shown mixed results. Carroll, et al.8 found that PDNV was not related to
PONV in a descriptive study of 211 outpatients. Conversely, Parlow and others,19 conducted an
interventional study and found that patients with PONV were found to be four times more likely
to experience PDNV than those who had not suffered PONV. While there is no definitive answer
yet, it is possible that the physiological mechanisms responsible for PONV are different from the
physiological disturbances responsible for PDNV.
Guidelines developed to this point for the prevention and care of patients with PONV
have focused on the preoperative and intraoperative period, while a few have targeted rescue
treatment in the PACU.3 One consensus conference was held in 2003 to develop guidelines for
PONV. These guidelines focused on prevention and rescue treatment in the immediate
postoperative area, but there were no recommendations for established nausea and vomiting after
discharge or new onset nausea and vomiting after discharge.20

Published algorithms and

guidelines have focused on prophylaxis and therapy,21 risk factors, prophylactic antiemetic
therapy and options for pharmacology.2 A decision tree for prophylaxis22 and an extensive
algorithm that begins with assessment of risk factors and continues through the immediate
31

postoperative period including suggestions for rescue have been presented.23

ASPAN’s newly

developed evidence-based guideline on prevention and management of PONV/PDNV is the first
to cover the entire period of the patient’s perioperative experience, including post discharge.18
Methods

Systematic Search
To perform the literature search for applicable articles, the authors searched MEDLINE
(Pubmed, from 1966) limited to research literature on adults.

The keywords used were

“postdischarge nausea and vomiting” (26 results), “post discharge nausea and vomiting (62
results) “postoperative nausea and vomiting” (1761 results), “complementary medicine” (85287
results), and “outpatient surgery” (6116 results).

“Outpatient surgery” and “complementary

medicine” were combined for a total of 58 articles, “ outpatient surgery” and “postoperative
nausea and vomiting” for a total of 255 articles and “complementary medicine” and
“postoperative nausea and vomiting” for a total of 73 articles. The Cochrane Controlled Trials
Register (2005, Issue 4) was also searched. CINAHL (from 1960) was searched though no
additional literature was identified. Abstracts were searched for suitable articles, and reference
lists were examined for additional sources.

The search resulted in 20 articles specific to

interventions for the purpose of preventing or dispelling nausea and vomiting after discharge
home.

Inclusion and Exclusion Criteria
Articles that were not interventional studies or systematic reviews of intervention studies
were excluded. Any articles reporting findings on the pediatric population (age < 19 y) were
excluded.

Studies reporting on PONV risk assessment, PONV prophylaxis or treatment of

immediate PONV were excluded as well as any studies that had mixed populations of inpatients
and outpatients. The review was restricted to studies published in the English. The included
studies described interventions specific to PDNV in the adult population after outpatient surgery.
(Table 3-1.)
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Analysis
Variables used by the authors in this analysis included sample description and size,
research design, objective or purpose of the study, methodology, time of data retrieval after
discharge, outcome measures, findings, and limitations. The strength of the evidence was rated as
suggested by ASPAN’s evidence-based practice (EBP) conceptual framework24 and Stetler, et
al.25 The level of evidence ranges from Level 1, a meta-analysis to Level VI, expert opinion. The
quality of each study is rated from A to D with A representing a well-designed study and D
representing a study with a major flaw or questions about scientific credibility.25 (Table 3-2.)

Results
The search identified two systematic reviews, 17 randomized controlled trials (RCTs),
and one non-experimental study with a convenience sample. All of the studies were published
between 1990 and 2004. All of the studies were published in medical journals; none in nursing
journals.

The two systematic reviews were rated as IA according to strength of reviewed

literature.25 The 17 RCTs were classified as IIA to IIC, with the one non-experimental study
classified as IIIB.
Four of the studies (20%) concerned anesthetic techniques, comparing some form of total
intravenous anesthesia (TIVA) to inhalation anesthesia. Ten studies (50%) compared various
antiemetics and one study (5%) compared analgesics and the effect on PDNV. Five studies
included non-pharmacological variables. One study (5%) compared therapeutic suggestions via
tape to a comparison tape, three studies (15%) looked at acupuncture or acustimulation, and one
study (5%) compared ginger to placebo. See Table 3-1 for a full list of studies.
Interestingly, none of the 17 RCTs included information on the recruitment of patients.
All authors assured that approval had been obtained from their facility IRBs and informed
consent was obtained, but no recruitment guidelines were included in any of the studies. None of
the studies included reliability or validity data on the instruments used to obtain information. In
some studies, it was unclear as to how the information was obtained from the patient, or by
whom. Only four studies included information on the data collectors after discharge. The
training of research assistants or other data collectors was not addressed.
On the other hand, power analysis was included in 12 of the 17 RCTs. The sample
population was described in detail in all studies with a clear and concise purpose stated in all
studies. Exclusion and or inclusion information was detailed.
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Pharmacological Interventions

Anesthetic Techniques
14

Paech, Lee, and Evans conducted an RCT of 144 outpatients who were divided into 3
groups: (1) inhalational anesthesia plus dolasetron, (2) total intravenous anesthesia (TIVA) plus
dolasetron. and (3) TIVA alone. Significantly more outpatients in the inhalational/dolasteron
group had postdischarge nausea (PDN) with the lowest incidence of PDN in the TIVA plus
dolasetron group. There was no significant difference among groups in regard to post discharge
vomiting (PDV).14 Visser and others,26in an RCT oof 563 outpatients, found significantly less
PONV in TIVA patients at 24 hours compared to patients who received inhalational anesthesia
with isoflurane and nitrous oxide. There was no significant difference at 14 days.
Carvalho and associates27 separated 99 outpatients undergoing laparoscopic sterilization
into two groups: one receiving TIVA with propofol and the other receiving inhalational
anesthesia with isoflurane. There were no significant differences with regard to PDNV between
the groups. Gupta and others15 conducted a systematic review to determine the effects of four
different anesthetic techniques on postoperative recovery and complications, including PDNV.
The incidence of PDNV was less frequent with intraoperative use of propofol compared to
isoflurane, but not when compared to desflurane or sevoflurane. The authors conclude their
review by stating that the specific anesthetic appears to play a minor role in outcome after
outpatient surgery.15

Antiemetics
7

Gupta and others completed a systematic review to determine whether the routine
prophylactic use of antiemetics affects the incidence of PDNV following outpatient surgery. The
review included only RCTs published in the English language. They found an overall beneficial
effect of using either combination treatment with two drugs or ondansetron alone for prevention
of PDNV. Dexamethasone prevented nausea, but not vomiting after discharge. No differences
between placebo and treatment groups were found when droperidol or meoclopramide were used
as the antiemetic. Numbers-needed-to-treat (the number of patients who would need to be treated
for PDNV to prevent one adverse outcome) favored the use of combination therapy for
prophylaxis of PDNV, especially in high-risk patients.7
Coloma and others17 investigated the antiemetic effect of dexamethasone (4 mg) as an
adjunct to a 5-HT3 antagonist. All patients who had undergone laparoscopic cholecystectomies
received dolasetron 12.5 mg. The control group received saline and the treatment group received
dexamethasone 4 mg IV. The dexamethasone group had significantly less nausea at home.
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Rothenberg and others28 compared the incidence of PDNV after dexamethasone versus droperidol
following laparoscopic gynecologic outpatient surgery. They found significantly less PDNV in
patients who received dexamethasone even though there were no significant differences in early
PONV before discharge. The authors conclude that dexamethasone is as efficacious as droperidol
and may have a longer duration of action.
Tang, Watcha, and White16 compared the efficacy, safety, and cost-effectiveness of
ondansetron 4 mg with 2 differing doses of droperidol (0.625 mg and 1.25 mg) in the prevention
of PONV and a placebo group. They found that PDV was significantly decreased in groups
receving droperidol of either amount and ondansetron versus placebo. In regard to PDN, the only
significant difference was between ondansetron and the placebo. Their conclusion was that the
lower dose of droperidol provided the same antiemetic relief as ondandsetron 4 mg and was more
cost-effective.16
Gan, Franiak, and Reeves29 compared ondansetron orally disintegrating tablet (ODT)
with placebo to determine if administration of ondansetron ODT (8 mg) would result in decreased
PDNV. All patients received ondansetron 4mg IV prior to induction. The treatment group
received ondansetron ODT immediately before discharge and were given a second tablet to take
12 hours later. The investigators found that the patients in the treatment group had significantly
less severe nausea and fewer vomiting episodes after discharge. There was also a significant
difference in patient satisfaction scores between groups.29 Thagaard and others30 compared
ondansetron ODT 8 mg twice daily for three days to placebo. There was no significant difference
in groups, so the authors concluded that use of ondansetron ODT did not decrease PDNV in
outpatients undergoing laparoscopic surgery.
Rajeeva and others31 compared an ondansetron/dexamethasone combination to
ondansetron alone for prevention of PONV.

The medications were given intravenously

immediately after intubation. At 24 hours, there was significantly less PDNV in the combination
group. The authors concluded that PDNV was better controlled with the combination group than
early PONV, where there was no significant difference between the two groups.
Bailey and others32 evaluated the effect of transdermal scopolamine on the incidence of
PDNV. After surgery, there was overall significantly less nausea, retching and vomiting in the
scopolamine-treated group.

However, after discharge, only 10 of 138 patients experienced

nausea, vomiting, or retching with no significance between groups.
Parlow and others19 assessed the efficacy of administering promethazine prophylactically
prior to discharge home from the healthcare facility. All patients received 0.5 mg droperidol
during surgery and were then randomized to receive 0.6 mg/kg promethazine or a placebo
35

intramuscularly prior to transfer from PACU. There was no significant difference between
treatment and placebo groups; however the incidence of drowsiness was higher in those receiving
the promethazine on arrival home and bedtime. Promethazine did not change the incidence of
PDNV in this study.19 In a non-experimental study, Wright, Jilka, and Gentry33 assessed the
usage of promethazine and evaluated the efficacy in ameliorating PDNV. All outpatients during
a year who had excessive PONV and were at risk for PDNV were sent home with two
promethazine suppositories. Fifty five percent of the patients in this groups experienced PDN,
and of that group, 89% used the suppositories. All of those patients reported improvement in
symptoms with no reported side effects. The authors concluded that promethazine suppositories
were effective in treating PDNV and were well tolerated.33

Pain Medication
34

Claxton and others compared the analgesic efficacy and incidence of side effects of
intravenous morphine and fentanyl for pain after ambulatory procedures. Fifty-eight patients
were randomized into either a morphine or fentanyl group for postoperative analgesia in the
PACU. There was no significant difference between groups in the PACU, but there was a
significantly higher incidence of PDNV in the morphine group at 24 hours.34

Non-Pharmacological Interventions

Therapeutic Suggestions
Lebovits, Twersky, and McEwan35 compared two groups of outpatients, one group who
listened to a therapeutic tape (TT) during surgery and the other group who listened to a
comparison tape to determine if the TT resulted in improved recovery for the surgical outpatients.
They found a significant difference between groups during the first 90 minutes, but no significant
difference in PDNV at 2,4, or 24 hours. The TT group did experience fewer overall side effects.

Acupuncture/Acustimulation
Al-Sadi, Newman, and Julious36 assessed the efficacy of acupuncture as a prophylactic
antiemetic.

Eighty-one outpatients were randomized to two groups: a treatment group that

received acupuncture intraoperatively at the PC6 point, and a group that received placebo. They
found a significant difference between groups before and after discharge with the placebo group
four times more likely to have PDNV than the acupuncture group.
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Coloma and others37 compared acustimulation to ondansetron for the treatment of
established PONV in outpatient laparoscopic surgery patients. All patients received prophylaxis
with either droperidol 0.625 mg IV or metoclopramide 10 mg IV. Ninety of 268 enrolled patients
developed PONV and were randomized to one of three treatment groups: ondansetron 4 mg IV
and sham acustimulation, acustimulation and 2 ml of IV saline, or a combination of ondansetron
4 mg IV and acustimulation. The combination group of ondansetron and acustimulation had a
higher complete response rate (no emesis or complaints of nausea) than the acustimulation group
within two hours. Fewer patients in the combination group versus the acustimulation group
experienced further emetic events. There were no other significant differences among the three
groups. The authors conclude that acustimulation may be a satisfactory alternative to ondansetron
for established PONV, and that ondansetron seems to enhance the efficacy of acustimulation for
treatment of established PONV.37
White and others38 compared the efficacy of acustimulation to ondansetron when used
alone or in combination. The 120 outpatients were divided into 3 treatment groups: ondansetron
and sham acustimulation, acustimulation and saline, and a combination of ondansetron and
acustimulation. They found that acustimulation in combination with ondansetron significantly
reduced PDN and PDV and the need for rescue antiemetics compared to ondansetron alone at 24
hours post discharge. There were no significant differences between the acustimulation and
ondansetron groups. At 72 hours the only significant difference was satisfaction with antiemetic
treatment

The authors concluded that acustimulation with ReliefBand® appeared to be an

effective alternative to ondansetron for prevention of PDNV in the plastic surgery patient.

Ginger
39

Pongrojpaw and Chiamchanya

conducted a study of 80 outpatients to determine the

efficacy of ginger in prevention of PONV after discharge. The treatment group received two
capsules of ginger (0.5 mg ginger powder each) one hour before the procedure. The control group
received placebo tablets. They found significantly less nausea at two and four hours, but no
significant difference at 24 hours. There was no significant difference in PDV at any time during
the study.

The authors concluded that ginger significantly reduced postoperative nausea

compared to the placebo in outpatient laparoscopic gynecology procedures. However the group
taking ginger experienced no significant difference in PDN or PDV than placebo.39
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Discussion

Pharmacological Interventions
Three RCTs and one systematic review determined whether TIVA or inhalational
anesthesia was more closely related to PDNV. The results of one study determined that there was
significantly more nausea with the isoflurane plus dolasetron group compared to other
inhalational agents and TIVA.14 There was no significant difference among groups in regard to
PDV. One study found significantly less PONV in the TIVA group at 24 hours, but no difference
in PDNV at 72 hours and 14 days.26 The third RCT found no significant difference between
groups anesthetized either with TIVA or isoflurane at seven days post discharge.27 Results of a
systematic review showed that the incidence of PDNV was less frequent with propofol than with
isoflurane, but not compared to desflurane or sevoflurane.15

Based on Stetler et al.25 and

ASPAN’s EBP conceptual framework,24 the studies ranked from IA to IIB. See Tables 3-1 and 32.
The evidence supports the use of isoflurane as an influencing factor in early PONV, but
not PDNV. The evidence also points to TIVA as decreasing early PONV, but not an influence on
PDNV. This evidence is supported by Apfel and others40 who concluded that volatile anesthetics
are the main cause of early PONV, but have no impact on delayed PONV (2-24 hours).
The overall evidence concerning antiemetics as prophylaxis or treatment for PDNV is
sparse. One systematic review that summarized whether routine prophylaxis with antiemetics
had an effect on PDNV was found. Nine studies compared antiemetics with other antiemetic
treatments or placebo. Strong evidence exists to support prophylaxis with antiemetics versus
placebo, a beneficial effect of combination treatment as well as a beneficial effect of
dexamethasone for prevention of PDN.7,

17, 31

There was mixed evidence as to the effect of

ondansetron orally disintegrating tablets (ODT) to decrease PDNV, although there is evidence
ondansetron does have a beneficial effect on PDNV.7,

16, 29-31, 37, 38

There is evidence that

droperidol is not an effective prophylaxis for the post discharge population.7, 16, 28 The evidence
in these studies varied from IA to IIC and is sufficient to recommend prophylaxis in the post
discharge population.
There is some evidence that transdermal scopolamine reduces PDNV (IIB).32

This

evidence is supported by a systematic review of efficacy and safety of transdermal scopolamine
for prevention of PONV.41 Even though the review did not differentiate PDNV from PONV, the
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conclusion was that transdermal scopolamine significantly reduces the risk of postoperative
vomiting although associated with some side effects such as visual disturbances or dry mouth.41
There is evidence (IIB) that promethazine given IM prior to discharge home does not
decrease the incidence of PDNV, but does increase the incidence of drowsiness.19 There is some
evidence (IIIB) from a non-experimental study that promethazine suppositories did improve the
symptoms of PDNV.33
One study addressed the preferential use of an opioid on the incidence of PDNV. There
is some evidence (IIB) to indicate that even though morphine was associated with a better level of
analgesia, it was also associated with an increased incidence of PDNV.343

Non-Pharmacological Interventions
Based on the available evidence, it appears that therapeutic suggestions in outpatients do
not decrease the incidence of PDNV (IIC).35 Although there was a significant difference over the
first 90 minutes, the treatment group did not experience a difference in PDNV over later
assessment periods. This evidence is supported by a study conducted by Jelicic, Bonke, and
Millar42 to determine the effect of different therapeutic suggestions on postoperative recovery
well-being. The results of that study demonstrated no significant differences on well-being the
third and fifth day.
There is evidence (IIB) to support the use of acupuncture in the prevention of PDNV.
Patients in the placebo group were four times as likely to experience PDNV as those in the
treatment group.36 There is also evidence to support the use of acustimulation for the prevention
of or treatment for PDNV.

Acustimulation in combination with ondansetron had a higher

complete response rate than acustimulation alone (IIC).37 In another study, acustimulation in
combination with ondansetron significantly reduced PDNV and the need for rescue antiemetics
compared with ondansetron alone at 24 hours after surgery (IIB).38
Ginger is a botanical remedy used in China to alleviate nausea and vomiting that has also
been suggested as beneficial to PONV. The recommended dose is 1 g of powdered ginger given
before surgery.43

There is no evidence supporting the use of ginger for PDNV (IIB). This

evidence is supported by a study conducted primarily on inpatients that showed no significant
benefit of ginger for PONV.44
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Limitations
The limited number of studies evaluated in each category limits the conclusions of the
review. On the other hand, only studies that specifically addressed the post discharge period of
the perioperative period were included. No previous reviews have addressed interventional
studies to determine evidence for treatment of the postdischarge patient.

Recommendations
There is a dearth of research that specifically targets and directly affects the patient after
discharge home. More studies should be conducted focusing on interventions for PDNV in the
outpatient after discharge. Research addressing those interventions that can best prevent or
alleviate symptoms of PDNV need to be conducted. Researchers need to determine if risk factors
for PONV are the same for PDNV.
There was a total lack of nursing research in this review; all studies were conducted by
physicians.

Nurse researchers could conduct studies on the effects of patient education or

education of the responsible adult, preoperative anxiety, interactions of pain and pain medication,
and non-pharmacologic methods of relief. Nurse researchers could collaborate with physician
researchers to determine the best antiemetics for use in the postdischarge setting or the most
appropriate medication for pain relief in the postdischarge setting that will alleviate pain, but
cause less symptoms of PDNV.
Other research indications include the most effective risk identification tools in prediction
of PDNV, reliable and valid tools to measure PDNV, most effective prophylactic interventions to
prevent or relieve PDNV, identification of common self-care activities used by patients and
effectiveness, most effective patient educational content, the impact of PDNV on patient
satisfaction and quality of life, and the economic impact.18
Finally, the terminology needs to be standardized in future research on this population.
Until the terminology is standardized by all researchers, confusion will still exist. Use of the
definitions as identified by ASPAN’s multidisciplinary strategic work team18 will begin to
alleviate the confusion surrounding the operational definition of each term.
Conclusion
Thousands of patients continue to experience PDNV every year. In spite of newer
anesthetic medications and a focus in the past few years on PONV and PDNV, a significant
percentage of patients still suffer. This review attempted to consolidate the findings from research
that has been conducted specifically for the patient experiencing PDNV.

It is certain that

prophylactic antiemetics and combination medications work significantly better than placebo to
40

curtail the symptoms post discharge. It is unlikely that the type of anesthetic administered has
any effect on PDNV. It appears that acupuncture and acustimulation may work, but others, such
as use of ginger and therapeutic suggestions may not work as effectively. More research needs to
be conducted to discover the interventions that allow patients to recover to their pre-surgery
conditions at a quality and rate of recovery that is satisfactory to the patient and to the health care
provider.

Copyright © Jan Odom Forren 2009
41

Table 3.1 Interventional Studies in Adults for PDNV in the Discharge Setting
Study

Population

Design

Objective

Method & Tools

Duration

Outcome
Measures

Findings

AlSadi, et
al.,
199736

81
outpatients
undergoing
gynecological
laparoscopic
surgery

Double
blind
RCT

To assess the
efficacy of
acupuncture
as a
prophylactic
antiemetic

2 treatment
groups:
acupuncture and
control

24 hr

PDNV

Significant difference
between groups before
and after discharge;
placebo group 4 times
more likely to have
PDNV than acupuncture
group

199
outpatient
laparoscopy
patients
enrolled; 53
excluded due
to breach in
study
protocol

RCT:
Double
blind,
placebo
controled
Study

To evaluate
the effect of
transdermal
scopolamine
on the
incidence of
PON,
retching, and
vomiting

Band-aid-like
patch containing
either
scopolamine or
placebo was
placed behind
the ear the night
before surgery.

Bailey
et al,
199032

48 hr

PDNV and
retching

42

Overall significantly less
nausea, retching, and
vomiting in the
scopolamine-treated
group. Only 10 patients
experienced nausea,
vomiting, retching at
home with no
significance between
groups. Safe and
effective antiemetic

Limitations/
Quality of
Evidence
Severity of
PDNV was not
measured
IIB

Only 10 patients
had PDNV
IIB

Table 3.1 (Continued) Interventional Studies in Adults for PDNV in the Discharge Setting
Study

Population

Carvalho, 99
et al.,
outpatients
200227
undergoing
laparoscopic
sterilization

43
Claxton,
et al.,
199734

58
outpatients
undergoing
surgery
anticipated
to be
painful

Design

Objective

Method &
Tools

Duration

Outcome
Measures

Findings

RCT: semiopen
(attending
anesthesia
provider
aware of
allocated
treatment, but
neither
patient,
research
nurse, nor
recovery staff
were aware)
RCT:
prospective,
double blind

To evaluate the
influence of
anesthetic
technique on
functional
recovery and
symptom
distress

2 groups:
received
either total
intravenous
anesthesia
with propofol
or isoflurane
inhalational
anesthesia

7 day

Functional
recovery
and
symptom
distress
including
PDNV

No significant
differences
between the
groups

To compare the
use of IV
morphine and
fentanyl after
ambulatory
procedures
with respect to
analgesic
efficacy and
incidence of
side effects

2 groups:
received
either
morphine or
fentanyl IV
for
postoperative
analgesia
during PACU
stay

24 hr

Limitations/
Quality of
Evidence
Study was
underpowered to
detect differences
in regard to
nausea and
vomiting
IIB

Side effects
including
PDNV

Even though
PONV not
significantly
different between
groups in PACU,
there was a
significantly
higher incidence
of PDNV in the
morphine group at
24 hours.

Small groups
IIB

Table 3.1 (Continued) Interventional Studies in Adults for PDNV in the Discharge Setting
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Study

Population

Design

Objective

Method & Tools

Duration

Outcome
Measures

Findings

Coloma
et al,
200237

Enrolled
268
outpatients
receiving
laparoscopic
surgery; 83
of 90
patients with
established
PONV
studied

RCT:
Doubleblind,
placebo
and shamcontrolled
study

To evaluate
acustimulation
compared
with
ondansetron
for
treatment of
established
postoperative N/V of
outpatient
laparoscopic
surgery
patients

All patients
received
prophylaxis with
either droperidol
0.625 mg IV or
metoclopramide 10
mg IV. 90 patients
developed PONV
and were
randomized to 1 of
3 treatment groups:
ondansetron 4mg
IV and sham
ReliefBand®;
ReliefBand® and 2
ml IV saline; or
combination of
4mg IV
ondansetron and
ReliefBand®.
Requested to keep
ReliefBand® on
arms for 72 hours
except when
bathing.

24 and
72 hr

PDNV as
well as
other
effects,
such as
patient
satisfaction
and quality
of recovery

Combination group
had significantly
higher complete
response rate than
acustimulation group
(73% vs 40%; P <
.01) within 2 hours.
Fewer patients in
combination group vs
acustimulation had
further emetic events
( P < .03). No other
significant
differences between 3
groups. Ondansetron
in combination with
acustimulation
improved complete
response rate to
acustimulation
therapy.

Limitations/
Quality of
Evidence
Effect of
acustimulation
may have been
increased if
applied before
surgery instead
of after
established
PONV.
Relatively
small group
sizes
(N = 30).
IIC

Table 3.1 (Continued) Interventional Studies in Adults for PDNV in the Discharge Setting
Study
Population
Design
Objective
Method & Tools
Duration Outcome
Measures
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Coloma,
et al.,
200217

140
outpatients
undergoing
laparoscopic
cholecystectomy

RCT:
placebocontrolled,
doubleblind

Gan et
al.,
200229

60
outpatient
laparoscopic
gyn patients

RCT:
Randomly
assigned
to groups.
Research
personnel
collecting
data were
blinded

To
investigate
the effect of
administering
4 mg IV
dexamethasone as
adjunct to a
5-HT3
antagonist
To determine
if administration of
ondansetron
ODT would
result in
decreased
PDNV

24 hr
2 groups: control
group received 1
ml IV saline,
dexamethasone
group received 4
mg IV
dexamethasone.
All patients
received 12.5 mg
dolasetron
2 hr and
All patients
24 hr
received
ondandsetron 4
mg IV at
induction.
Treatment group
received
ondansetron ODT
immediately
before discharge
and given second
tablet to take 12
hours later; control
group received
placebo tablets.
Nausea scored
using 11-point
linear numerical
scale from 0 – 10.

Findings

Post
discharge
side effects

Dexamethasone
group had
significantly less
nausea at home.

PDNV:
incidence,
severity of
nausea, side
effects,
satisfaction

Ondansetron ODT
patients had
significantly less
severe nausea and
fewer vomiting
episodes after
discharge.
PDV: ondansetron
ODT 3%; Placebo
23%. P <.05
Severity of nausea:
ondansetron ODT 0
(0-10), placebo 2
(0-10). P < .05.
Patient satisfaction:
ondansetron ODT
90%, Placebo 65%; P
< .05.

Limitations/
Quality of
Evidence
IIB

Small groups.
IIC

Table 3.1 (Continued) Interventional Studies in Adults for PDNV in the Discharge Setting
Population

Design

Objective

Method &
Tools

Gupta,
et al.,
20037

22 articles

Systematic
review of
RCTs

To assess whether
routine
prophylactic use of
antiemetics
influences
incidence of PDNV

Gupta,
et al.,
200415

58 articles

Systematic
review

To assess whether
use of propofol
infusion,
isoflurane,
sevoflurane, or
desflurane is
associated with
faster recovery and
fewer side effects
during ambulatory
surgery in adults

Duration

Outcome
Measures

Findings

MEDLINE
via PubMed

PDN,
PDV

Incidence of PDN
(32.6%) & PDV (14.7%)
in placebo vs treatment
groups significantly
different (P < .05).
Beneficial effect of
combination treatment or
ondansetron 4 mg for
prevention of PDNV;
beneficial effect of
dexamethasone which
prevented PDN, but not
PDV; droperidol not
effective as prophylactic
for PDN

MEDLINE
via PubMed,
hand search
through
references

PDNV as
subset of
side
effects

IA
The incidence of PDNV
was less frequent with
propofol compared to
isoflurane but not
compared to desflurane or
sevoflurane. Specific
anesthetic appears to play
minor role in outcome.
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Study

Limitations/
Quality of
Evidence
IA

Table 3.1 (Continued) Interventional Studies in Adults for PDNV in the Discharge Setting
Study

Population

Design

Objective

Method &
Tools

Duration

Outcome
Measures

Findings

Lebovits,

70 adults
undergoing
elective
outpatient
hernia repair
under
general
anesthesia

RCT:
Double
blind

Pain,
nausea,
vomiting

Significant difference
between groups during
first 90 minutes, but
no significant
difference in PDNV at
2, 4, or 24 hours. TT
group did experience
fewer side effects.

RCT:
Prospective
double
blind

2 groups:
therapeutic
tape group
(TT) and
comparison
tape group.
Played
continuously
during
surgery.
3 groups:
Inhalational +
dolasetron
(I+D); TIVA
+ dolasetron
(T+D); TIVA
alone (T)

24 hr

144
outpatients
receiving
laparoscopic
gynecology
surgery

To determine if
patients receiving
intraoperative
therapeutic
suggestions
would result in
improved
recovery in
surgical
outpatients
To compare the
incidence of
PONV using
TIVA with or
without
dolasetron with
balanced
inhalational
anesthesia using
sevoflurane and
dolasetron

24 hr and
4th day

PDN,
PDV

Significantly more
nausea in I+D, no
significant difference
of PDV between
groups

et al.,
199935
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Paech,
et al.,
200214

Limitations/
Quality of
Evidence
IIC

IIB

Table 3.1 (Continued) Interventional Studies in Adults for PDNV in the Discharge Setting
Population

Design

Objective

Method & Tools

Duration

Outcome
Measures

Findings

Parlow et al,
199919

95 women
who
received
ambulatory
laparoscopic
cholecystectomy or
gynecologic
surgery

RCT:
Double
blind,
placebo
controlled
study

To determine
the incidence of
PDNV after
outpatient
laparoscopic
procedures and
assess the
efficacy of the
prophylactic
administration
of promethazine
prior to
discharge from
hospital

24 hr

PDNV

PDN = 48%
(moderate to
severe = 30%)
PDV = 17%
Rescue antiemetic use 28%
No statistical
difference
between groups
regarding PDNV.
Incidence of
excessive
drowsiness higher
in those receiving
promethazine or
arrival home (P =
.001) and bedtime
(P < .001)

Pongrojpaw,
et al., 200339

80
outpatient
gynecological
laparoscopy
patients

RCT:
Double
blind

To study the
efficacy of
ginger in
prevention of
PONV/PDNV

All patients
received
prophylactic 0.5
mg droperidol
during surgery.
Randomized to
receive 0.6
mg/kg -1
promethazine or
placebo IM
before transfer
from PACU.
Incidence and
severity of
nausea, pain,
drowsiness
documented
using patient
diaries at 4
intervals using
4-point scales.
2 treatment
groups: 2
capsules of
ginger 1 hr
before
procedure and
placebo

2, 4, 24
hr

PONV/
PDNV

Significantly less
nausea at 2 and 4
hours, but no
significant
difference at 24
hrs; no significant
difference in PDV.
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Study

Limitations/
Quality of
Evidence
IIB

IIC

Table 3.1 (Continued) Interventional Studies in Adults for PDNV in the Discharge Setting
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Study

Population

Design

Objective

Method & Tools

Duration

Outcome
Measures

Findings

Rajeeva, et
al., 199931

51 female
outpatients
receiving
diagnostic
laparoscopic
gynecologic
al surgery

RCT:
Double
blind

To compare the
efficacy of
ondansetrondexamethasone
with ondansetron
alone for
prevention of
PONV

24 hr

PONV/
PDNV

Significantly
less PDNV in
combination
group
(ondansetrondexamethasone)

95
outpatient
undergoing
laparoscopic
gynecology
procedures

RCT:
Double
blind

2 treatment
groups:
ondansetrondexamethasone
or ondansetron
alone. Drugs
given IV
immediately after
intubation
2 groups:
dexamethasone
0.17 mg/kg IV or
droperidol 0.02
mg/kg IV just
before abdominal
incision.

Rothenberg
, et al.,
199828

To compare the
incidence of
PONV after
dexamethasone
versus droperidol
following
laparoscopic
gynecologic
outpatient surgery

24 hr

PONV/
PDNV

Significantly
less PDNV in
patients who
received
dexamethasone.
No difference in
early PONV
before
discharge.

Limitations/
Quality of
Evidence
Small group
size
IIC

IIC

Table 3.1 (Continued) Interventional Studies in Adults for PDNV in the Discharge Setting
Study
Population
Design
Objective
Method & Tools Duration
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Outcome
Measures

Findings

PDV significantly
less in groups
receiving
droperidol of
either amount and
ondansetron
versus placebo.
PDN only
significantly
different between
ondansetron and
placebo.
No significant
differences
between groups on
nausea, vomiting,
or other side
effects

Tang, et
al.,
199616

161 elective
outpatients
undergoing
gynecologic
procedures

RCT:
Prospective
, doubleblind,
placebocontrolled

To compare the
efficacy, safety,
and costeffectiveness of
ondansetron 4mg
with 2 doses of
droperidol (0.625
mg and 1.25 mg) in
prevention of
PONV

4 treatment
groups: saline
placebo,
droperidol 0.625
mg, droperidol
1.25 mg, or
ondansetron
4mg given
immediately
before induction

24 hr; 7
days

PDN,
PDV

Thagaard
, et al.,
200330

96 outpatients
requiring
elective
laparoscopic
surgery

RCT:
Double
blind

PDNV

563 outpatients
(and 1447
inpatients)
requiring
elective surgery
with general
anesthesia)

RCT: all
personnel
except
anesthesia
blinded to
group

2 groups:
placebo and
treatment,
received 6
tablets with one
tablet taken
twice a day until
box was empty
2 treatment
groups: TIVA
with propofol,
inhalational
anesthesia with
isoflurane/
nitrous oxide

24 and
72 hr

Visser, et
al.,
200126

To compare
ondansetron ODT
with placebo during
first 72 hours after
ambulatory surgery
focusing on PONV
and other side
effects
To assess the
incidence of PONV
after TIVA with
propofol versus
inhalational
anesthesia with
isoflurane/nitrous
oxide

24, 72 hr,
14 d

PONV,
PDNV

Significantly less
PONV in TIVA
group at 24 hr. No
difference at 72 hr
and 14 d.

Limitations/
Quality of
Evidence
IIA

IIB

IIA
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Study

Population

Design

Objective

Method &
Tools

Duration

Outcome
Measures

Findings

White
et al.,
200238

120
outpatients
undergoing
plastic
surgery

RCT:
Doubleblind,
placeboand shamcontrolled
study

To compare
the efficacy of
acustimulation
to ondansetron
when used
alone or in
combination

All patients
received low
dose droperidol
prophylaxis.
Groups were:
ondansetron 4
mg IV and
sham
ReliefBand®;
acustimulation
and 2ml saline
IV;
combination
with 4 mg
ondansetron IV
and active
ReliefBand®.
IV medications
were given in
the PACU. All
groups request
to wear
ReliefBand®
for 72 hours
except when
bathing.

24 hr and
72 hr

PDNV,
quality of
recovery
score,
patient
satisfaction,
need for
rescue
antiemetics,
ability to
resume
normal diet
within 24
hours

Acustimuation using
ReliefBand® in
combination with
ondansetron significantly
reduced PDN and PDV,
and need for rescue
antiemetics compared with
ondansetron alone at 24 hr
after surgery. No
significant differences
between the acustimulation
and ondansetron groups.
At 24 hr:
combination group 20%
with PDN and 0% with
PDV; Acustimulation PDN
35%; PDV 10%;
ondansetron group PDN
50%, PDV 20%. PDN,
PDV and need for rescue
antiemetic medication were
significantly reduced in the
combination (vs
ondansetron) group
(P
< .05). At 72 hr only
significant difference was
satisfaction with antiemetic
(P < .05.)

Limitations/
Quality of
Evidence
IIB

Table 3.1 (Continued) Interventional Studies in Adults for PDNV in the Discharge Setting
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Study

Population

Design

Objective

Method &
Tools

Duration

Outcome
Measures

Findings

Wright
et al.,
199933

99 adult OP
discharged OP
surgery with
promethazine
suppositories
(80 GA, 18
MAC, 1
spinal)

Nonexperimental
study

To assess the
usage of 52
romethazine
and evaluate
the efficacy
in
ameliorating
nausea &
vomiting in
adult OP
following
discharge

All patients
who had
excessive
PONV& at
risk for
PDNV sent
home with
two
promethazine
suppositories

24 hr

PDNV
Choice of
responses to
supp use: no
improvement,
great
improvement,
worsening of
symptoms

PDN = 55%
(N = 54);
PDV = 15%
(N = 15);
89% of PDN used
suppositories
(N = 48). All
reported
improvement.
There were no
reported side
effects.
Promethazine
suppository was
effective in
treating PDNV.
Well tolerated.

Limitation
/Quality of
Evidence
Study design was
non-experimental
IIIB

Abbreviations: GA, general anesthesia; MAC, monitored anesthesia care; N/V, nausea/vomiting; ODT, orally disintegrating tablet; OP –
outpatient; RCT, randomized controlled trial; TIVA, total intravenous anesthesia.
ODT – orally disintegrating tablet

Table 3.2 Rating Study Design and Quality of Evidence
Level I
Level II
Level III
Level IV
Level V
Level VI

Meta-analysis/Systematic review
Experimental
Quasi-experimental
Non-experimental or qualitative
Case reports
Expert opinion

Quality Rating
A
B
C
D

Well-designed study with up to one issue unaddressed
Well-designed study with two issues unaddressed
Design of study fair, with two – three issues unaddressed
Design of study has major flaw

Quality Indicators
 Power analysis
 Recruitment of patients detailed
 Hypothesis/objective of study
 Randomization issues
 Blind assessment issues
 Drop-outs/attrition rates addressed
 Exclusion/inclusion information
 Data collection methodology
 Appropriate statistical analyses
 Instruments addressed
 Factor analysis/dimensions on instruments, if appropriate
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CHAPTER FOUR
MEASUREMENT OF NAUSEA AND VOMITING FOR PATIENTS WITH POST
DISCHARGE NAUSEA AND VOMITING: A CRITICAL REVIEW AND ANALYSIS
ABSTRACT
Both postoperative nausea and vomiting (PONV) and post discharge nausea and vomiting
(PDNV) continue to affect over 30% of patients after surgery. There is a lack of standardized
definitions and instruments that measure PONV and PDNV, and a reliance on instruments
developed by the individual investigator. This article presents a critical review and analysis of
measurement of patient nausea and vomiting after discharge from outpatient surgery and
discusses relevant needs and new directions in the area of measurement.

Introduction
Despite newer anesthetic agents and antiemetic drugs, post surgery patients continue to
experience nausea and vomiting at a rate of over 30%.1-3 Postoperative nausea and vomiting
(PONV), nausea and vomiting immediately after surgery, has been studied in more detail than
nausea and vomiting after discharge home from an outpatient setting.4 In a recent study of six
interventions designed to prevent PONV, the average incidence was 34%.5 Some patient or
anesthesia-related factors, (i.e. female gender, nonsmoking status, postoperative opioids, history
of PONV, elevate the risk of PONV for patients to 70-80%).6
Today more than 34 million patients undergo ambulatory surgery annually in the United
States and over one third will experience post discharge nausea and vomiting (PDNV).7

2, 4, 8-10

The need for research into this growing population of patients has intensified. With that research
comes the necessity for reliable and valid instruments to study the phenomena surrounding the
experience of PDNV.

The purpose of this paper is to present a critical review and analysis of

measurement of nausea and vomiting after discharge from outpatient surgery.

Defining PDNV
Post discharge nausea and vomiting (PDNV) is not well defined in studies that measure
nausea and vomiting. The terms PONV and PDNV are frequently used interchangeably with
some investigators using PONV as nausea and vomiting immediately after surgery and others
using the term to denote nausea and vomiting after discharge home. In some instances, any
nausea and vomiting experienced from the moment the patient leaves the ambulatory surgery
center or hospital is defined as PDNV. In other instances, PDNV is defined as any nausea and
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vomiting that occurs more than 24 hours after the patient is discharged. In some studies, PDNV
has been measured over a 24 hour period and in other studies, where the phenomena is considered
to be PDNV, PDNV has been measured for 5 – 7 days.
Knapp and Beecher in 1953 defined nausea as a subjective sensation; the desire to vomit
without the expulsive muscular movements.11 The authors also noted that vomiting produced
stomach contents as a result of the expulsive efforts of the patients and retching did not.11
Definitions of nausea and vomiting as well as retching have remained similar to definitions
offered by Rhodes12 who defined nausea as a subjective, unobservable experience of an
unpleasant sensation experienced in the back of the throat that may or may not end in vomiting.
She further defined vomiting as the forceful ejection of the contents of the stomach, duodenum, or
jejunum through the mouth, and retching as an attempt to vomit, otherwise known as dry heaves.
The terms vomit or emesis are used interchangeably to describe the forceful ejection of contents
through the mouth in medical literature.

Retching and dry heaves are occasionally used

interchangeably.
Twenty years ago, Olver, et al.13 stated the “clear need for standardization of definitions”
in antiemetic studies and went on to declare that one of the greatest needs was the adaptation of
standards of measurement with nausea and vomiting. Researchers have specifically called for a
standardized definition of PDNV.10 The members of a multidisciplinary PONV/PDNV Strategic
Work Team convened by the American Society of PeriAnesthesia Nurses differentiated PONV
from PDNV for the purpose of the consensus guideline they were charged to develop and, further,
to aid in future research.8 This group defined PONV as nausea and/or vomiting that occurs to
patients after inpatient surgery. Post discharge nausea and vomiting is defined as nausea and/or
vomiting that occurs after discharge from the health care facility following outpatient surgery.
PONV and PDNV are further delineated as early, late, or delayed PONV or delayed PDNV. See
Figure 1 and Figure 2. The ASPAN guideline contained the first published definition of PDNV
that addressed standardization for research.3, 8
Measurement of PDNV
Research using measurement of nausea and vomiting began in the patient population
receiving chemotherapy. The instruments used now in PONV or PDNV began as instruments to
measure nausea and vomiting after treatment for cancer and then were refined for use with
surgery patients and pregnant women. Measurement of PONV and PDNV has been conducted
for the most part through the use of investigator-developed instruments.

Most commonly,

patients are asked to rate nausea on a subjective visual analog scale (VAS), numerical rating score
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(NRS), or verbal rating scale (VRS). Emesis has been measured in most studies by reporting the
number of episodes.

Rhodes noted the lack of information on reliability and validity of

instruments used to measure nausea and vomiting. Her concern was that the results of studies
may not be valid if the instrument used to measure nausea and vomiting is not an accurate
measure.12
Method
To perform the literature search for appropriate articles that measured nausea and
vomiting after discharge in the outpatient surgery patient, the author searched MEDLINE
(PubMed from 1966-2009) using the keywords “postdischarge nausea and vomiting” (37 results),
“post discharge nausea and vomiting” (95 results), “ambulatory surgery-index of nausea,
vomiting, and retching,” (0 results), Morrow assessment of nausea and emesis (MANE; 15
results) and “functional living index emesis” (45 results). A search through CINAHL did not add
further articles. The author then searched the abstracts for suitable articles. The author also
examined reference lists in those articles for additional sources. The result was 28 articles that
specifically mention nausea and vomiting after discharge home.
Only articles that were descriptive or interventional studies of PDNV were included.
Any articles findings, in which were reported on the pediatric population (age <19 years) were
excluded. The review was restricted to studies published in English.
Results
In 28 studies of PDNV, only in four studies were instruments with established reliability
and validity used (14.3%). (Table 4-1.) In nine studies (32.1%) only the incidence of nausea and
vomiting was obtained by telephone. In the other nineteen studies (67.9%) a VRS, VAS, or NRS
scale was used to obtain incidence and intensity of symptoms. In twenty-one (76%) of the studies
telephone calls were used to interview the patients, in seven (25%) a mail-in investigatordeveloped diary or questionnaire was used that required return to the investigator. In many of the
studies, patients completed an investigator-developed questionnaire, but these were supplemented
with telephone interviews to obtain the information from the diary. In one study a telephone
interview at 24 hours was used in conjunction with a mail-in questionnaire to return after five
days. In one study data were obtained with a phone call at 24 hours and then another telephone
call 1 –2 weeks later to ask if PDNV was present from 24 to 48 hours after surgery.
In the majority of studies (22), data were obtained at 48 hours; thirteen of those had data
obtained exclusively at 24 hours. Of those 22 studies, in the remaining nine studies data were
also obtained at other time points including 48 hours, 72 hours, 5 days, or 7 days. In one study
56

data were obtained at 9 hours after surgery, in three studies data were obtained after 7 days only,
and in one study at 5 days only.
Description of Existing Self-Report Measures of Nausea and Vomiting

Diaries and Scales
Ponce de Leon, et al. studied the performance of VRS, VAS, and NRS scales for rating
visual stimuli.14 The VRS was a 5-point response scale using the terms “very little”, “little”,
“intermediate”, “much” and “very much.” The VAS was a 100 mm line with “none” and “the
highest possible” as anchors. The NRS was an 11-point scale (0 – 10) with 0 = white and 10 =
black. Participants were shown cards showing five intensities of gray. The VRS (kw = 0.71)
ranked as more consistent than either the VAS (kw = 0.58) or NRS (kw = 0.63). Validity was
analyzed by distribution, progression and correlation. The authors stated that it is unknown if the
greater consistency of the VRS results from its verbal descriptors or use of only five response
categories, but go on to assert that some clinicians believe subjective phenomena are articulated
more easily in words than numbers. 14
In an article on methodology and assessment in clinical anti-emetic research, Morrow15
discussed the use of categorical scales using adjectives such as mild, moderate, or severe, and
VAS with a 10 cm line marked as no nausea on one end and extreme nausea on the other end as
useful for standardized reports of nausea. Both types of scales have been reported as reliable and
valid using correlations between scales and consistent results over time.15-19 Interestingly,
reliability and validity of scales used in PDNV studies, whether VRS, VAS, or NRS, are not
typically reported.
In many of the studies for PDNV a patient diary and the number of nausea and emetic
episodes as recorded by the patient or nurse before patient discharge was used. The investigator
created these diaries; there are no standardized diaries with reliability and validity mentioned in
the literature for report of nausea and vomiting.20 Investigators also reported use of visual analog
scales (VAS), numerical rating score (NRS), and verbal rating scales (VRS) to evaluate
subjective and objective stimuli.
In most studies, to rate nausea, the VAS and NRS scales are 0 – 102, 21-30, but have been
reported as 0 – 3.31, 32 Grimsehl, et al. and Tang, et al. used a VAS of 0 to 100 mm.33, 34 VRS
scales have descriptors that vary among investigators, e.g., worst possible, severe, or as bad as it
can be.9, 23, 35 Some investigators simply asked whether nausea occurred. 36-43 One study used a 0
cm to 10 cm VAS, but converted those findings to yes or no (less than 1 cm was counted as no
nausea).44 Only two instruments for measuring PDNV have been reported in any PDNV studies,
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the Ambulatory Surgery Index of Nausea, Vomiting, and Retching (AS-INVR)22 and the
Functional Living Inventory-Emesis (FLIE).26, 45
The frequency of vomiting was not reported consistently in studies. In some studies the
number of times a patient vomited per day were reported while in other studies whether the
patient experienced emesis during the day was reported as “yes” or “no.” A confusing factor in
reporting the number of episodes of emesis is whether the patient who is self-reporting
understands the difference between an episode of vomiting (with results) or an episode of
retching (dry heaves). In two studies an emetic episode was defined as vomiting or retching.29, 33
Rajeeva et al.

27

was the only investigator to rate the severity of vomiting by number of episodes

over a 24-hour period other than Fetzer who used the AS-INVR.22

For a patient who is in the

hospital or still present at the ambulatory surgery facility, an observer can rate the objective
symptom of emesis. However, in the PDNV population, because the patient is at home and not
observable, emesis must be self-reported, as is the experience of nausea.

Ambulatory Surgery Index of Nausea, Vomiting, Retching (AS-INVR)
The Ambulatory Surgery-Index of Nausea and Vomiting (AS-INVR), an instrument
based on Rhodes Index of Nausea and Vomiting (INV), was developed and modified for use in
the ambulatory surgery population.46 The Rhodes INV was developed to separately measure the
patient’s perception of nausea and vomiting.47 The instrument included the patient’s perception
of duration of nausea, frequency of nausea and vomiting, distress from nausea, and amount of
vomiting. The final instrument had five items using a 5-point numerical score with verbal
descriptors such as “I did not throw up during the last 12 hours.”48 Reliability for the instrument
was determined using Cronbach’s alpha as .89 – .97 and the split-half correlation was .90.
During tests using the Rhodes INV, patients reported also experiencing retching or dry
heaves, as well as distress from vomiting.

49

The Rhodes INV Form 2 added 3 items to the

original Rhodes INV to measure those constructs. Cronbach’s alpha for Form 2 was calculated as
.98. Concurrent validity was assessed during two administrations using Spearman’s correlation
coefficient and were r = .87 and r = .83.49 Construct validity was supported by the ability of the
instrument to distinguish between cancer patients and well persons .50 Zhou, et al.51 performed a
confirmatory factor analysis of the Rhodes INV Form 2 in a sample (N = 161) of pregnant
women. The model that treated nausea and vomiting as one-factor, and the model that included
two factors (symptom occurrence and symptom distress) did not fit the data.

The authors

concluded that the three-factor structure measuring nausea, vomiting and retching should be used
when measuring the nausea and vomiting of pregnancy.51
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In an effort to modify the Rhodes INV Form 2 to a more-user friendly format, Rhodes
and McDaniel developed a new version entitled the Index of Nausea, Vomiting and Retching
(INVR).52 The INVR has eight items that begin with an introductory statement using the same
component as the INV-2 and allows the patient to complete the sentence by inserting one of five
possible responses by checking the appropriate response box.

In a study to determine the

reliability of the INVR and using a population of cancer, medical-surgical, and obstetric patients,
the responses to the INVR were more frequently consistent than the INV-2.52 Ming, et al.53 used
the INVR to measure incidence of PONV in an interventional study in the postoperative setting.
Cronbach’s alpha was .85. Fu, et al.54 examined the reliability and validity of the Chinese
translation of the INVR and the INV-2. Cronbach’s alphas for the Chinese translation of the
INV-2 in two different samples were .95 and 0.93, and 0.95 and 0.94 for the INVR. Both
versions were found to have good reliability and validity and high agreement rates, although a
majority of patients expressed preference for the INVR.
Fetzer et al.22, 46 evaluated a modified version of the INVR for use with an ambulatory
surgery population. The 8-item Rhodes INVR was modified by rewording the introductory
statements as applicable to the ambulatory surgical patient and collecting the data via telephone
call 24 hours after patient discharge. Internal consistency reliability of the Ambulatory Surgery
(AS)-INVR was determined using Cronbach’s alpha (0.897); the Guttman split-half procedure
produced a correlation of .90. The authors suggested that these data indicate the AS-INVR
measures upper gastrointestinal distress as a single concept in ambulatory surgical patients. Item
eight was dropped from further analysis due to poor correlations of that item with the other seven
items as well as the weak internal consistency of the retching subscale. After dropping item
eight, the Cronbach’s alpha increased to .91.46 Both Ming et al.53 and Fetzer et al.46 found a much
lower incidence of retching among postoperative patients than in the pregnant and cancer
populations.

Functional Living Index Emesis (FLIE)
The only other preexisting scale used in the articles in Table 4-1 is the Functional Living
Index Emesis (FLIE) developed to address the impact of CINV on daily living. 55 This
instrument consists of 18 items and has nine items for nausea and nine for emesis. Each item
asks a question and then offers options of 1-7 using the anchors “not at all” or “none” and “a
great deal” or “not at all”, e.g. “How much nausea have you had in the past three days?” The
instrument was used first to compare two groups of patients who had received chemotherapy,
those who had emesis and those who did not for a three-day period.55
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There was a significant decrease in FLIE scores in patients who experienced emesis and a
constant score for those who did not indicating that the instrument measured what it was intended
to measure. Pearson correlations between FLIE scores after treatment and patient-reported
nausea and vomiting (-.65, -.68) show a negative effect on the patient’s daily living. The nausearelated subscale of the FLIE correlated (r = .83) with the nausea factor of the Functional Living
Index Cancer (FLIC).55. Cronbach’s alpha was .90 for before and after responses to FLIE. The
authors conclude that the results demonstrated FLIE was a responsive instrument for assessing
the effects of CINV on quality of life and daily function of patients after chemotherapy
treatment.55
Martin and others56 modified the original FLIE for use with 5-day recall instead of 3-day
recall of the original FLIE. The patients completed the modified version on day one for training
purposes and on day six after the first cycle of chemotherapy. Cronbach’s alpha for nausea and
vomiting domains was .79. Acceptable construct validity was supported by item-domain
correlations within domains (r = .74 to .97; p < .0001) stronger than across domains (r = .52 to
.76; p < .0001).56 The modified version of the FLIE was a reliable and acceptable instrument to
determine impact on daily living of patients after initiation of chemotherapy.
Only 45 studies were found during a PubMed search using the search term “functional
living index emesis”. Of those studies, only two were found for the PONV/PDNV population.
The cancer population was the focus in the other 43 studies. Zarate et al.45 used the FLIE to
determine nausea and vomiting in a study on the use of transcutaneous acupoint electrical
stimulation for preventing PONV after laparoscopic surgery. The respondents were a mix of
inpatients and outpatients who were evaluated after a 9-hour period of time. No reliability or
validity data are included in the published study. It is interesting to note that even though existing
reliability and validity statistics are for use after three days and five days, the authors used the
instrument to measure PONV/PDNV after only nine hours, using a telephone call to contact
outpatients who had been discharged. Pan and others26 used a study investigator to administer the
modified FLIE on the last day of the study (day 5) to participants. The authors do note that the
FLIE is a validated instrument for assessing impact of nausea or vomiting after chemotherapy.
The modified FLIE used in this study differed from the original FLIE because items were rated 0
to 10 instead of 1 to 7 as in the original instrument. Also, no items were reverse scored as in the
original FLIE. No reliability or validity data were included in the study.

60

Morrow Assessment of Nausea and Emesis (MANE)
One instrument that has been used in studies of chemotherapy induced nausea and
vomiting (CINV) is the Morrow Assessment of Nausea and Emesis (MANE).57. This instrument
has 17 items that assess occurrence, duration, and severity of pre-and post CINV. The items are
6-point verbal descriptive scales. Reliability and validity of the MANE have been supported in
the cancer-related chemotherapy population in use of this instrument.57. This instrument has
never been used for a study in the PDNV or PONV population, probably due to suspected
differences in the cancer chemotherapy population and ambulatory surgery population related to
the issue of anticipatory nausea. Anticipatory nausea and vomiting are measured in the MANE,
and those symptoms have not been established for the PONV/PDNV population.

Discussion

Definitions and Measurement
Assessment and findings of PONV and PDNV have been inconsistent because endpoints
are defined differently by study.
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Consistency of the term PDNV in future studies should

improve with the definitions published in ASPAN’s multidisciplinary clinical practice guideline
for prevention and management of PONV and PDNV.8 At the present time, the terminology of
nausea and vomiting is still used interchangeably in the literature PDNV, defined in some articles
as late PONV and in others as after discharge from the hospital without specifying whether the
patient was an outpatient or inpatient discharged after 24 or 48 hours from the hospital. The term
PDNV should be defined as nausea and vomiting after outpatient discharge from the healthcare
facility. Delayed PDNV defines nausea and vomiting that occurs after 24 hours post outpatient
discharge. For the outpatient, PONV would refer to nausea and vomiting experienced while in
the PACU. Any nausea and vomiting for the inpatient is defined as early, late, or delayed PONV.
(Figures 1 and 2).
One difficulty with measurement of PONV and PDNV is the confusion with terminology
of nausea, vomiting, and retching. Rhodes12 addressed the issue, defined all three terms, and
went on to create an instrument that distinguishes between the three. Khamales and others59
define emesis for their study as “the number of vomits (excluding dry retches) in each 24 hours
period.” Not all studies distinguish between vomiting and retching. For example, Zarate et al

45

defined an emetic episode as “a vomiting, or retching event, or a combination of these events, that
occurred in a rapid sequence (<1 minute between events.)” One study defined vomiting as
“emesis or retching.”29
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Fetzer et al.22,

46

determined that retching was not as significant a problem for the

PONV/PDNV population as for the pregnant and cancer populations. However, until further
studies are completed that determine whether patients experiencing PDNV do not experience
retching as a separate entity, nausea, vomiting, and retching should be measured separately.
Researchers suggest that nausea and vomiting occur independently and should be assessed
separately.13, 16, 60, 61

Outcomes of Studies
Consistency when determining outcomes is an important measurement issue with PDNV.
In some studies, emesis is measured as “no emesis” or “any number of emetic episodes”. In other
studies, the number of episodes of emesis that occur each day is measured. In some studies
participants are simply asked if any emesis occurred during the day at all using a yes/no format.
In a methodological discussion of antiemetic studies, Olver et al.13 discussed the importance of
distinguishing between a complete response with no nausea or vomiting and a lesser response that
the authors state is obtainable by use of a severity of nausea scale and recording the number of
vomiting episodes during the study. The authors go on to say that a “standardized system would
be ideal and agreement on such a scale is of paramount importance.”13
The outcome of paramount interest should be the experience of PDNV for the patient.
Nausea is a subjective experience and cannot be measured by an observer. The patient must selfreport nausea. Investigators should use the simplest scales that give the information needed.
Vomiting is an observable behavior, but for the outpatient surgery patient who has been
discharged, must also be measured by self-report. It would be possible for a responsible adult to
observe and report vomiting and/or retching, but none of the studies found described using
observers.
Other outcomes that may be of interest in research about the patient experiencing PDNV
are appetite, pain or comfort, quality of life, patient satisfaction with care, sedation issues (related
to antiemetic use), anxiety, or an overall question to describe any changes in degree of severity.
See Table 4-2 for suggested measurement of PDNV.
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Difficulties with Collecting Data
New research is needed to establish how effective self-reporting instruments are for
patients who are asked to evaluate the phenomena while experiencing nausea and vomiting.
Research should also determine other factors that may come into play and affect how the patient
feels and is able to conduct activities of daily living, such as fatigue and anxiety. Research
should also determine the most effective method of rating PDNV, e.g. a 12-hour or daily basis.
Some patients have difficulty distinguishing retching from vomiting or counting emetic
episodes if they are continuous or prolonged. This could affect the data obtained from a patient
who had to self-report the information. It is possible that the two instruments mentioned in this
paper (FLIE, AS-INVR) would aid the patient in determining the best answers to the questions.
Tonato, et al.17 believe that any information obtained by telephone or by questioning the patient
on their next visit was unreliable. Use of a daily diary card with scales imbedded in the card
proved more satisfactory. Studies of PDNV should incorporate a written instrument for the
patient as well as telephone calls to maintain contact with the patient and encourage follow
through.
Both the FLIE and the AS-INVR are easy to use and reproducible. They also allow the
patient to record the information on a daily basis. Follow-up telephone calls could be used to
obtain the information or remind the patient to mail the card to the investigator in a pre-stamped,
pre-addressed envelope.

Reporting of Reliability and Validity of Instruments
Studies in the medical literature rarely discuss the issues of reliability and validity of the
instrument used to determine nausea or emesis unless the study was designed for that specific
purpose. None of the studies reported in Table 4-1 discuss reliability or validity issues except
Fetzer et al.22 when using the AS-INVR. Pan, et al,26 when using the FLIE mentions the past
reliability of the instrument, but gives no reliability data. Use of established instruments to
determine the frequency and distress associated with nausea and vomiting is warranted. At this
point in the PDNV literature, there are only three studies that have used established instruments,
the FLIE or the AS-INVR.22, 26, 45 More studies should be performed using the two established
instruments with normative values, timing needed to complete the instrument, and grade level
established. See Table 4-3. Those studies that are performed should report reliability and validity
of instruments.
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Conclusion
In conclusion, approximately one third of patients continue to experience nausea and
vomiting after discharge from outpatient surgery settings. In studies for that group of patients,
there have been no clear and definitive instruments in use to measure the phenomena of nausea
and vomiting. The AS-INVR and the FLIE provide the possibility of standardization of outcome
for studies with those patients. Although they both possess strengths, more study is clearly
needed to progress the measurement of nausea and vomiting in the post discharge ambulatory
surgery patient.

Copyright © Jan Odom Forren 2009
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Table 4.1 Measures Used to Assess PDNV
Reference
Candiotti, et al.62

Publication
Year
2008

Carroll, et al.2

Study

Outcome
PONV/PDNV

1995

Patient experiences with nausea and vomiting
after discharge from outpatient surgery

PDNV

Claxton, et al.36

1997

Evaluate morphine and fentanyl for analgesia
after outpatient surgery

PDNV

Coloma, White,
Ogunnaike, et al.21

2002

Evaluation of acustimulation compared to
ondansetron for established PONV

PONV/PDNV

Coloma, White,
Markowitz, et al.37

2002

PONV/PDNV

Ernst, et al.38

1997

Evaluate dexamethasone in combination with
dolasetron on outcome after laparoscopic
cholecystectomy
Incidence and impact of pain nausea and
vomiting after outpatient surgery
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Evaluate efficacy and safety of three doses of
palonsetron versus placebo for preventing
PONV

PDNV, pain,
serious problems
post discharge

Measurement Used for
PDNV
Emetic episodes and
intensity of nausea
measured at 2, 6, 24, 48,
and 72 hours. Intensity
measured on 4 point scale
(none to severe).
Phone interview after 24
hours with VRS 0 (no
nausea or vomiting) to 10
(very severe); mail in
questionnaire after 5 days
(incidence only).
Phone interview at 24
hours. Asked if they
experienced nausea or
vomiting (yes, no).
Phone call at 24 and 72
hours. Incidence of N or V;
VRS to score nausea
(0 = none to 10 = worst
imaginable).
Phone call at 24 hours to
determine incidence of
nausea or vomiting.
Questionnaire for 72 hours:
Incidence of nausea and
vomiting (yes/no)

Table 4.1 (Continued) Measures Used to Assess PDNV
Reference
Fetzer, et al.22

Publication
Year
2005

Study

Fish, et al.39

1999

Gan, et al.23

2002

Grimsehl, et al.33

2002

Comparison of cyclizine and ondansetron for
prevention of PONV in outpatients

PONV/PDNV

Hache, et al.40

2009

Aprepitant in a multimodal approach for
prevention of PONV

PONV/PDNV

Mattila, et al.31

2005

Postdischarge symptoms after ambulatory
surgery

PDN/PDV

Monagle, et al.24

1997

Compared ondansetron to moderate dosage of
metoclopramide in minor gynecologic surgery

PONV/PDNV

Self-care activities for PDNV

Compare sevoflurane with use of TIVA in
regard to rapidity of recovery to home
readiness
Administration of ondanetron ODT (orally
dissolving tablet) for PDNV

Outcome
PDNV required
for inclusion in
study
PONV/PDNV

PDNV
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Measurement Used for
PDNV
Phone call at 24 hours. ASINVR for PDNV; NRS 0 –
10 for distress of PDNV
Telephone call at 24 hours.
Asked about occurrence of
N or V
VRS 0 (no nausea) to 10 (as
bad as it can be). Incidence
of vomiting—phone call at
24 hours.
Questionnaire for first 24
hours. Nausea rated as none,
mild, severe, and with use
of 100-mm VAS. Emetic
event—nausea or retching.
Information received on
postop phone call for 24
hours. Follow up phone
interview in 1 -2 weeks that
asked if there was any
PDNV during 1st 48 hours.
Recorded incidence only.
Mail-in questionnaire
covering 7 days using 4
point scale (0 = nonexistent
to 3 = severe)
Phone call at 24 hours.
Verbal scale 0 – 10.
Incidence of emesis
recorded.

Table 4.1 (Continued) Measures Used to Assess PDNV
Reference
Moore, et al.44

Publication
Year
2008

Paech, et al.25

Study

Outcome
PONV/PDNV

2002

Effect of anaesthetic technique on outpatient

PDNV

Pan, et al.26

2008

Antiemetic prophylaxis for postdischarge
nausea and vomiting and impact on functional
quality of living during recovery in patients
with high emetic risks

PDNV and QOL

Parlow, et al.32

1999

PDNV after ambulatory laparoscopy is not
reduced by promethazine prophylaxis

PDN, PDV

Pfisterer, et al.9

2001

An international study of PONV in outpatient
surgery

PONV/PDNV
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Effect of anaesthetic agents on induction,
recovery, and patient preferences in adult day
case surgery

Measurement Used for
PDNV
Patients given 7 day mail-in
diary to record N,V on 0 cm
to 10 cm VAS. Converted
to Yes/No (<1cm = No).
Phone call at 24 hours and 4
days. Nausea = 0 to 10
verbal scale; # of episodes
emesis
Daily diary for 5 days after
surgery to record daily
incidence and severity (010) of emetic symptoms.
Phone call at hours 8, 24,
72, and 120 hours to go
over diary. On last day,
administered modified
FLIE.
24 hour diary with 4 point
scale for nausea (none,
mild, moderate, severe); #
episodes emesis.
Information retrieved with
phone call.
Patient diary cards for DOS
plus 4 days reporting nausea
(none, mild, moderate,
severe); distress by nausea
(not at all to extreme); #
emetic episodes

Table 4.1 (Continued) Measures Used to Assess PDNV
Reference
Rajeeva, et al.27

Rothenberg, et
al.41

Publication
Year
1999

1998

Study

Outcome

Compare ondansetron with ondansetron and
dexamethasone in prevention of PONV

PONV/PDNV

Compare dexamethasone versus droperidol
following outpatient laparoscopy with
propofol general anesthesia
Comparison of ondansetron and droperidol
for antiemetic prophylaxis in outpatinet
gynecological procedures

PONV/PDNV
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Tang, et al. 34

1996

Thagaard, et al.42

2007

Analgesic and antiemetic effect of ketorolac
compared to betamethasone and
dexamethasone

PONV/PDNV

Waterman, et al.35

1998

Assess the frequency and duration of PONV
over 7 days post orbital hydroxyapatite
implant surgery

PONV/PDNV

White, et al.28

2002

Comparing efficacy of acustimulation to
ondansetron when used alone or in
combination

PDNV

PDN, PDV

Measurement Used for
PDNV
Interviewed patient at 24
hours. Nausea 0 (none) to
10 (as bad as it can be);
Vomiting episodes >2 =
severe; 2 = moderate; <2 =
mild; 0 = none.
Phone call at 24 hours.
Presence of nausea or
vomiting noted.
Nausea VAS 0 mm (none)
to 100 mm (maximum); #
emetic episodes; phone call
at 24 hours and 7 days.
Questionnaire for patient to
complete at 24 and 72 hours
that asked about nausea and
vomiting.
Nausea—ordinal scale (nil,
mild,moderate, severe).
Vomiting—presence or
absence. Rated 4 times daily
for 7 days by patient.
VRS 0 (no nausea) – 10
(worst imaginable); #
episodes emesis; patient
diary for 72 hours. Phone
call at 24 and 72 hours.

Table 4.1 (Continued) Measures Used to Assess PDNV
Reference

White, et al.43

2007

Zarate, et al.30

2000

Zarate, et al.45

2001

Study

Outcome

Evaluate the hypothesis that oral granisetron
would be cost-effective alternative to IV
ondandsetron for preventing PONV and/or
PDNV

PONV/PDNV

Comparison of two antiemetic strategies in
high risk patients undergoing minor
gynecologic surgery
Compare costs and efficacy of ondansetron
versus dolasetron

PONV/PDNV

PONV/PDNV
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White, et al.29

Publication
Year
2006

Use of transcutaneous acupoint electrical
stimulation for prevention of PONV

PONV/PDNV

Measurement Used for
PDNV
At 24 and 48 hours, patients
asked about incidence of
N/V. Nausea measured on
11 point scale (0 = none; 10
= maximum). Emesis =
vomiting or retching.
Phone call at 24 hours to
determine presence or
absence of PDNV
Phone call at 24 hours; Post
discharge side effects noted.
Maximum nausea during
previous 24 hours—VRS
0(none) to 10 (worst
possible).
Phone call after 9 hours to
outpatients; FLIE measured
nausea scores; # episodes
vomiting or retching

PDNV = Post discharge nausea and vomiting; PONV = Post operative nausea and vomiting; PDN = Post discharge nausea; PDV = Post discharge
vomiting; N = nausea; V = Vomiting; VRS = verbal rating scale; AS-INVR = Ambulatory Surgery-Inventory of Nausea, Vomiting, and Retching;
NRS = Numerical rating scale; VAS = visual analog scale; IV = intravenous; FLIE = Functional living index of emesis; Postop = postoperative,
DOS = Day of Surgery.

Table 4.2 Measurement of PDNV
Instrument should contain:
• Nausea, vomiting, and retching measured as a separate entities
• PDNV as outcome
• Separate measures of frequency, severity (intensity), and duration
• Format should be daily diary card (mailed in, or data retrieved from telephone calls)
Measurement:
• Nausea
o Easy to use scales (VAS, NRS, or VRS) that are simple and reproducible
• Vomiting
o Number of episodes
o Duration
o Volume (Information less useful)
When to measure
• Report every 12-24 hours
• PDNV reported for 5 – 7 days after discharge
Indirect measures of PDNV
• Time to food intake
• Appetite change over time
• Comfort
• Quality of life
• Sedation as related to antiemetic side effects
• Anxiety
• Overall quality of life assessment
• Overall question to capture change in degree of severity
Data from: 13, 15-17, 51, 60, 61
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Table 4.3 Comparison of Two Self Report-Measures of PONV/PDNV
Instrument Year
Number of
Response
Scoring and
Items
Options for
Range
Each Item

Time Required
to Complete

Grade Level

Normative
Values

71

Functional Living
Index Emesis 1992 (3
Day) with validation
in 2003 (5 Day)

18 items ( 9 for
nausea and 9 for
vomiting)

Scale range is
from 1 (not at
all affected) to
7 (affected a
great deal.)

Responses for
items are
summed with a
possible score
range of 18 to
126.

Unknown

Unknown

Unknown

Ambulatory Surgery
Index of Nausea,
Vomiting, and
Retching 2004

7 items (3
related to
nausea, 3
related to
vomiting, 1
related to
retching,
symptoms
distress 3 items,
symptom
occurrence 4
items)

Patient has 5
choices for each
item, such as
no, 1-2, 3-4, 56, 7 or more.

5 choices per
item are scored
as 0-4 with a
total score of
possible of 0 –
28.

Unknown

Unknown

Unknown

Figure 4.1 PONV Timeline

Used with permission.8

Figure 4.2 PDNV Timeline

Used with permission.

8
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CHAPTER FIVE
Over 34 million patients undergo ambulatory surgery annually in the U.S.1 with as many
as 35-50% experiencing nausea and/or vomiting after discharge following ambulatory surgery.
This phenomenon is called post discharge nausea and vomiting (PDNV),.2-6 With more than 60%
of all surgeries performed in the ambulatory setting and millions of patients experiencing PDNV
every year, it is imperative that we look more closely at incidence, management strategies, and
outcomes for these patients.7 The impact of PDNV requires that treatment of this complication
extend well beyond discharge.
Researchers have focused on patient risk for postoperative nausea and vomiting (PONV),
nausea and/or vomiting that occurs within the first 24-hour period after inpatient surgery.2, 8, 9
PONV has been well-described, risk factors determined, and is far better studied than PDNV.8, 9
Little research is available in which the incidence and severity of PDNV is described. PDNV is
an underreported condition that can affect quality of recovery, has the potential for morbidity and
hospitalization in high-risk patients, and impacts patient satisfaction.

10-15

Patients who

experience PDNV are likely to manage their symptoms using self-care strategies at home,
sometimes by discontinuing medications they believe are contributing to the problem.16
Nausea and vomiting after surgery was noted by Kapur as the “big, little problem” over a
decade ago.12 Recently, an editorial entitled “We’re tired of waiting” called for an end to nausea
and vomiting after surgery noted the importance of solving
17

emphasized treatment in the post discharge period.

our “big, little problem” and

In another editorial this past year, authors

called PDNV “an overlooked aspect of ambulatory anesthesia.”18 Although variable, earlier
investigators described the incidence of PDNV to be as high as 55%. 4 5, 19 In current studies of
this continuing problem, an incidence of 30-60% has been reported. 3, 10, 11, 13, 15
Patients have expressed their aversion to nausea and vomiting after surgery.20, 21 When
asked to rank postoperative and postanesthesia outcomes from the most undesirable to least
undesirable, patients rated vomiting as the most undesirable outcome, ranking it as more
undesirable than pain or shivering.20

Patients who had experienced nausea after surgery were

willing to pay $73 (USD) out-of-pocket for a preventative drug, and those who experienced
vomiting were willing to pay $100 (USD).22 It is likely that nausea and vomiting after surgery
affects not only the cost of healthcare, but directly impacts patient satisfaction.23
The purposes of this study were to: 1) describe the incidence and severity of PDNV over
a 7-day period in a sample of adult surgical patients undergoing outpatient surgeries under
general anesthesia, 2) describe the pharmacologic and nonpharmacologic modalities of care used
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by patients with PDNV to manage it, 3) compare the incidence and severity of PDNV between
those who do and do not use pharmacologic and nonpharmacologic modalities, 4) determine
outcomes associated with PDNV, and 5) determine predictions for late (Days 3-7) PDNV. This
study was part of a multi-site study that had as a primary objective development of a simplified
risk model for predicting patients most likely to suffer PDNV.3 This study differed from the
primary study by following a subset of patients over a 7-day period to better describe the
incidence and management of PDNV.

Methods

Design and Sample
The methods for this prospective, descriptive multi-site study have been described
previously.3

Briefly, twelve U.S. ambulatory surgery sites received approval from local

institutional review boards to conduct the study. Ten of the twelve sites collected data for 48
hours post discharge and two of the twelve sites collected data for 7 days post discharge. Eligible
patients were adults (> 18 years of age) who were undergoing an outpatient procedure under
general anesthesia requiring a tracheal tube or laryngeal mask airway. Excluded from the study
were those unable to communicate in English, individuals whose surgery ended in a planned or
unplanned inpatient stay, current pregnancy, persistent or recurrent nausea and/or vomiting before
anesthesia, and patients who required regional anesthesia only.

Eligible participants were

recruited consecutively either in preadmission testing or in the preoperative area on the day of
surgery by the primary investigator or trained research assistant. Informed consent was obtained
from all participants.

Variables and Measurement
Participants were asked to provide self-reported data including demographics, medical and
surgery-related history, and to answer questions rating distress caused by pain, nausea, and
vomiting; how these symptoms impaired their functional living and satisfaction, and the
frequency of symptoms and actions taken to alleviate symptoms.

Postoperative data were

assessed using standardized questions about severity of symptoms per time interval on an 11point numeric rating scale. Specifics about measurement of each of these follow.
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Demographics and Clinical Characteristics
An inpatient data report sheet was used to obtain patient characteristics including age,
gender, height, weight, and ethnicity; medical history including history of smoking, motion
sickness, and migraines; previous general anesthetics, and current diagnoses; surgical procedure;
anesthesia data including the type and length of surgery, airway device, anesthetic drugs (e.g.
type and concentration of inhalational anesthetics), and type and dose of intraoperative opioids
and other medications; and PACU/StepDown data including PACU and Step-Down arrival and
departure, incidence and severity of nausea, presence of vomiting or retching, and drugs given to
the patient. Basic demographics and clinical measures were obtained from patient interview
during initial contact with the primary researcher or other trained personnel. Other perioperative
data were obtained from the clinical record.

The Patient Diary
Employment of a daily diary for the patient to record symptoms at home has been used
successfully in assessment of patient nausea and vomiting.24 The investigators placed all the study
questions regarding nausea and vomiting into one packet of information for the patients to take
home and called it a Patient Diary. The cover page reminded the patient of the times they would
receive phone calls; listed definitions of nausea, vomiting, and retching; and specified time-points
to record symptoms within the diary. During the Day of Surgery (DOS) through Day 2, the
patients were asked to record symptoms at specific time intervals. Patients were asked to rate
nausea on day of surgery during drive home, from ride home to dinnertime and dinnertime to
bedtime. On Days 1 and 2 patients rated nausea during the night, morning, afternoon and evening.
From Days 3 – 7, nausea was rated for a 24-hour period each day. Patients were asked to record
the number of times and worst severity of vomiting/retching during the same time periods they
recorded nausea. Quality of life questions were included in the Patient Diary and rated once every
24 hours. The Patient Diary also had a space to record all new medications or remedies that the
patient took for the past 24-hour period. They were asked to record name of medication or
remedy, time of the day, reason for taking and effectiveness of medication.

Incidence and Severity of PDNV— Definitions for terms used in this study were the
following: 1) nausea--a subjective, unobservable occurrence of the desire to vomit without
expulsive muscular movements--an unpleasant sensation experienced in the back of the throat
that may or may not end in vomiting; 2) vomiting-- the forceful ejection of the contents of the
stomach, duodenum, or jejunum through the mouth; and 3) retching--an attempt to vomit with no
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stomach contents expelled, otherwise known as dry heaves.25,

26

These symptoms may occur

alone or on their own.25, 26 Retching usually indicates an empty stomach, but is as unpleasant for
the patient as vomiting.25 Because retching may or may not occur in these patients due to a much
lower incidence of retching in the ambulatory surgery population than in the pregnant or cancer
population, 27, 28 retching was noted, but combined with vomiting for this study.
The operational definition of PDNV for the purpose of this study was

“nausea and/or

vomiting that occurs after discharge from the health care facility after outpatient surgery.”2
Nausea is a subjective experience that is defined by the patient and requires a self-report
approach.25, 29 Severity of nausea was measured using an 11-point numerical rating scale where 0
represented “no nausea” and 10 represented “worst nausea imaginable.” Categorical rating scales
(verbal rating scales, numerical rating scales, visual analog scales) have been found to yield
consistent and reliable data when used to measure nausea.24, 30-34 Incidence and severity of nausea
were recorded during the PACU stay at admission, 15, 30, 60, 120 and 240 minutes and
discharge; during the ride home; and for 48 hours in 10 study sites and 7 days in two study sites.
Incidence was measured as any number greater than 0 on the numerical rating scale, and severe
nausea was defined as nausea of 7 or greater on the verbal rating scale.
Vomiting was measured as the number of episodes that occurred at least one minute apart
and severe vomiting as three or more emetic episodes. Retching was included with vomiting in
the analysis. The PDNV data were collected from the clinical record and patient interview on
Days one, two, and seven, and from the Patient Diary.

Pharmacologic and Nonpharmacologic Modalities of Care
Pharmacologic modalities of care were measured by review of the Patient Diary where
patients were asked to note the use of any medications during the previous 24-hour period for
nausea or vomiting post discharge. Over the counter medications and nutraceuticals (e.g. ginger)
that were used by the patient for treatment of PDNV were included as pharmacologic modalities
of care. Nonpharmacologic care was measured by description of any nonpharmacologic modality
used by the patient as prevention or treatment of PDNV post discharge. The Patient Diary
included a question at Day 2 that asked “Did you use any of the following means to prevent or
treat nausea or vomiting since your surgery?” The checklist included: acupressure bands, lying
still, slow progression of diet to regular diet, drinking carbonated drinks, eating food, not taking
pain medication on empty stomach, and a blank line for any other modality the patient wished to
specify.35 These data were captured by review of the Patient Diary.
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Outcomes Associated with PDNV
Outcomes were measured by use of investigator developed quality of life (QOL)
questions. Quality of life is an important dimension in the postanesthesia experience of the
patient.36 Developing an instrument to measure quality of life is difficult because there is no
“gold standard.”37 However, verbal analog scales and visual analog scales have been used for
assessment of specific clinical outcomes such as emesis, pain and fatigue.37. Any questions that
pertain to quality of life should incorporate dimensions of physical functioning, mental health,
cognitive functioning, symptoms, role and social functioning, general health perceptions, sleep,
and energy, and should include aspects of life that are valued by the patient.37, 38 A single, global
quality of life question has been recommended in clinical trials.39 Therefore, the investigatordeveloped questions included a global quality of life question that stated “How much did nausea
affect your quality of life yesterday?” and “How much did vomiting affect your quality of life
yesterday?” The use of surrogate measures for nausea and vomiting should be considered, e.g.
food intake, appetite change, and other measures of well-being.29 Therefore, other quality of life
questions that were included related separately to the effect of nausea and vomiting on the
patient’s ability to eat and drink, ability to do necessary tasks, enjoyment of leisure, enjoyment of
social activities, ability to do normal daily work, and ability to sleep. The QOL questions for this
study were measured by an 11-point numeric rating scale where 0 represented “not at all” and 10
represented “most bothersome.” Cronbach alpha coefficients for the QOL questions for each 24
hour time period in this study were >.90.
Patients were asked the following question to rate recovery from surgery on a scale of 0
to 10 with 0 “far worse than expected”, 5 “as expected”, and 10 “far better than expected.” At one
site, the researchers captured data regarding patient calls to health care providers during the first
week after surgery by asking, “Did you call your health care provider during this past week” and
“If yes, why?”

Procedure
At the time of consent, participants were informed that an investigator would call to ask
questions about nausea, vomiting, and other symptoms that occurred after discharge on Days 1
and 2, and again on Day 7, if applicable. Patients were instructed on use of the Patient Diary (see
appendix A). The Patient Diary also contained a space for patients to record medication use each
day. At ten sites, the data were collected via phone interview. At two sites where patients
reported symptoms for 7 days, data were collected by phone interview on Days 1 and 2, and
patients were reminded with a phone call on Day 7 to place the Patient Diary in the mail to the
investigator in a self-addressed, stamped envelope. Upon return of the Patient Diary, patients
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received a $10 gift card in the mail from the primary investigator site. Patient medical treatment
remained fully at the discretion of the treating anesthesia provider and surgeon in order to reflect
real-life conditions and current clinical practice in the US.

Data Analysis
Descriptive statistics, including means and standard deviations or frequency distributions,
were used to describe the sample, and summarize the data. Bivariate analyses, including twosample t-tests and chi-square tests of association, were used to determine factors associated with
PNDV. One-way analysis of variance (ANOVA) with Tukey HSD post hoc tests were used to
determine significant differences in means of nausea between groups. A one-way ANOVA was
conducted to look at impact of antiemetic use and nonpharmacologic modalities of care on the
mean of nausea ( 0 = none; 10 = worst). Patients were divided into four groups according to use
of pharmacologic and nonpharmacologic modalities (Group 1 = No use of antiemetics, no use of
nonpharmacologic modalities of care; Group 2 = No use of antiemetics,

Yes

use

of

nonpharmacologic modalities of care; Group 3 = Yes use of antiemetics, No use of
nonpharmacologic modalities of care; Group 4 = Yes use of antiemetics, Yes use of
nonpharmacologic modalities of care.) A logistic regression was conducted to examine factors
relevant for predicting PDNV in days 3 – 7. Significance is set at the p < 0.05 value.
A power analysis determined that with a sample size of 120 and a PDNV prevalence rate
of approximately 30% approximately 36 participants would have this adverse event and the
remaining 84 would not. With these group sizes and an alpha level of .05, the power of a twosample t-test to detect a significant group difference was approximately 84% if the ratio of the
difference in means to the standard deviation was as small as 0.6. Cohen40 considers a difference
of this magnitude to be slightly larger than a medium effect size. With a total of 120 subjects and
a significance level of .05, the power of the chi-square test of association to detect an odds ratio
as small as 4 was approximately 84%. One way to obtain an odds ratio of this magnitude would
be if one group had a proportion of cases with a certain attribute of 20% while the other group
had a 50% rate. With approximately 36 PDNV cases and 84 participants without this event,
assuming a .05 level of significance, the power of the logistic regression to detect a significant
odds ratio as small as 2.5 will be approximately 92%; if the odds ratio is as small as 2, the power
under these conditions will be approximately 83%. Power estimates were obtained using nQuery
Advisor.41 More subjects were available due to the requirements of the multi-site study, so the
data analyses are at least as powerful as determined before data collection.42 Data analyses were
performed with SPSS (version 17.0).
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Results
Two thousand four hundred ninety three patients were screened for the multi-site study.
Data for the first 48 hours post-surgery were obtained from the 2170 patients who completed the
study. Within this group of 2170 was a subset of 260 patients from two centers who also
completed data for a 7-day period. Demographic and clinical characteristics for these two groups
are included and compared in Table 5-1. The subset of 260 patients was significantly different
from the 1910 in the 48-hour sample in age, gender, ethnicity, income level, educational level,
previous PONV, type of procedures performed, surgical approach, American Society of
Anesthesiologists (ASA) physical status, and operating room (OR) time. There was a significant
difference in the presence of PDNV between groups, and significant difference in mean nausea
scores between the groups.

Incidence
The overall incidence of nausea for the study was 36.8% and emesis was 12.0% with an
overall incidence of PDNV of 37.1%. (Figure 5-1). During the ride home, 21.8% of patients had
nausea with 4.6% of patients experiencing emesis. During DOS, after arriving home, nausea
increased to the highest of any single day (28.7%) and emesis increased to 8.5%. The next day
after surgery (Day 1) the incidence of nausea and vomiting decreased to 18.2% and 3.9%,
respectively. The incidence of nausea and vomiting in the 48-hour group is presented in Figure
5-2. On Day 3, the subset of 260 patients reported the incidence of nausea and vomiting at 18.1%
and 2.3%. Nausea decreased to 6.3% on Day 7. Emesis was stable Days 5 – 7 at 1.2%. The
incidence of nausea and vomiting over a 7-day period is presented in Figure 5-3.
Demographic and clinical characteristics of patients who experienced PDNV and did not
experience PDNV are listed in Table 5-2. The presence of PDNV was significantly higher for
females than males (p < 0.001). There was a significant difference between means of age with
younger patients more likely to experience PDNV than younger patients. There was also a
significant difference among ethnic groups when analyzing presence of PDNV with Latinos and
Asians having a higher percentage of PDNV. No significant differences were found among those
with and without nausea in the categories of BMI, educational level, or income.

The clinical characteristics of history of motion sickness, previous PONV, and migraine
headaches were all significantly related to the presence of PDNV (p < 0.001; Figure 5-4). The
use of certain opioids (hydromorphone, p < .024; morphine, p < .027) during surgery was
significantly related to presence of PDNV, although use of meperidine, remifentanil, and fentanyl
during surgery were not significantly related to PDNV. However, the use of certain opioids in the
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PACU were significantly related to the presence of PDNV.

Use of oxycodone, morphine,

meperidine, hydromorphone, and fentanyl in the PACU were related to presence of PDNV while
use of codeine and hydrocodone were not related. American Society of Anesthesiologists’
physical status classification system rating was significantly different for those patients who
experience nausea and those who do not with the healthiest patients (ASA Class I and 2) more
likely to experience PDNV than ASA Class 3. There were not enough ASA Class 4 patients in
that category (N = 8) to statistically compare although the few patients in that category seemed to
follow the same pattern with only 25% experiencing PDNV. Overall OR time was significantly
different for those with or without PDNV (p <0. 01) with those patients who had a longer OR
Time more likely to experience PDNV. Interestingly, patients who received a regional block
were more likely to have nausea than those who did not have a regional block (p < 0.001).
Nitrous oxide had no effect on PDNV.
Patients who experienced nausea and vomiting in the PACU were significantly more
likely to experience PDNV (p < 0.001). There was a significant difference in pain score means (0
= no pain; 10 = worst pain) for pain during activity between patients who reported PDNV and
those who did not (p = <0.008) until Day 4 when the difference was non-significant. Mean scores
for pain at rest show a significant difference (p<0.001) between those with and without nausea
until Day 4 (p = 0.94), but are significant again on Day 5 only (p = 0.026). Those patients with
higher pain scores during activity or at rest were more likely to experience PDNV. The use of
hydrocodone was significantly related to the presence of PDNV until Day 2.

The use of

oxycodone after surgery was significantly related to the presence of PDNV until Day 3.

Severity of Nausea
Nausea was rated with an 11-point scale where 0 was no nausea and 10 represented the
worst possible nausea. Severe nausea (> 7 on scale of 0 to 10) affected 10.2% of patients on day
of surgery and continued to affect 2% of patients on Day 7. (Figure 5-5). Of those who were
nauseated, 31.2% experienced severe nausea during the drive home increasing to 35.5% of those
with nausea during the day of surgery. Of the 6.3 % with nausea on Day 7, almost a third
(31.7%) continued to have severe nausea.
Females reported a significantly higher overall mean of nausea (as measured on a 0 – 10
numerical rating scale) than males (p < 0.001). When analyzed by day, there was a significant
difference in means of nausea scores between males and females until Day 3. (See Figure 5-6).
Mean nausea intensity was compared between age groups (<42, 43-57, and > 58). There was a
statistically significant difference (p < 0.001) between all age groups with the youngest age group
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(< 42) experiencing the highest mean. (Figure 5-7). Using overall mean nausea scores, there no
statistically significant differences for ethnicity [F (4, 2147) = 1.465, p = .21].
Type of surgical procedure was significantly related to mean scores of nausea (p < .001).
(Figure 5-8).

Prostate surgery was associated with the lowest nausea mean score (.2821) and

cholecystectomy with the highest nausea mean score (1.4386). There were significant differences
between general surgery and knee arthroscopy (p = .013), breast surgery and knee arthroscopy (p
= .04), cholecystecomy and prostate surgery (p < .001), gynecological and prostate surgery (p =
.037) and knee arthroscopy and prostate surgery (p < .001). The impact of gender and surgical
procedure on mean nausea scores was explored. The interaction effect between gender and
surgical procedure was significant [F(10, 2126) = 1.943, p = .036]. The type of surgical approach
was also related to mean nausea scores with the endoscopic and conventional approach having a
lower mean nausea and less likely to have nausea than the arthroscopic and laparoscopic
approaches (p < .007). (Figure 5-9)
Patients at the lowest risk for anesthesia complications (ASA 1) had a mean nausea score
of 1.12 and those with a highest risk (ASA 4) of 0.29. However there were only 8 patients
classified as ASA 4, and mean nausea scores were not significantly different than any other
group. (Figure 5-10). The ASA 1 (p < .001) and ASA 2 (p < .02) patients had significantly higher
nausea means than ASA 3.
The use of analgesics codeine and hydrocodone in PACU for pain were not significantly
associated with mean nausea scores (p >.58). The use of morphine (p < 0.001), meperidine (p <
0.001), hydromorphone (p < 0.001), fentanyl (p < 0.001), and oxycodone (p < .001) for pain in
the PACU were significantly associated with overall mean post discharge nausea scores. When
analyzed by post discharge day, the use of opioids in PACU became nonsignificant for PDNV for
all opioids by Day 3.

Prediction of Late PDNV
Using the data from this study and completing the primary objective for the multi-site
study, Independent risk factors for early PDNV (within 48 hours) were determined: female
gender, age less than 50 years, history of PONV, opioids administered in the PACU, and nausea
in the PACU.3 To determine which factors predict the presence or absence of PDNV for days 37, we performed a logistic regression analysis with possible factors ethnicity, age, gender, BMI,
Previous PONV, previous motion sickness, ASA status, smoking status, OR Time, surgical
procedure, surgical approach, use of antiemetics (three variables, one each for use in surgery,
PACU, or post-discharge), use of opioids (again three variables, one each for use in surgery,
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PACU, or post-discharge), and pain scores (divided into none for pain=0, mild for pain=1,2,3,
moderate for pain=4,5,6, or severe for pain=7,8,9,10).
Variable selection was done by backward elimination using approximate likelihood ratio
tests (logistic regression is a special case of a generalized linear model, the likelihood ratio tests
are a substitute for the F-tests used in ordinary linear regression), at the 0.05 level for the
exclusion of variables. Most variables were eliminated resulting in a final model that included a
previous history of PONV, OR Time, and pain score. The significance of these variables is
described in Table 5-3.
The coefficients of the regression are contained in Table 5-4, with 95% confidence
intervals for the odds ratios (note the estimates in a logistic regression provide estimated log odds
and must be exponentiated for odds ratios, the confidence intervals for the log odds are symmetric
around the estimated logodds).
Note for pain level, all odds ratios are computed relative to “no pain”. Thus, the estimated
odds ratios of 10.40 for Moderate Pain is the odds ratio concerning the likelihood of PDNV with
moderate pain compared to the likelihood of nausea with no pain. The long upper tails of the odds
ratios are due to the fairly minimal number of individuals who had no pain but also had nausea, as
seen in table 5.5.
As can be seen in Table 5.5, the observed proportion of individual experiencing PDNV
dramatically increases as the pain level increases. Furthermore, of the 70 individuals with “no
pain”, only 3 reported nausea. When computing odds ratios relative to “no pain”, this small
number of individuals with PDNV produces much variation in the resulting estimates. While we
may be quite confident that individuals with pain are sizably more likely to experience PDNV,
the exact magnitude of these effects is hard to pin down.

Management Strategies
The most commonly used antiemetics in the OR during surgery were: ondansetron
(77.4% of patients); steroids (48.5% of patients); droperidol (12.8% of patients); and dopamine
antagonists (12.8% of patients.) After discharge home, 4.2% of patients recorded use of an
antiemetic. The antiemetics used by patients were ondansetron (15 patients), a 5HT-3 antagonist;
dexamethasone (6 patients), a steroid; diphenhydramine (3 patients), an antihistamine; and
promethazine (67 patients), a butyrophenone (Figure 5-11). Only one patient recorded use of
metoclopramide, a benzamide.
A wide variety of nonpharmacologic methods were reported by patients in order to
relieve nausea. Only 3 patients reported use of acupressure wrist bands (0.1%), while 341
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(15.7%) gradually moved from liquids to food, 471 (21.7%) took medication with food, 451
(20.8%) ate food to relieve or prevent nausea, 399 (18.4%) drank carbonated drinks, and 592
(27.3%) lay down to relieve the nausea. Other non-pharmacologic strategies for the relief of
nausea that were reported by patients included resting/being still (154), stopping their medication
(9), air conditioning or fresh air (16), wet washcloth or cold compress (10), deep breathing,
relaxing (11), and letting it “go away by itself (23).”
Patients were divided into four groups according to use of pharmacologic and
nonpharmacologic modalities. Of those patients who had severe nausea on the Day of Surgery
(DOS), 34.1% were in Group 1 using neither antiemetics or nonpharmacologic means of nausea
control. Over half of those with severe nausea on DOS (52.7%) used nonpharmacologic methods
of control only, 1.4% used antiemetics only, and 3.2% used antiemetics and nonpharmacologic
modalities. (See Table 5-3). By Day 3 the majority of patients with severe nausea were using the
combination of antiemetics and nonpharmacologic methods of nausea relief.

There was a

significant difference in mean nausea scores among the 4 groups divided according to use of
pharmacologic and nonpharmacolotic modalities (Figure 5-12). Post hoc comparisons using the
Tukey HSD test indicated that the mean nausea score for Group 1 (M = .4170, SD + 1.16) was
significantly less than Group 2 (M = 1.6780, SD + 1.93), Group 3 (M = 2.0159, SD + 2.05), and
Group 4 (M = 3.3952, SD + 2.49). Less nausea was associated with patients in Group 1 than in
Groups 2, 3, or 4. More nausea was associated with Group 4 than Groups 1, 2, or 3. There were
no differences in mean nausea scores between Groups 2 and 3.

Outcomes
Quality of Life
Patients were asked to separately rate the effect of both nausea and vomiting on overall
QOL. The mean score (0 = not at all and 10= most bothersome) for effect of nausea on overall
quality of life for patients was significantly higher (p < 0.002) for those who did experience PDN
than for those who did not. The significance was present on all days (Day of Surgery – Day 6).
See Figure 5-13. When patients were asked to rate the effect of vomiting on QOL, the mean
score on overall quality of life was significantly higher for those with PDV (meaning more
bothersome) than those without PDV (p < 0.001). By Day 3, there was no longer a significant
difference (p = 0.164). See Figure 5-14.
Patients were asked the degree to which nausea affected ability to eat and drink; do
necessary activities and tasks; enjoy leisure and recreational activities; enjoy social activities; do
normal work; and sleep. The QOL was significantly different based on nausea score in all areas
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compared to those without PDN for every day post discharge (p < 0.006). By Day 6, only normal
work (p = .06) and sleep (p = .112) were non-significant.
Post discharge vomiting significantly affected (p < 0.001) ability to eat and drink; do
necessary activities and tasks; enjoy leisure and recreational activities; enjoy social activities; do
normal work; and sleep until Day 3, when the effect of vomiting on each of these indicators of
QOL was non-significant.
To further determine outcomes in patients with PDNV, patient expectation of PDNV,
healthcare provider calls during the first week, and patient rating of prevention and treatment of
nausea was documented.
Patient Expectation of PDNV
There was a significant difference in rates of nausea and vomiting based on patient
expectation of PDNV. Patients were asked to rate the likelihood that they would experience
nausea or vomiting (0 = not likely; 10 = likely; Figure 16) Patients who experienced nausea rated
themselves before surgery as more likely to experience nausea (M = 2.57) than those patients
who did not experience nausea (M = 1.42). Patients who experienced vomiting, as well, rated the
likelihood they would experience vomiting as higher (M = 2.06) than those who did not
experience it (M = 1.30).
Healthcare Provider Calls
Out of the seven day subset of patient (N = 260), 180 patients answered the question “Did
you call your health care provider during this past week, and if yes, why?” Forty-six patients out
of the 180 patients (25%) had called the physician or physician’s office during the past week.
However, only 2 patients (1.1%) called to report symptoms of nausea and vomiting. No patients
were rehospitalized due to nausea and/or vomiting. In contrast 15 patients called regarding pain
issues such as continuing pain or problems with the pain medication.
Patient Rating of Prevention and Treatment of Nausea
Patients were asked to compare how their recovery from surgery met their expectations
before surgery. When asked to rate prevention and treatment of nausea between 0 and 10 with 0
(far worse than expected), 5 (as expected) and 10 (far better than expected), patient responded
with an overall mean of 7.81. Patients without nausea rated treatment as significantly higher than
those who did experience nausea (p < 0.001; Figure 17). Of patients who reported nausea, 19.5%
rated treatment below expectations compared to 1.2% of patients without nausea who rated
treatment as below expectations. Of patients who reported nausea, 80.5% rated treatment as
expected or better than expected while 98.8% of those who did not report nausea rated treatment
as expected or above expectations.
84

Discussion
The data in this study substantiate the continuing problem of nausea and vomiting after
outpatient surgery, a population of patients that has been unrecognized and undertreated. 15, 16 The
overall PDN incidence of 36.8%, PDV incidence of 12%, and overall PDNV rate of 37.1% falls
within the published range of 30-55%.4-6, 15, 19 Several demographic and clinical characteristics
were significantly related to the PDNV in this study including female gender, use of
postoperative opioids, a history of PONV or motion sickness. Some characteristics that are
associated with PONV were not associated with this population of patients, e.g. nonsmoking
status. We found that severity of PDNV peaks on the day of surgery and gradually decreases
over the next 7 days. Sicker patients (higher ASA classification), those who experienced PONV
in the PACU, patients with higher pain scores, and younger patients were more likely to
experience PDNV. Only a small number of patients manage their symptoms with the use of
antiemetics or nonpharmacologic modalties of care such as acupressure. Most patients use minor
self-care treatments, e.g. cool cloths, lying down, drinking carbonated fluids, and do not contact a
healthcare provider. Both PDN and PDV have a negative effect on the patient’s perception of
global QOL.
In this study we attempted to provide a real-world incidence of PDNV in a sample of
patients who received general anesthesia for outpatient surgery by not excluding by procedure,
dictating anesthesia regime, or stratifying by risk. The only high-risk inclusion criterion was use
of inhalation anesthesia. This study focused on the ambulatory surgery population over a 7-day
period describing incidence, severity, management strategies and quality of life.

Without

focusing specifically on patients at demographic or procedural high-risk, the overall incidence of
PDNV was 37.1%. Other studies have established an overall PDNV incidence of 35.7% over a 5
day period 4, PDN of 57% in a control group versus 20% in a study group and PDV of 20%
versus 3% for 5 days post discharge15, a PDV incidence of 5 – 9% based on risk factor
stratification (2 – 4 factors) at 24 – 72 hours10, 17% PDNV in patients who received inhalation
anesthesia and 11% in those with total intravenous anesthesia (TIVA)43, 32.6% PDN and 14.7%
PDV,5 and in a systematic review and analysis, an overall PDN of 17% with a range of 0 to
55%.

19

Incidences of PDNV across studies are difficult to compare because of the varying

patient samples, e.g. high risk patients, specific procedures performed, or using female gender
only. Many of the studies that have reported PDNV in the past have reported PDNV as a
secondary outcome or only assessed PDNV for the first 24 hours instead of the 7 days post
discharge in our study.15
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The incidences of PDN and PDV during the ride home have seldom been reported in the
few studies available on PDNV

44

, although Ernst and Thwaites reported 20% with nausea and

4% with vomiting during the ride home.45

In our study, 21.8% of patients experienced PDN

during the ride home and 4.6% experienced PDV. The incidence of PDN and PDV peaks after
arrival home on the day of surgery to 28.6% PDN and 12%. After DOS the incidence of PDN
and PDV decrease gradually until Day 7 when overall incidence is 6.3% of nausea and 1.2%
emesis. Results from this study are similar to those reported in an abstract by Philip, et al.46 who
reported an incidence of PDN of 46% in high-risk patients during the first 24 hours after surgery
decreasing to 8% on Day 7, and an incidence of PDV of 12% during the first 24 hours decreasing
to 1% on Day 7. It is significant that even a week later some patients were still experiencing the
negative symptoms of nausea and vomiting, a symptom that has been described by patients as
worse than pain.20 21
Apfel et, al. determined that female gender, nonsmoking status, history of PONV or
motion sickness, and use of perioperative opioids were strong predictors for PONV.8 Using the
Apfel simplified risk assessment tool, the risk for PONV increased from 10% for no risk factors
to 79% if all 4 factors were present. Patients in this study who experienced PDNV were also
more likely to be female, had a history of PONV, motion sickness or migraine headaches,
undergone laparoscopic surgery, and spent more time in the OR during the procedure. Other
differences that were significant were younger age, healthier patient status (ASA 1 status) and
cholecystectomy. It is possible that cholecystectomy was significant because of the laparoscopic
surgical approach which has been identified as related to PONV.47
Interestingly, nonsmoking status, strongly related to PONV,8, 47 was not related to PDNV
experienced in this study. As other studies have found, BMI, educational status, and income are
not related to PDNV.47, 48 Nitrous oxide or use of inhalation agents was not related to PDNV as
has been found significantly related to PONV.47, 49-52 This is more than likely due to the short
acting effects of the volatile anesthetics. 50 One interesting finding in this study that has not been
identified in other studies is that use of local anesthetic at the surgery site was significantly
related to PDNV, and does merit further study. It is possible that more surgeons are using local
anesthetics for pain control during surgery, so it may be related to care of the patient. It may be
used for the more major surgeries in which we expect more pain, and therefore when it
metabolizes in the first 24 hours, the patient experiences a spike in pain. In one study, patients
who experienced PONV in the PACU were unlikely to experience PDNV4, while Wright found
that patients who experienced PONV in PACU were more likely to have PDNV.53 In this study,
we found that patients who experienced PONV in the PACU were significantly more likely to
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experience PDNV. Use of intravenous opioids in the PACU was significantly related to PDNV
until the third day post-surgery, and use of oral opioids was related to the presence of nausea on
most days after discharge. This finding is similar to other studies, in which researcher have found
postoperative opioids in the PACU linked to PONV.8, 47 Use of short-acting opioids in the PACU
should not be related to delayed PDNV. However, the use of those IV opioids in the PACU may
be significant until Day 3 because patients who need IV opioids may continue to need an oral
opioid after discharge home. However, use of hydrocodone was not associated with PDNV after
Day 2 and oxycodone after Day 3. Patients with higher pain scores, however, were associated
with higher pain scores. It is possible that patients who have stopped taking pain medication have
higher pain scores and then a resulting increase in PDNV.54
Risk factors have not been identified for PDNV until now. Apfel, et al. using the data
from this multi-site study recently determined predictors for a simplified assessment tool for early
PDNV (48 hours after surgery).3 The five statistically significant independent risk factors for
PDNV for the first 48 hours are female gender, age less than 50 years, history of PONV, opioids
administered in the PACU, and nausea in the PACU.3 In this study, we determined factors that
impact the presence of PDNV during Days 3 – 7 using logistic regression analysis. The final
model included history of PONV, OR time and pain score. It is possible that the presence of
nausea later post discharge has different causes than the PDNV that has resolved over the first 48
hours. Opioids given in the PACU or presence of PONV in the PACU are no longer significant
factors. It is also possible that age was not in our final model for late PDNV because it correlated
with pain, e.g. the younger the patient, the higher the pain score for those with late PDNV. The
odds of having PDNV with severe pain are estimated to be 4.49 times as high as the odds of
PDNV with no pain. It is interesting that OR time continues to be a factor for late PDNV. For
every one hour of OR time the odds of PDNV are 1.86 times higher. We thought it possible that
the more major surgeries were related to the OR time, and the patient may have a longer recovery
based on type of surgery. However, even with OR times removed from the model and surgery
type and approach added, neither surgery type nor surgical approach were significant. Thus, OR
time is not acting simply as a surrogate for surgical procedure. The history of PONV continues as
a factor for late PDNV.

The odds of nausea are 2.9 times higher when one has a history of

PONV.
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Management Strategies
In this study, patients with PDNV were likely to use minor self-care strategies to manage
symptoms. In the subset of patients who answered the question about calling the healthcare
provider, only 2 persons with PDNV contacted a healthcare provider (HCP) for those symptoms.
This is in line with results other researchers have found in patients with PDNV. Patients tend to
manage symptoms themselves4, seldom contact a HCP4, 55, and stop taking pain management
medication16, 56.
Of significance in this study is that only 4.2% of patients recorded use of an antiemetic
even though 37.1% recorded evidence of PDNV. Patients with the lowest mean nausea scores did
not use antiemetics. Patients who do not have nausea or who have only mild cases of nausea may
be less likely to take a pharmacologic modality or use any nonpharmacologic method of nausea
control. The mean nausea level (0 – 10) for patients who used nonpharmacologic modalities only
(Group 2) and patients who used antiemetics only (Group 3) were not significantly different from
each other.

Patients who had the highest mean for nausea were more likely to use both

antiemetics and nonpharmacologic methods of controlling PDNV. In this study, patients who are
experiencing severe nausea were more likely to take antiemetics for their symptoms. We were
able to determine that a small percentage of patients who have PDNV actually take antiemetics
for control of symptoms. Many studies that have reported incidences of PDNV are interventional
studies with anesthetic routine pre-prescribed. It is significant that in a real-time environment
only 9.7% of patients who had PDNV actually took an antiemetic.
We do not know the percentage of patients who actually went home with a prescription
for an antiemetic. This information should be obtained in any future studies. Also of note is the
fact that only 3 patients recorded use of acupressure or acustimulation bands which have been
found to decrease incidence of PDNV in studies.57, 58 Future guidelines for care of the patient
with PDNV should suggest appropriate antiemetics for patients at risk for PDNV, and any
algorithm for care of the patient with PDNV should include nonpharmacologic methods of nausea
control such as acupressure.

These patients relied on self-care techniques as shown in other

studies, sometimes to the detriment of care, such as stopping pain medication.16

88

Outcomes
We found that nausea was significantly related to overall QOL on every day post
discharge and that vomiting was significantly related to overall QOL until Day 3. Other studies
have shown a negative relationship of PDNV and QOL. Pan found that 33% of the study group
and 60% of the control group were negatively affected by emetic symptoms.15 Carroll found that
patients who experienced PDNV were negatively affected in performing normal daily activities.4
Few studies have related QOL questions specifically to nausea or vomiting. When quality of
recovery is studied, typically QOL is related to a number of outcome measures. For example, the
Quality of Recovery Score has nine questions with only one related to nausea and vomiting.36
The FLIE focuses on nausea and vomiting, but does not incorporate other QOL indicators that
would aid in determining the effect of PDNV on patient QOL.15
Nausea affected patients’ ability to eat and drink; do necessary activities and tasks;
enjoyment of leisure and recreational activities; and enjoy of social activities on all 7 days.
Ability to do normal work and ability to sleep were affected until Day 6. Vomiting affected all
QOL questions until Day 3 which correlates with the decrease in incidence of vomiting. It is
clear that some patients are affected by nausea up to one week after surgery.
PDNV does affect patient satisfaction with treatment. Interestingly, though, even the
patient with PDNV rated their treatment as 6 on a scale of 0 – 10 (0 as far worse than expected, 5
as expected, and 10 far better than expected). Patients without PDNV had a higher satisfaction
with a rating of 8.8. However, even a rating of 6 is better than expected on the scale used by the
patient. This could mean that some patients believe that PDNV is to be expected after surgery, or
that the PDNV experienced by the patient was less than expected.

Research Implications
Future studies should focus on patient education needs related to PDNV and use of risk
assessment tools for PDNV. Future studies should include determination of a detailed patient
education program and its effectiveness. More research should be conducted to determine the
relationship of pain and PDNV including the association of post discharge opioids. Barriers to
patient decision to take pain medication and antiemetic medication should be determined. It is
imperative that randomized controlled trials that determine appropriate long-term antiemetics and
non-pharmacologic methods to control nausea and vomiting are conducted. Other factors of
interest that need to be studied are patient anxiety and how it relates to PDNV, patient
comprehension of discharge instructions, and ability to discern appropriate strategies for self-
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care. Research should be conducted to determine instruments with validity and reliability to
accurately capture the effect of nausea or vomiting on QOL.

Practice Implications
Patients should be screened for risk of PONV and treated according to published
guidelines based on risk factors. With further identification of PDNV risk factors, ambulatory
surgery patients should be screened for risk of PDNV. Prophylactic interventions for PDNV,
such as transdermal scopolamine; longer acting 5HT3 receptor antagonists, such as palonsetron;
promethazine suppository; ondansetron dissolving tablet; or NK1 receptor antagonist agent, such
as aprepitant should be available and incorporated into any guideline for care. Nonpharmacologic
interventions should be available and taught to the patient, such as acupressure.

A rescue

antiemetic should be prescribed upon discharge as part of the medication regimen for the post
discharge patient. Effective pain medication of the patient who is discharged is imperative, as
well as assuring that the patient understands the importance of taking the medication. Patient
education is imperative. This study did not obtain information that related to the quality of
discharge instruction, but adding information on treatment of PDNV to patients before discharge
is suggested. The anesthesia department should become a larger partner with the surgeon when
determining effective post discharge care of pain and nausea and other anesthesia related
symptoms. An appropriate follow-up program should be in place in all healthcare facilities.

Limitations
Limitations to this study include the differences between the 48-hour sample and the 7day sample. The 48- hour sample was comprised of 2140 patients from 12 sites across the United
States. On Day 3, the sample decreased to 260 patients from two sites. The 7-day sample was
significantly more likely to experience PDNV. This may be related to the higher percentages of
females to males; history of PONV; cholecystectomies performed; and laparoscopic incisional
approach which are all risk factors for PDNV. It is also possible that patients were treated
differently in the 2 centers preoperatively and intraoperatively that may have contributed to the
differences in samples. However, both sites had differing populations; one a university setting,
and the other a private hospital. And the smaller sample (N = 260) was powered to detect
significant group differences between those with PDNV and those without.
The sample was a convenience sample, although purposeful with consecutive patients
who met inclusion criteria recruited for the study. The study could be replicated using random
assignment of patients who met inclusion criteria. However, the sample was large and from
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multiple centers across the U.S. and should give a real-life picture of the incidence and severity of
PDNV, management strategies, and QOL outcomes for a week-long period of time.
Questions used to obtain patient QOL have undergone face validity, but no further
validity or reliability testing. The statements were taken from the literature by experts and are
similar to statements in other instruments, e.g. modified Osoba module11, 59, FLIE,15, 60 but have
not specifically been tested in the postoperative population.

Summary
The incidence of PDNV continues to be unacceptably high in a population of patients
who until recently have flown beneath the anesthesia, surgical, and perioperative radar. There are
some patients who suffer with PDNV up to a week after surgery. The majority of these patients
are not taking any antiemetic or using productive nonpharmacologic methods of symptom
control. Quality of life is affected by these symptoms for several days after surgery. A directed
patient education program may be helpful in instructing patients in medication compliance, how
to manage PDNV symptoms as well as other anesthesia outcomes, and informing patients on an
appropriate follow-up with the healthcare provider.

Copyright © Jan Odom Forren 2009
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Table 5.1 Demographic and Clinical Characteristics

Demographics
Age
Mean + SD
Median
Range
BMI
Mean + SD
Median
Range
Gender
Female
Male
Ethnicity
African-American
Asian
Caucasian
Latino
Other
Educational level
High school
College
Graduate degree
None of these
Did not answer
Income level
<$25,000
$25, 000 - $50,000
$50,000 - $75,000
$75,000 - $100,000
>$100,000
Did not answer
Clinical Characteristics
Smoker
No
Yes
Previous PONV
No
Yes
Previous motion sickness
No
Yes
History migraine
headaches
No
Yes

DOS – 48 hours
N = 1910

DOS – 7 days
N = 260

P value

Total
N = 2170

49.19 + 15.46
49.0
17 - 90

51.99 + 14.71
53.5
19 - 87
28.99 + 6.6
27.62
17.6 – 57.7

0.006

49.52 + 15
50
17 - 90

.10

28.24 + 6.9
26.65
14.5 – 63.7
N (%)

N (%)

1220 (63.9)
690 (36.1)

184 (70.8)
76 (29.2)

0.029

1404 (64.7)
766 (65.3)

185 (9.7)
69 (3.6)
1371 (71.8)
108 (5.7)
177 (9.3)

24 (9.2)
224 (86.2)
3 (1.2)
9 (3.5)

<0.0001

209 (9.6)
69 (3.2)
1595 (73.5)
111 (5.1)
186 (8.6)

282 (14.8)
764 (40)
204 (10.7)
37 (1.9)
622 (32.6)

96 (36.9)
139 (53.5)
13 (5.0)
5 (1.9)
7 (2.7)

<0.001

378 (17.4)
903 (41.6)
217 (10)
42 (1.9)
529 (20)

196 (10.3)
242 (12.7)
202 (10.6)
200 (10.5)
292 (15.3)
777 (40.7)

32 (12.3)
58 (22.3)
53 (20.4)
48 (18.5)
47 (18.1)
22 (8.5)

<0.0001

228 (10.5)
300 (13.8)
255 (11.8)
248 (11.4)
339 (15.6)
799 (36.8)

1619 (84.8)
291 (15.2)

221 (85)
39 (15)

.994

1840 (84.8)
330 (30.2)

1317 (69)
526 (27.5)

150 (57.7)
110 (42.3)

<0.0001

1467 (76.6)
636 (69.8)

1433 (75)
477 (25)

187 (71.9)
73 (28.1)

.316

1620 (74.7)
550 (53.1)

1462 (76.5)
447 (23.4)

199 (76.5)
61 (23.5)

28.33 + 6.9
14.5 – 63.7

.987
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1661 (76.5)
508 (46.9

Table 5.1 (Continued) Demographic and Clinical Characteristics
DOS – 48 hours
N = 1910

DOS – 7 days
N = 260

P value

Total
N = 2170

Clinical Characteristics
Procedures
<0.0001
441(20.3)
39 (15)
402 (21)
General
223(10.3)
28 (10.8)
195 (10.2)
Breast
96(4.4)
35 (13.5)
61 (3.2)
Cholecystectomy
131 (6.0)
10 (3.8)
121 (6.3)
Cystoscopy
183 (8.4)
24 (9.2)
159 (8.3)
D&C
186 (8.6)
17 (6.5)
169 (8.8)
ENT
238(11.0)
22 (8.5)
216 (11.3)
Gynecologic
90 (4.1)
21 (8.1)
69 (3.6)
Hernia
230 (10.6)
40 (15.4)
190 (9.9)
Knee arthroscopy
132 (6.1)
7 (2.7)
125 (6.5)
Orthopedic
78 (3.6)
3 (1.2)
75 (3.9)
Prostate
141 (6.5)
14 (5.4)
127 (6.6)
Upper extremity
Surgical Approach
<0.0001
1127 (51.9)
96 (36.9)
1031 (54)
Conventional
304 (14.0)
51 (19.6)
253 (13.2)
Arthroscopic
451 (20.8)
42 (16.2)
409 (21.4)
Endoscopic
287 (13.2)
71 (27.3)
216 (11.3)
Laparoscopic
ASA Status
ASA 1
388 (20.3)
44 (16.9)
0.037
432 (19.9)
ASA 2
1145 (59.9)
179 (68.8)
1324 (61)
ASA 3
368 (19.3)
37 (14.2)
405 (18.7)
ASA 4
8 (0.4)
8 (0.4)
OR Time in Hours
1.40 + .723
1.71 + .868
<0.0001
1.67
Mean + SD
1.53
1.48
Median
1.18
0.22 – 11.20
0.22 – 11.20
Range
0.48 – 5.15
Presence of PDNV
No
1235 (65.5)
107 (43.1)
<0.001
1335 (62.8)
Yes
649 (34.5)
141 (56.9)
790 (37.2)
Mean Nausea Scores
Mean + SD
.8506 + 1.60
1.491 + 2.10
<.001
.9274 + 1.68
Median
0
.50
0
Range
0 - 10
0 – 8.67
0 - 10
DOS = Day of Surgery; PONV = Postoperative nausea and vomiting; D & C = Dilatation and
Curettage; ENT = Ear, Nose, and Throat; ASA = American Society of Anesthesiologists; OR =
Operating Room; PACU = Post Anesthesia Care Unit
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Table 5.2 Demographic and Clinical Characteristics of Patients with PDNV and without PDNV
PDNV
No PNDV
P value
Demographics
Age
Mean + SD
Median
Range
BMI
Mean + SD
Median
Range
Gender
Female
Male
Ethnicity
African-American
Asian
Caucasian
Latino
Other
Educational level
High school
College
Graduate degree
None of these
Did not answer
Income level
<$25,000
$25, 000 - $50,000
$50,000 - $75,000
$75,000 - $100,000
>$100,000
Did not answer
Clinical Characteristics
Smoker
No
Yes
Previous PONV
No
Yes
Previous motion sickness
No
Yes
History migraine
headaches
No
Yes

44.93 + 14.60
44.0
17 - 88

52.29 + 15.23
53.0
18 - 90

<0.001

28.57 + 7.05
26.96
14.53 – 58.72
N (%)

28.21 + 6.89
26.65
15.35 – 63.70
N (%)

598 (43.4)
192 (25.5)

780 (56.6)
562 (74.5)

<0.001

76 (37.8)
32 (47.1)
580 (36.9)
49 (45.0)
53 (29.1)

125 (62.2)
36 (52.9)
992 (63.1)
60 (55.0)
129 (70.9)

<0.029

137 (37.0)
331 (37.4)
78 (35.9)
16 (38.1)
228 (37.0)

233 (63.0)
554 (62.6)
139 (64.1)
26 (61.9)
389 (63.0)

.990

90 (40.4)
113 (38.6)
87 (34.7)
95 (39.1)
115 (34.4)
290 (36.8)

133 (59.6)
180 (61.4)
164 (65.3)
148 (60.9)
219 (65.6)
497 (63.2)

.642

662 (36.6)
128 (39.4)

1145 (63.4)
197 (60.6)

.345

469 (32.6)
297 (47.3)

969 (67.4)
331 52.7)

<0.001

544 (34.3)
246 (45.2)

1044 (65.7)
298 (54.8)

<0.001

561 (34.4)
229 (45.9)

1071 (65.6)
270 (54.1)

<0.001

.247
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Table 5.2. (Continued) Demographic and Clinical Characteristics of Patients with PDNV and
without PDNV
Clinical Characteristics
Procedures
General
Breast
Cholecystectomy
Cystoscopy
D&C
ENT
Gynecologic
Hernia
Knee arthroscopy
Orthopedic
Prostate
Upper extremity

PDNV

No PNDV

P value

140 (32.2)
79 (35.9)
62 (66.0)
36 (27.5)
66 (37.3)
61 (33.5)
103 (43.6)
28 (32.2)
104 (46.0)
46 (35.9)
11 (14.1)
54 (39.4)

295 (67.8)
141 (67.9)
32 (34.0)
95 (76.5)
111 (62.7)
121 (66.5)
133 (56.4)
59 (67.8)
122 (54.0)
82 (60.6)
67 (85.9)
83 (80.6)

<0.001

Surgical Approach
<0.001
720 (65.2)
385 (34.8)
Conventional
169 (56.3)
131 (43.7)
Arthroscopic
318 (71.6)
126 (28.4)
Endoscopic
134 (47.5)
148 (52.5)
Laparoscopic
ASA Status
<0.001
241 (47.2)
184 (43.3)
ASA 1
807 (62.1)
493 (37.9)
ASA 2
287 (72.1)
111 (35.8)
ASA 3
6 (75)
2 (25)
ASA 4
OR Time in Hours
1.74 + .913
1.63 + .811
<0.01
Mean + SD
Median
1.48
1.46
Range
.42 – 11.20
.22 – 7.15
Regional Block
No
603 (34.7)
1137 (65.3)
<0.001
Yes
187 (47.7)
205 (52.3)
Nitrous oxide
No
701 (36.5)
1222 (63.5)
.08
Yes
89 (42.6)
89 (42.6)
DOS = Day of Surgery; PDNV = Post discharge nausea and vomiting; PONV = Postoperative
nausea and vomiting; D & C = Dilatation and Curettage; ENT = Ear, Nose, and Throat; ASA =
American Society of Anesthesiologist; OR = Operating Room; PACU = Post Anesthesia Care
Unit
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Table 5.3 Significance Levels for Final Logistic Regression Model
Variable
Intercept
Previous PONV
OR Time
Pain Factor

df
1
1
3

Deviance
214.715
224.517
222.615
241.005

Likelihood Ratio

p-value

9.802
7.900
26.290

0.0017
0.0049
<0.0001

Table 5.4 Estimated Regression Coefficients
Variable

Estimated
Log Odds

Estimated
Odds Ratio

1.0662

Standard
Error of Log
Odds
0.3475

Previous
PONV
OR Time
Mild Pain
Moderate
Pain
Severe Pain

2.90

Lower CI
limit for
Odds Ratio
1.47

Upper CI
limit for
Odds Ratio
5.74

0.6209
1.5968
2.3417

0.2275
0.6614
0.6635

1.86
4.94
10.40

1.19
1.35
2.83

2.91
18.05
38.17

2.9183

0.7230

18.51

4.49

76.35

Table 5.5 Pain Level and Presence/Absence Nausea in Days 3-7

No Pain
Mild Pain
Moderate Pain
Severe Pain

No late Nausea
67 (95.7%)
71 (80.7%)
42 (56.0%)
15 (53.6%)
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Some late Nausea
3 (4.3%)
17 (20.3%)
33 (44.0%)
13 (46.4%)

Table 5.6 Percentages of Patients with Severe Nausea who Used Pharmacologic and NonPharmacologic Methods of Nausea Control
Group 1
Group 2
Group 3
Group 4
Days Post
No AE
No AE
Yes AE
Yes AE
Surgery Severe
No NP
Yes NP
No NP
Yes NP
Nausea (% of
Total Severe
Nausea)
Day of Surgery
30%
55%
1.8%
13.2%
(12.8%)
Day 1 (4.6%)
27%
53%
2%
18%
Day 2 (2.8%)
26.2%
50.8%
4.9%
18%
Day 3 (4.5%)
25%
25%
0
50%
Day 4 (2.3%)
0
33.3%
0
66.7%
Day 5 (1.9%)
0
40%
0
60%
Day 6 (2.7%)
0
42.9%
0
57.1%
Day 7 (2%)
20%
0
20%
60%
AE = Antiemetics; NP = Nonpharmacologic modalities
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Percentages of Partients

Figure 5.1 Overall Incidence of Patients With PDNV
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Figure 5.2 Incidence of Patients With Post Discharge Nausea
and Vomiting By Day in Overall Study (N = 2170)
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Day 2

Percentages of Patients

Figure 5.3 Incidence of Post Discharge Nausea and Vomiting in
7-Day Study (N = 260)
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Figure 5.4 History of PONV, Motion Sickness, Or
Migraines on Mean Scores of Nausea
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Figure 5.5 Severity of Nausea for 7 Days
Severe Nausea

100%
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Figure 5.6 Nausea of Males and Females Over 7 Days
on a 0 - 10 Scale
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Age by Category

Figure 5.7 Mean Nausea Scores by 3 Age Groups
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Figure 5.8 Mean Nausea Scores by Surgical Procedure
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Mean Nausea Scores

Figure 5.9 Mean Nausea Score by Surgical Approach
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Percentages of Patients

Figure 5.11 Percentages of Antiemetics Used After Discharge
4

Yes

3
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0
Ond

Dex
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Prometh

Ond = Ondansetron; Dex = Dexamethasone; Diphen = Diphenhydramine; Prometh =
Promethazine
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Effect of Nausea on QOL

Figure 5.13 Mean Effect of Nausea on Overall Quality of Life
(0 = None, 10 = Most Bothersome)

Effect of Nausea
Overall QOL Scores

DOS Day 1 Day 2 Day 3 Day 4 Day 5 Day 6
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Figure 5.14 Effect of Vomiting on Overall Quality of Life
(QOL) Mean Scores
Mean Score Effect of Vomiting
on QOL
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Mean Scores of Expected
Likelyhood

Figure 5.15 Expected Likelihood of Post Discharge Nausea or Vomiting
(0 = Not Likely, 10 = Very Likely)
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Figure 5.16 Mean Score of Rating of Treatment of Nausea by Those
With and Without PDNV
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CHAPTER SIX
Conclusions and Discussion
The purposes of this dissertation were to (1) review the current knowledge in the area of
post discharge nausea and vomiting; (2) present results of an integrative review of the research
literature to determine best evidence for prevention of PDNV in adults or rescue of patients who
suffer from post discharge nausea and vomiting (PDNV); (3) present a critical review and
analysis of measurement of nausea and vomiting after discharge from outpatient surgery, and (4)
present findings of a prospective research study. The purposes of the empirical research study
conducted as part of this dissertation were to: 1) describe the incidence and severity of PDNV
over a 7-day period in a sample of adult surgical patients undergoing outpatient surgeries under
general anesthesia, 2) describe the pharmacologic and nonpharmacologic modalities of care used
by patients with PDNV to manage it, 3) compare the incidence and severity of PDNV between
those who do and do not use pharmacologic and nonpharmacologic modalities, 4) determine
outcomes associated with PDNV, and 5) determine predictions for late (Days 3-7) PDNV.
In this dissertation, four papers are presented, two of which have been published to date.
In the first paper, current knowledge of PDNV was systematically reviewed.2 We found that
PDNV had not been assessed and evaluated as thoroughly as postoperative nausea and vomiting
(PONV). It was evident from the literature review, that covered a decade of studies, that patients
have continued to have problems with nausea and vomiting upon discharge. We do not know how
those symptoms impact the patient’s recovery, how extensive the delay in recovery is due to the
symptoms, or the costs attributable to these symptoms.3 Suggestions for research based on this
systematic review included study of (1) antiemetic efficacy in the post discharge setting, (2) the
effectiveness of a detailed education program to manage symptoms for these patients, and (3)
economic impact of the symptoms.
In the second paper, interventions for PDNV in the outpatient surgery population were
specifically targeted.4 In the paper an integrative review was presented in which the evidence for
prevention of PDNV in adults or for the rescue of patients who suffer from PDNV was reviewed.
The evidence included information on the association of anesthetic techniques (e.g. total
intravenous anesthesia was associated with decreased PDNV for the first 24 hours, but not 14
days later), antiemetics (e.g. use of transdermal scopolamine as an effective antiemetic for the
outpatient), and pain medication (e.g. patients who received morphine in PACU were more likely
to have PDNV at 24 hours than those who received fentanyl) with PDNV incidence. The paper
also included several studies in which nonpharmacologic methods of controlling nausea and
vomiting were included, (e.g. acupuncture/acustimulation and ginger). We found that there was a
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paucity of nursing research focused on PDNV. Since physicians have focused on research that
requires a treatment regime intraoperatively, we concluded that nurse researchers could conduct
studies on the effectiveness of patient or caregiver education, preoperative anxiety, interactions of
pain and pain medication, and non-pharmacologic methods of relief. We also suggested that
nurse researchers collaborate with medical researchers to determine the best antiemetics for use in
the postdischarge setting or the most appropriate medication for pain relief in the postdischarge
setting that will alleviate pain, but cause less PDNV.
The third paper was a critical review and analysis of the literature on measurement of
patient nausea and vomiting after discharge from outpatient surgery and in which we discussed
relevant needs in the area of measurement. In that paper, we determined there was a lack of
standardized definitions of PONV and PDNV, of psychometrically sound instruments to measure
PONV and PDNV, and a reliance on investigator developed instruments used in only one study.
Assessment of nausea and vomiting has been inconsistent throughout studies. For example, there
is not only inconsistency with the definition of PONV and PDNV per study, but also differing
definitions of the basic terms, nausea, vomiting and retching, with some researchers measuring
each entity separately and others considering all as emetic episodes. That inconsistency has
contributed to the difficulty comparing study findings. We found that there are no clear and
standardized instruments in use to measure the phenomena of PDNV.

There were two

instruments found with adequate psychometric properties, the ambulatory surgery-inventory of
nausea vomiting and retching (AS-INVR) and the functional living inventory-emesis (FLIE),
whose use will provide the possibility of standardizing assessment of PDNV symptoms in
research studies. Most of the psychometric testing for these instruments was in the chemotherapy
population. Although these two instruments both possess strengths, more study is needed to
progress the measurement of nausea and vomiting in the post discharge ambulatory surgery
patient.
The fourth paper was the results of a research study in which we described the incidence
and severity of PDNV in adult outpatients after ambulatory surgery. In the study we also
describe the pharmacologic and nonpharmacologic modalities of care used by patients with
PDNV to manage it, compare the incidence and severity of PDNV between those who do and do
not use pharmacologic and nonpharmacologic modalities, and determine outcomes associated
with PDNV.
We found that over one third of ambulatory surgery patients experience PDNV. With
over 34 million patients undergoing ambulatory surgery annually in the U.S. alone, that translates
to millions of patients who go home after surgery and suffer these post discharge symptoms of
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nausea and vomiting. We found that PDNV peaks on the day of surgery and continues to
decrease over the week; however, some patients are still experiencing PDNV one week after
discharge home. Predictors for early PDNV (48 hours) were determined recently by investigators
using data from this study as: female gender, age less than 50 years, history of PONV, opioids
administered in the PACU, and nausea in the PACU. We determined that predictors for late
PDNV (history of PONV, OR time and pain score) were somewhat different than early
predictors.
Even though 37.1% of our patient experienced PDNV, only 4.2% of those patients used
antiemetics for management of symptoms. Most patients self-managed at home with lying down,
carbonated drink intake, and taking medication with food. Some patients stopped taking their
pain medication, and only 3 patients in the study used acupressure bands. Those who did use
antiemetics had a higher mean nausea score than those who did not. Only two patients out of 180
who responded to the question called their healthcare provider for PDNV symptoms.
We found that PDNV negatively affected the mean quality of life (QOL) scores. PDNV
affected the patients’ ability to eat and drink, to sleep, to socialize and to perform activities of
daily living. We also found that patients who expected to have nausea or vomiting were more
likely to experience nausea and vomiting. Patients with PDNV rated their satisfaction with
treatment as lower than patients who did not have PDNV.
Implications for the Future
Nausea and vomiting after surgery has been a long-term problem that began with
hospitalized patients after surgery and moved out into the home with the advent of ambulatory
surgery.

There is a death of literature that describes this phenomenon.2,

4

In this study we

addressed the issue of PDNV with the first long-term multi-site study to focus on a description of
this phenomena since Carroll, et al.5 What we discovered was that over one third of ambulatory
surgery patients suffer from PDNV after discharge. That tells us there has been no progress in
relieving those symptoms since the first report in 1995 in which 35.7% of participants
experienced PDNV.5

Research Recommendations
Systematic inquiry to discover appropriate venues of prevention and treatment for
patients who suffer from PDNV is needed.

Patients with PDNV are typically unseen and

unheard. These patients tend not to call a healthcare provider during the week after surgery, but
try to manage symptoms with self-care, or they may report the symptoms to the surgeon, and the
information never gets back to the anesthesia team.6 Imperative to further research conducted in
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this population of patients is clear definition and measurement of research terms. Inconsistency
with assessment and measurement of nausea, vomiting, and retching throughout studies has made
it difficult to compare study results in the area of PDNV. PDNV should clearly be defined as
nausea and vomiting after discharge from the healthcare facility. Studies of PDNV should follow
patients for at least 48 hours after discharge. In this dissertation, we discovered that 6.3% of
patients had symptoms of nausea up to a week after surgery, so long-term studies are also needed
to further describe this smaller segment of PDNV population.
Reliable and valid instruments are not consistently used in studies with patients who have
PDNV, although use of the visual analogue scale (VAS), verbal descriptor scale (VDS), and
numerical rating score (NRS) is common, and use of these instruments has been described as
valid and reliable by other researchers.7-10 More studies should be performed using the two
established instruments, Ambulatory Surgery-Inventory of Nausea, Vomiting, and Retching (ASINVR) and Functional Living Index-Emesis (FLIE), to establish normative values, timing needed
to complete the instrument, and grade level. The AS-INVR and the FLIE provide the possibility
of standardization of outcome for studies with those patients.11-14 In all studies on PDNV,
reliability and validity of instruments should be reported. Researchers should also determine
whether it is more effective for the patient to rate PDNV on a daily basis, at 12- hour intervals, or
shorter intervals after arrival home.
Further research needs to be conducted into the newer specific drugs that are available for
care in the PDNV population. The short-acting antiemetics that are given typically in the PACU
before patient discharge do not protect against PDNV once the patient is home. Some work has
begun in this area with recent studies on palonosetron, a 5HT-3 receptor antagonist much like
ondansetron, but longer-acting.15,16 Other drugs that possibly will protect against PDNV include
transdermal scopolamine,17 promethazine suppositories,18 ondansetron dissolving tablets (ODT)19,
, and aprepitant, a new NK-1 receptor antagonist.21,

20

22

Researchers should focus on

nonpharmacologic means to manage symptoms of PDNV including, but not limited to
acupressure, acupuncture,

23

acustimulation,24, 25 imagery, music therapy, distraction, relaxation,

aromatherapy, and use of ginger.26 There is little research to document effectiveness in the PDNV
population, but some of the nonpharmacologic methods have shown potential. These
nonpharmacologic means of control could work in conjunction with antiemetics to resolve
symptoms of PDNV.
Through research, we should develop an algorithm to guide management of PDNV.6 At
the present time, only one practice guideline attempts to guide management of PDNV. An
algorithm to guide care for PDNV would use the predictors determined by Apfel, et al. to assess
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patients for risk. Then the patient could be assigned treatment based on risk. That same algorithm
could make recommendations for anesthesia care based on patient risk as available algorithms for
PONV do presently, e.g. total intravenous anesthesia (TIVA) instead of volatile anesthetics.27, 28
That same algorithm could then drive rescue treatment in the PACU. Assessing patient risk
before surgery is extremely important because three of the medications are effective in this
population of patients require administration before surgery for adequate prophylaxis (i.e.,
aprepitant, palonsetron, transdermal scopolamine).

Then the algorithm can guide rescue

treatment in the PACU and then later at home.
There are other areas of research that could be advanced. Only one group of investigators
tested a patient education intervention designed to compare the efficacy of existing generic
education instructions with specially designed procedure-specific instructions.29 Patients in both
groups felt they received adequate discharge instructions, so there was no significant difference
between groups. However, other researchers have pointed out the need to improve preoperative
patient teaching, including topics of drug and nondrug interventions.30 In PDNV studies, patients
have attempted to self-manage symptoms, so research that looked at self-efficacy issues would be
appropriate. Genetic and other molecular biological patient characteristics that predispose a
patient to PDNV need to undergo research.31
Many of the research suggestions mentioned above could be conducted by nurses in a
nursing research program. Some of the research suggestions could be conducted with nurses as
part of a research team including pharmacy, anesthesia and surgery for the total care of the
patient.
Research of PDNV symptoms could be part of a larger program that focuses on all
discharge symptoms experienced by the patient after ambulatory surgery. These symptoms
include, but are not limited to pain,32-34, the emetogenic role of opioids in PDNV,35 somnolence or
level of sedation, bleeding, dizziness, fatigue, headache, backache, sore throat, hoarseness,
elevated temperature and voiding difficulty. Also of importance is how the patient symptoms
affect the quality of recovery including ability to drink liquids, eat, make meals, do
recreation/leisure activities, interact with family and friends, affect daily functions, and affect
ability to return to work.36-40 This research has focused on the adult population. Research should
also continue in the pediatric population because PDNV affects children as well as adults.
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Clinical Recommendations
Specifically for nursing, the preanesthesia nurse in the ambulatory setting is a part of the
anesthesia team and can assess the patient for risk, as well as collaborate with the team for
management of PONV and PDNV. If the patient has come in for preadmission testing before the
day of surgery, this is a perfect opportunity for the nurse to assess the patient early for the risk of
PDNV and to also provide specific patient education for management of symptoms at home
should they occur. In the PACU, the postanesthesia nurse, also a part of the team, assesses the
patient for PONV, and assesses the severity of nausea when it does occur. That nurse is also a
vital member of the anesthesia care team and collaborates in making treatment recommendations
for the patient. The nurse in the postanesthesia phase II unit prepares the patient for discharge
home which includes patient education for the patient and caregiver. This is another point of care
where the nurse can provide education and support for management of symptoms should they
occur at home. The weak link is after discharge home when the patient may suffer without
contacting a health care provider, or with care managed by the surgeon who may or may not be
aware of newer medications and techniques for managing symptoms. The anesthesia care team
should be more involved in planning patient care for negative anesthesia symptoms at home. An
algorithm could guide care for this period of patient recovery and would be an asset for surgeon,
anesthesia provider, or nurse who was in contact with the patient.

Summary
PDNV is not a symptom that typically causes mortality, but is a negative symptom that
can impact a patient’s feeling of well-being, as well satisfaction with care and the healthcare
facility.41 The economic effect of any postdischarge symptom is unclear at the present time, but is
related to incidence, impact of the symptom, and delays in return to normal function by the
patient.3 The incidence of PDNV has not changed in the last decade, and it is time that we moved
forward with interventions that can affect this group of patients with either prevention or effective
treatment. This study is a foundation that tells us where we are and where we should go in the
future for care of this negative, uncomfortable, and many times, serious entity.

Copyright © Jan Odom Forren 2009
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APPENDIX A: Patient Diary Instruction:
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PATIENT DIARY INSTRUCTION
Participant Code: _________________
Thank you for participating in our survey. We hope that by following up with you to better understand difficulties you might have encountered
after anesthesia and surgery so that we will be able to treat our patients better in the future.
and .
We will call you on your 1st day after surgery between
and .
We will call again on your 2nd day after surgery between
We will call again on your 7th day after surgery between
and .
For Days 1-2, please fill out your diary at each of the following times (morning, lunchtime, dinnertime and bedtime) so that we can go through
questions with you more effectively when we call you.
For Days 3 – 7, please fill out the information when you first wake up in the morning. After the last page is filled out, please send back to the
researcher in the self-addressed stamped envelope.
For the purposes of this survey, you may find the following definitions of symptoms useful.
Nausea is a sensation of queasiness in your stomach or throat that may lead to vomiting.
Vomiting is bringing up stomach contents due to involuntary muscle contractions.
Retching is similar to vomiting with the exception that no stomach contents come up, it is also known as “dry heaves”.
We will also be asking you to enter your symptoms according to different time intervals. In some instances, the time points might not literally fit.
For example, when we talk about bedtime we mean when you decided to try to go to sleep for the night, even if you have actually been in bed all
day because of your surgery. Here is a rough definition of the time-points and intervals:
Morning to Lunchtime: From wake-up until just before your lunchtime, e.g. around noon.
Lunchtime to Dinnertime: From start of your lunchtime until just before your dinnertime, e.g. around 6 pm.
Dinnertime to Bedtime: From start of your dinnertime until your bedtime, e.g. around 10 pm.
Bedtime to Morning: From your bedtime until you wake-up the next morning.
Thank you in advance for completing this survey! Your information will help us take better care of patients in the future.
You will receive your $10 gift card in the mail approximately 2-4 weeks after we have received your completed diary.
Jan Odom Forren, PhD candidate, MS, RN, CPAN, FAAN; College of Nursing, University of Kentucky, Lexington, KY 40506; email: jan.forren@uky.edu; phone 502.552.8299

DAY OF SURGERY
Symptoms after Surgery
Your self-assessments below are most accurate and useful to us if you complete them near the end of each time interval. For example, you should
fill out how you felt during your ride home as soon as you arrive home. If you were asleep at the end of the time interval please complete the
assessment as soon as you can.
Please use the 0-10 scale with 0 being “none at all” and
0
1
2
3
4
5
6
7
8
9
10
10 being the “worst possible” to rate your symptoms.
none at all
worst possible
As the day goes on please fill out each question at the
end of each time interval. If you have no symptoms please enter a “0.”

Please answer each question below at the
end of each time interval to the right Æ
1. What was your severity of pain at rest?
2. What was your severity of pain during activities?
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3. What was your worst severity of nausea?
4. If you had nausea, for how long did you have it?[min]
5. How many times did you have vomiting/retching?
6. What was your worst severity of vomiting/retching?

During
Ride
Home

Ride Home
to
Dinnertime

Dinnertime
to
Bedtime

Answer these questions at the end of each day.
Day of Surgery
7. How tired were you during the day (0-10)
8. How much headache did you have (0-10)
9. What made your pain worse during the day?
10. What relieved your pain during the day?
11. What made your nausea worse during the day?
12. What relieved your nausea during the day?
13. What made your vomiting worse during the day?
14. What relieved your vomiting during the day?
PLEASE CIRCLE THE ANSWER TO CORRECTLY FILL IN THE BLANKS:
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1. In the last 24 hrs, I threw up
_____times.
2. In the last 24 hours, from retching or
dry heaves I have felt _____distress
3. In the last 24 hours, from vomiting or
throwing up, I have felt____distress
4. In the last 24 hours, I have felt
nauseated or sick at my stomach____
5. In the last 24 hours, from
nausea/sickness at my stomach, I have
felt ____ distress
6. In the last 24 hours, each time I threw
up I produced a_______amount.
7. In the last 24 hours, I have felt
nauseated or sick at my stomach ____
times

7 or more

5-6

3-4

1-2

I did not throw up

No

Mild

Moderate

Great

Severe

Severe

Great

Moderate

Mild

No

Not at all

1 hour or less

2-3 hours

4-6 hours

More than 6 hours

No

Mild

Moderate

Great

Severe

Moderate (½
- 2 cups)
3-4

Small (Up to
½ cup)
1-2

I did not throw up

Very large (3 Large (2-3
cups or more) cups)
7 or more
5-6

No

1ST DAY AFTER SURGERY
Symptoms after Surgery
Your self-assessments below are most accurate and useful to us if you complete them near the end of each time interval. If you were asleep at the
end of the time interval please complete the assessment as soon as you can.
Please use the 0-10 scale with 0 being “none at all” and
10 being the “worst possible” to rate your symptoms.
As the day goes on please fill out each question at the
end of each time interval. If you have no symptoms
please enter a “0.”

0
1
none at all

Please answer each question below at the
end of each time interval to the right Æ
15. What was your severity of pain at rest?
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16. What was your severity of pain during activities?
17. What was your worst severity of nausea?
18. If you had nausea, for how long did you have it?[min]
19. How many times did you have vomiting/retching?
20. What was your worst severity of vomiting/retching?

Bedtime
to
Morning

2

3

4

Morning
to
Lunchtime

5

6

Lunchtime
to
Dinnertime

7

8

Dinnertime
to
Bedtime

9

10
worst possible

Answer these questions at the end of each day.
1st Day after Surgery
21. How tired were you during the day (0-10)
22. How much headache did you have (0-10)
23. What made your pain worse during the day?
24. What relieved your pain during the day?
25. What made your nausea worse during the day?
26. What relieved your nausea during the day?
27. What made your vomiting worse during the day?
28. What relieved your vomiting during the day?
Please answer questions below when you wake up in the morning on the 1st day after surgery.
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29. In the space below, please list all new medications or remedies that you took from when you returned home yesterday to when you woke
up today. New medications or remedies are those that you did not take regularly before your surgery.
Name of new medication
or remedy

Time
of the day

Strength of doses
taken (mg)

Reason for taking

How effective was it?
0 = not at all,
10 = completely effective

Below indicate how much nausea, vomiting and pain
bothered you during your recovery and please use the
0-10 scale with
0 being “not at all” and 10 being “most bothersome”.
Nausea

Vomiting

0
not at all

1

2

3

4

5

6

7

8

9

10
most bothersome

Pain

30. How much did

Affect your quality of life yesterday?

31. How much did

Affect your usual ability to eat and drink yesterday?

32. How much did

34. How much did

Affect your usual activities and tasks yesterday?
Affect your usual enjoyment of leisure and recreational activities yesterday
(for example: reading, listening to music)?
Affect your usual enjoyment of social activities yesterday?

35. How much did

Affect your usual ability to do your normal daily work yesterday?

36. How much did

Affect your usual ability to sleep yesterday?

33. How much did
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PLEASE CIRCLE THE ANSWER TO CORRECTLY FILL IN THE BLANKS:
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1. In the last 24 hrs, I threw
up __times.
2. In the last 24 hours, from
retching or dry heaves I
have felt ___distress
3. In the last 24 hours, from
vomiting or throwing up, I
have felt____distress
4. In the last 24 hours, I
have felt nauseated or sick
at my stomach____
5. In the last 24 hours, from
nausea/sickness at my
stomach, I have felt ____
distress
6. In the last 24 hours, each
time I threw up I produced
a_______amount.
7. In the last 24 hours, I
have felt nauseated or sick
at my stomach ____ times

7 or more

5-6

3-4

1-2

No

Mild

Moderate

Great

I did not
throw up
Severe

Severe

Great

Moderate

Mild

No

Not at all

1 hour or
less

2-3 hours

4-6 hours

More than
6 hours

No

Mild

Moderate

Great

Severe

Very large
(3 cups or
more)
7 or more

Large (2-3
cups)

Moderate
(½ - 2
cups)
3-4

Small
(Up to ½
cup)
1-2

I did not
throw up

5-6

No

2ND DAY AFTER SURGERY
Symptoms after Surgery
Your self-assessments below are most accurate and useful to us if you complete them near the end of each time interval. If you were asleep at the
end of the time interval please complete the assessment as soon as you can.
Please use the 0-10 scale with 0 being “none at all” and
0
1
2
3
4
5
6
7
8
9
10
10 being the “worst possible” to rate your symptoms.
none
at
all
worst
possible
As the day goes on please fill out each question at the
end of each time interval. If you have no symptoms please enter a “0.”

Please answer each question below at the
end of each time interval to the right Æ
37. What was your severity of pain at rest?
38. What was your severity of pain during activities?
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39. What was your worst severity of nausea?
40. If you had nausea, for how long did you have it?[min]
41. How many times did you have vomiting/retching?
42. What was your worst severity of vomiting/retching?

Bedtime
to
Morning

Morning
to
Lunchtime

Lunchtime
To
Dinnertime

Answer these questions at the end of each day.
2nd Day after Surgery
43. How tired were you during the day (0-10)
44. How much headache did you have (0-10)
45. What made your pain worse during the day?
46. What relieved your pain during the day?
47. What made your nausea worse during the day?
48. What relieved your nausea during the day?
49. What made your vomiting worse during the day?
50. What relieved your vomiting during the day?
Please answer the questions below when you wake up in the morning on the 2nd day after surgery.
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51. In the space below, please list all new medications or remedies that you took yesterday.
New medications or remedies are those you did not take regularly before surgery.
Name of new medication
Time
Strength of doses
Reason for taking
or remedy
of the day
taken (mg)

0

1

2

3

4

5

6

7

How effective was it?
0 = not at all,
10 = completely effective

8

9

10

Below indicate how much nausea, vomiting and pain not at all
bothered you during your recovery and please use the 0-10 scale with
0 being “not at all” and 10 being “most bothersome”.
Nausea

Vomiting

most bothersome

Pain

52. How much did

Affect your quality of life yesterday?

53. How much did

Affect your usual ability to eat and drink yesterday?

54. How much did

Affect your usual ability to do necessary activities and tasks yesterday?

55. How much did
56. How much did

Affect your usual enjoyment of leisure and recreational activities yesterday
(for example: reading, listening to music)?
Affect your usual enjoyment of social activities yesterday?

57. How much did

Affect your usual ability to do your normal daily work yesterday?

58. How much did

Affect your usual ability to sleep yesterday?
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PLEASE CIRCLE THE ANSWER TO CORRECTLY FILL IN THE BLANKS:
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1. In the last 24 hrs, I threw
up __times.
2. In the last 24 hours, from
retching or dry heaves I
have felt ___distress
3. In the last 24 hours, from
vomiting or throwing up, I
have felt____distress
4. In the last 24 hours, I
have felt nauseated or sick
at my stomach____
5. In the last 24 hours, from
nausea/sickness at my
stomach, I have felt ____
distress
6. In the last 24 hours, each
time I threw up I produced
a_______amount.
7. In the last 24 hours, I
have felt nauseated or sick
at my stomach ____ times

7 or more

5-6

3-4

1-2

No

Mild

Moderate

Great

I did not
throw up
Severe

Severe

Great

Moderate

Mild

No

Not at all

1 hour or
less

2-3 hours

4-6 hours

More than
6 hours

No

Mild

Moderate

Great

Severe

Very large
(3 cups or
more)
7 or more

Large (2-3
cups)

Moderate
(½ - 2
cups)
3-4

Small
(Up to ½
cup)
1-2

I did not
throw up

5-6

No

59. Did you use any of the following means to prevent or treat nausea or vomiting since your surgery?
 Yes – No  Wearing acupressure wrist bands (elastic bands that pt pressure on the wrist)
 Yes – No  Moving slowly from clear liquids to solid food
 Yes – No  Taking medicines with food
 Yes – No  Eating food
 Yes – No  Drinking carbonated drinks or other fluids
 Yes – No  Laying down
Other (please specify)

60. If you are a smoker, when did you resume smoking: Date: _____
and did this cause you some nausea or vomiting?  Yes – No  – N/A 
For the following questions, please compare how your recovery from surgery has lived up to the expectations you had before surgery.
Please use the following scale. Please note that if your recovery went as expected, you would rate it as “5” per the scale below.

Compared to what you

0
1
2
3
far worse
as
than expected
expected

4

5

6

7

8

9

10
far better
than expected

61. …how would you rate your anesthesia?
62. …how would you rate your pain control?
63. …how would you rate your prevention and treatment of nausea?
64. …how would you rate your prevention and treatment of vomiting?
65. …how would you rate your overall medical treatment?
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66. If there were a drug that could have prevented the pain you had but you would have to
pay for it out of your own pocket to get it, how much would you be willing to pay for it? $ __________
67. If there were a drug that could have prevented the nausea you had but you would have to
pay for it out of your own pocket to get it, how much would you be willing to pay for it? $ __________
68. If there were a drug that could have prevented the vomiting you had but you would have to
pay for it out of your own pocket to get it, how much would you be willing to pay for it? $ __________
69. What is your highest level of education?  High School –  College –  Doctoral Degree –  none of these
70. What is your average annual household income?

 under $25,000 –  $25–$50,000 –  $50–$75,000 –  $75–$100,000 –  over $100,000
71. Do you have any suggestions about how we can improve patient recovery in the future?

expected before surgery

3RD DAY AFTER SURGERY
Symptoms after Surgery
Please use the 0-10 scale with 0 being “none at all” and 10 being the “worst possible” to rate your symptoms. As the day goes on please fill out
each question at the end of each time interval. If you have no symptoms please enter a “0.”
0
1
none at all

2

3

4

5

6

7

8

Please answer each question below at the
end of each time interval to the right Æ
72. What was your severity of pain at rest?
73. What was your severity of pain during activities?
74. What was your worst severity of nausea?
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75. If you had nausea, for how long did you have it?[min]
76. How many times did you have vomiting/retching?
77. What was your worst severity of vomiting/retching?

9

10
worst possible

3rd Day after Surgery

Answer these questions at the end of each day.
3rd Day after Surgery
78. How tired were you during the day (0-10)
79. How much headache did you have (0-10)
80. What made your pain worse during the day?
81. What relieved your pain during the day?
82. What made your nausea worse during the day?
83. What relieved your nausea during the day?
84. What made your vomiting worse during the day?
85. What relieved your vomiting during the day?
Please answer the questions below when you wake up in the morning on the 3rd day after surgery.
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86. In the space below, please list all new medications or remedies that you took yesterday.
New medications or remedies are those you did not take regularly before surgery.
Name of new medication
Time
Strength of doses
Reason for taking
or remedy
of the day
taken (mg)

0

1

2

3

4

5

6

7

How effective was it?
0 = not at all,
10 = completely effective

8

9

10

Below indicate how much nausea, vomiting and pain not at all
bothered you during your recovery and please use the 0-10 scale with
0 being “not at all” and 10 being “most bothersome”.

Nausea

Vomiting

most bothersome

Pain

87. How much did

Affect your quality of life yesterday?

88. How much did

Affect your usual ability to eat and drink yesterday?

89. How much did

Affect your usual ability to do necessary activities and tasks yesterday?

90. How much did
91. How much did

Affect your usual enjoyment of leisure and recreational activities yesterday
(for example: reading, listening to music)?
Affect your usual enjoyment of social activities yesterday?

92. How much did

Affect your usual ability to do your normal daily work yesterday?

93. How much did

Affect your usual ability to sleep yesterday?
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PLEASE CIRCLE THE ANSWER TO CORRECTLY FILL IN THE BLANKS:
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1. In the last 24 hrs, I threw
up __times.
2. In the last 24 hours, from
retching or dry heaves I
have felt ___distress
3. In the last 24 hours, from
vomiting or throwing up, I
have felt____distress
4. In the last 24 hours, I
have felt nauseated or sick
at my stomach____
5. In the last 24 hours, from
nausea/sickness at my
stomach, I have felt ____
distress
6. In the last 24 hours, each
time I threw up I produced
a_______amount.
7. In the last 24 hours, I
have felt nauseated or sick
at my stomach ____ times

7 or more

5-6

3-4

1-2

No

Mild

Moderate

Great

I did not
throw up
Severe

Severe

Great

Moderate

Mild

No

Not at all

1 hour or
less

2-3 hours

4-6 hours

More than
6 hours

No

Mild

Moderate

Great

Severe

Very large
(3 cups or
more)
7 or more

Large (2-3
cups)

Moderate
(½ - 2
cups)
3-4

Small
(Up to ½
cup)
1-2

I did not
throw up

5-6

No

4TH DAY AFTER SURGERY
Symptoms after Surgery
Please use the 0-10 scale with 0 being “none at all” and 10 being the “worst possible” to rate your symptoms. As the day goes on please fill out
each question at the end of each time interval. If you have no symptoms please enter a “0.”
0
1
none at all
Please answer each question below at the
end of each time interval to the right Æ
94. What was your severity of pain at rest?

2

3

4th Day after Surgery

95. What was your severity of pain during activities?
96. What was your worst severity of nausea?
97. If you had nausea, for how long did you have it?[min]
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98. How many times did you have vomiting/retching?
99. What was your worst severity of vomiting/retching?
Answer these questions at the end of each day.
4th Day after Surgery
100.

How tired were you during the day (0-10)

101.

How much headache did you have (0-10)

102.

What made your pain worse during the day?

103.

What relieved your pain during the day?

104.

What made your nausea worse during the day?

105.

What relieved your nausea during the day?

106.

What made your vomiting worse during the day?

107.

What relieved your vomiting during the day?

4

5

6

7

8

9

10
worst possible

Please answer the questions below when you wake up in the morning on the 4th day after surgery.
108.
In the space below, please list all new medications or remedies that you took yesterday.
New medications or remedies are those you did not take regularly before surgery.
Name of new medication
Time
Strength of doses
Reason for taking
or remedy
of the day
taken (mg)

How effective was it?
0 = not at all,
10 = completely effective
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Below indicate how much nausea, vomiting and pain
0
1
2
3
4
5
6
bothered you during your recovery and please use the
not
at
all
0-10 scale with
0 being “not at all” and 10 being “most bothersome”.
Nausea Vomiting Pain
109. How much did
Affect your quality of life yesterday?

7

8

9

10
most bothersome

110. How much did

Affect your usual ability to eat and drink yesterday?

111. How much did

Affect your usual ability to do necessary activities and tasks yesterday?

112. How much did
113. How much did

Affect your usual enjoyment of leisure and recreational activities yesterday
(for example: reading, listening to music)?
Affect your usual enjoyment of social activities yesterday?

114. How much did

Affect your usual ability to do your normal daily work yesterday?

115. How much did

Affect your usual ability to sleep yesterday?

PLEASE CIRCLE THE ANSWER TO CORRECTLY FILL IN THE BLANKS:
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1. In the last 24 hrs, I threw
up __times.
2. In the last 24 hours, from
retching or dry heaves I
have felt ___distress
3. In the last 24 hours, from
vomiting or throwing up, I
have felt____distress
4. In the last 24 hours, I
have felt nauseated or sick
at my stomach____
5. In the last 24 hours, from
nausea/sickness at my
stomach, I have felt ____
distress
6. In the last 24 hours, each
time I threw up I produced
a_______amount.
7. In the last 24 hours, I
have felt nauseated or sick
at my stomach ____ times

7 or more

5-6

3-4

1-2

No

Mild

Moderate

Great

I did not
throw up
Severe

Severe

Great

Moderate

Mild

No

Not at all

1 hour or
less

2-3 hours

4-6 hours

More than
6 hours

No

Mild

Moderate

Great

Severe

Very large
(3 cups or
more)
7 or more

Large (2-3
cups)

Moderate
(½ - 2
cups)
3-4

Small
(Up to ½
cup)
1-2

I did not
throw up

5-6

No

5TH DAY AFTER SURGERY
Symptoms after Surgery
Please use the 0-10 scale with 0 being “none at all” and 10 being the “worst possible” to rate your symptoms. As the day goes on please fill out
each question at the end of each time interval. If you have no symptoms please enter a “0.”
0
1
none at all
Please answer each question below at the
end of each time interval to the right Æ
116. What was your severity of pain at rest?

2

3

4

5

5th Day after Surgery

117. What was your severity of pain during activities?
118. What was your worst severity of nausea?
119. If you had nausea, for how long did you have it?[min]
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120. How many times did you have vomiting/retching?
121. What was your worst severity of vomiting/retching?
Answer these questions at the end of each day.
5th Day after Surgery
122. How tired were you during the day (0-10)
123. How much headache did you have (0-10)
124. What made your pain worse during the day?
125. What relieved your pain during the day?
126. What made your nausea worse during the day?
127. What relieved your nausea during the day?
128. What made your vomiting worse during the day?
129. What relieved your vomiting during the day?

6

7

8

9

10
worst possible

Please answer the questions below when you wake up in the morning on the 5th day after surgery.
130. In the space below, please list all new medications or remedies that you took yesterday.
New medications or remedies are those you did not take regularly before surgery.
Name of new medication
Time
Strength of doses
Reason for taking
or remedy
of the day
taken (mg)
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Below indicate how much nausea, vomiting and pain
bothered you during your recovery and please use the
0-10 scale with
0 being “not at all” and 10 being “most bothersome”.

Nausea

Vomiting

0
not at all

1

2

3

4

5

6

7

How effective was it?
0 = not at all,
10 = completely effective

8

9

10
most bothersome

Pain

131. How much did

Affect your quality of life yesterday?

132. How much did

Affect your usual ability to eat and drink yesterday?

133. How much did

Affect your usual ability to do necessary activities and tasks yesterday?

134. How much did
135. How much did

Affect your usual enjoyment of leisure and recreational activities yesterday
(for example: reading, listening to music)?
Affect your usual enjoyment of social activities yesterday?

136. How much did

Affect your usual ability to do your normal daily work yesterday?

137. How much did

Affect your usual ability to sleep yesterday?

PLEASE CIRCLE THE ANSWER TO CORRECTLY FILL IN THE BLANKS:
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1. In the last 24 hrs, I threw
up __times.
2. In the last 24 hours, from
retching or dry heaves I
have felt ___distress
3. In the last 24 hours, from
vomiting or throwing up, I
have felt____distress
4. In the last 24 hours, I
have felt nauseated or sick
at my stomach____
5. In the last 24 hours, from
nausea/sickness at my
stomach, I have felt ____
distress
6. In the last 24 hours, each
time I threw up I produced
a_______amount.
7. In the last 24 hours, I
have felt nauseated or sick
at my stomach ____ times

7 or more

5-6

3-4

1-2

No

Mild

Moderate

Great

I did not
throw up
Severe

Severe

Great

Moderate

Mild

No

Not at all

1 hour or
less

2-3 hours

4-6 hours

More than
6 hours

No

Mild

Moderate

Great

Severe

Very large
(3 cups or
more)
7 or more

Large (2-3
cups)

Moderate
(½ - 2
cups)
3-4

Small
(Up to ½
cup)
1-2

I did not
throw up

5-6

No

6TH DAY AFTER SURGERY
Symptoms after Surgery
Please use the 0-10 scale with 0 being “none at all” and 10 being the “worst possible” to rate your symptoms. As the day goes on please fill out
each question at the end of each time interval. If you have no symptoms please enter a “0.”
0
1
none at all
Please answer each question below at the
end of each time interval to the right Æ
138. What was your severity of pain at rest?

2

3

6th Day after Surgery

139. What was your severity of pain during activities?
140. What was your worst severity of nausea?
141. If you had nausea, for how long did you have it?[min]
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142. How many times did you have vomiting/retching?
143. What was your worst severity of vomiting/retching?
Answer these questions at the end of each day.
6th Day after Surgery
144. How tired were you during the day (0-10)
145. How much headache did you have (0-10)
146. What made your pain worse during the day?
147. What relieved your pain during the day?
148. What made your nausea worse during the day?
149. What relieved your nausea during the day?
150. What made your vomiting worse during the day?
151. What relieved your vomiting during the day?

4

5

6

7

8

9

10
worst possible

Please answer the questions below when you wake up in the morning on the 6th day after surgery.
152. In the space below, please list all new medications or remedies that you took yesterday.
New medications or remedies are those you did not take regularly before surgery.
Name of new medication
Time
Strength of doses
Reason for taking
or remedy
of the day
taken (mg)
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Below indicate how much nausea, vomiting and pain
0
1
2
3
4
5
6
bothered you during your recovery and please use the
not at all
0-10 scale with
0 being “not at all” and 10 being “most bothersome”.
Nausea Vomiting Pain
153. How much did
Affect your quality of life yesterday?

7

How effective was it?
0 = not at all,
10 = completely effective

8

9

10
most bothersome

154. How much did

Affect your usual ability to eat and drink yesterday?

155. How much did

Affect your usual ability to do necessary activities and tasks yesterday?

156. How much did
157. How much did

Affect your usual enjoyment of leisure and recreational activities yesterday
(for example: reading, listening to music)?
Affect your usual enjoyment of social activities yesterday?

158. How much did

Affect your usual ability to do your normal daily work yesterday?

159. How much did

Affect your usual ability to sleep yesterday?

PLEASE CIRCLE THE ANSWER TO CORRECTLY FILL IN THE BLANKS:
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1. In the last 24 hrs, I threw
up __times.
2. In the last 24 hours, from
retching or dry heaves I
have felt ___distress
3. In the last 24 hours, from
vomiting or throwing up, I
have felt____distress
4. In the last 24 hours, I
have felt nauseated or sick
at my stomach____
5. In the last 24 hours, from
nausea/sickness at my
stomach, I have felt ____
distress
6. In the last 24 hours, each
time I threw up I produced
a_______amount.
7. In the last 24 hours, I
have felt nauseated or sick
at my stomach ____ times

7 or more

5-6

3-4

1-2

No

Mild

Moderate

Great

I did not
throw up
Severe

Severe

Great

Moderate

Mild

No

Not at all

1 hour or
less

2-3 hours

4-6 hours

More than
6 hours

No

Mild

Moderate

Great

Severe

Very large
(3 cups or
more)
7 or more

Large (2-3
cups)

Moderate
(½ - 2
cups)
3-4

Small
(Up to ½
cup)
1-2

I did not
throw up

5-6

No

7TH DAY AFTER SURGERY
Symptoms after Surgery
Please use the 0-10 scale with 0 being “none at all” and 10 being the “worst possible” to rate your symptoms. As the day goes on please fill out
each question at the end of each time interval. If you have no symptoms please enter a “0.”
0
1
none at all
Please answer each question below at the
end of each time interval to the right Æ
160. What was your severity of pain at rest?

2

3

4

7th Day after Surgery

161. What was your severity of pain during activities?
162. What was your worst severity of nausea?
163. If you had nausea, for how long did you have it?[min]
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164. How many times did you have vomiting/retching?
165. What was your worst severity of vomiting/retching?
Answer these questions at the end of each day.
7th Day after Surgery
166. How tired were you during the day (0-10)
167. How much headache did you have (0-10)
168. What made your pain worse during the day?
169. What relieved your pain during the day?
170. What made your nausea worse during the day?
171. What relieved your nausea during the day?
172. What made your vomiting worse during the day?
173. What relieved your vomiting during the day?

5

6

7

8

9

10
worst possible

Please answer the questions below at dinnertime on the 7th day after surgery.
174. Below, please list all new medications or remedies that you took today since waking up.
New medications or remedies are those you did not take regularly before surgery.
Name of new medication
Time
Strength of doses
Reason for taking
or remedy
of the day
taken (mg)
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Below indicate how much nausea, vomiting and pain
bothered you during your recovery and please use the
0-10 scale with
0 being “not at all” and 10 being “most bothersome”.
Nausea

0
not at all

1

2

3

4

5

6

7

How effective was it?
0 = not at all,
10 = completely effective

8

9

10
most bothersome

Vomiting Pain

175. How much did

Affect your quality of life today?

176. How much did

Affect your usual ability to eat and drink today?

177. How much did

Affect your usual ability to do necessary activities and tasks today?

178. How much did
179. How much did

Affect your usual enjoyment of leisure and recreational activities today
(for example: reading, listening to music)?
Affect your usual enjoyment of social activities today?

180. How much did

Affect your usual ability to do your normal daily work today?

PLEASE CIRCLE THE ANSWER TO CORRECTLY FILL IN THE BLANKS:
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1. In the last 24 hrs, I threw
up __times.
2. In the last 24 hours, from
retching or dry heaves I
have felt ___distress
3. In the last 24 hours, from
vomiting or throwing up, I
have felt____distress
4. In the last 24 hours, I
have felt nauseated or sick
at my stomach____
5. In the last 24 hours, from
nausea/sickness at my
stomach, I have felt ____
distress
6. In the last 24 hours, each
time I threw up I produced
a_______amount.
7. In the last 24 hours, I
have felt nauseated or sick
at my stomach ____ times

7 or more

5-6

3-4

1-2

No

Mild

Moderate

Great

I did not
throw up
Severe

Severe

Great

Moderate

Mild

No

Not at all

1 hour or
less

2-3 hours

4-6 hours

More than
6 hours

No

Mild

Moderate

Great

Severe

Very large
(3 cups or
more)
7 or more

Large (2-3
cups)

Moderate
(½ - 2
cups)
3-4

Small
(Up to ½
cup)
1-2

I did not
throw up

5-6

No

Thank you for filling out and reporting these questions to us. Once our data are complete we will send you a gift card in the mail in
approximately 2-4 weeks. Please let us know what kind of gift card you would prefer:
Blockbuster · Borders/Waldenbooks ·Chevy’s · Cybelle’s Pizza · Jamba Juice · Pasta Pomodoro · Starbucks

APPENDIX B Permission

To Whom It May Concern:
This note is official permission on behalf of the American Society of PeriAnesthesia Nurses
(ASPAN) to allow Jan Odom-Forren, RN, CPAN, FAAN, PhD Candidate use Figure 1 and
Figure 2 from ASPAN’s Evidence-Based Clinical Practice Guideline for the Prevention and/or
Management of PONV/PDNV, J Perianesth Nurs 2006; 21:233-234 as part of her doctoral
dissertation at the University of Kentucky.

Terry Clifford
ASPAN President/Date 8/19/09

Kevin Dill
ASPAN CEO/Date 8/19/09

American Society of PeriAnesthesia Nurses
10 Melrose Avenue- Suite 110
Cherry Hill, NJ 08003-3696
Toll-Free: 877.737.9696
Telephone: 856.616.9600
Fax: 856.616.9601
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